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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 20, Revision 3 
(FGE.20Rev3): 
Benzyl alcohols, benzaldehydes, a related acetal, benzoic acids, and related 
esters from chemical groups 23 and 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to consider in this revision 3 of Flavouring Group Evaluation 20, 
the SCF Opinion on benzoic acid. Furthermore information on stereoisomeric composition for two 
substances [FL-no: 06.104 and 09.570] and new information to support the re-allocation of the 
structural class for the candidate substance piperonyl alcohol [FL-no: 02.205] has been submitted. The 
41 flavouring substances in Flavouring Group Evaluation 20 were evaluated using the Procedure in 
Commission Regulation (EC) No 1565/2000. None of the substances were considered to have 
genotoxic potential. The substances were evaluated through a stepwise approach (the Procedure) that 
integrates information on structure-activity relationships, intake from current uses, toxicological 
threshold of concern, and available data on metabolism and toxicity. The Panel concluded that all the 
substances do not give rise to safety concerns at their levels of dietary intake, estimated on the basis of 
the MSDI approach.  
© European Food Safety Authority, 2011 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Scientific Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission 
on the implications for human health of chemically defined flavouring substances used in or on 
foodstuffs in the Member States. In particular, the Panel was requested to evaluate 41 flavouring 
substances in the Flavouring Group Evaluation 20, Revision 3 (FGE.20Rev3), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000. These 41 flavouring substances belong 
to chemical group 23 and 30, Annex I of the Commission Regulation (EC) No 1565/2000. 
The present revision of FGE.20, FGE.20Rev3 includes the consideration of the SCF Opinion on 
benzoic acid (SCF, 2002c). Furthermore information on the stereoisomeric composition has become 
available for two substances [FL-no: 06.104 and 09.570] and new information to support the re-
allocation of the structural class for the candidate substance piperonyl alcohol [FL-no: 02.205] has 
been submitted.  
Four of the 41 flavouring substances can exist as optical isomers [FL-no: 06.104, 09.313, 09.317 and 
09.852] and three of the 41 substances can exist as geometrical isomers [FL-no: 09.314, 09.560 and 
09.570].  
Thirty-seven candidate substances are classified into structural class I and four [FL-no: 02.205, 
05.066, 05.221 and 06.104] are classified into structural class II according to the decision tree 
approach presented by Cramer et al., 1978. 
Twenty-two of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 37 flavouring substances allocated to structural class I 
have intakes in Europe from 0.001 to 610 microgram/capita/day, which are below the threshold of 
concern value for structural class I (1800 microgram/person/day). The four substances in structural 
class II [FL-no: 02.205, 05.066, 05.221 and 06.104] have estimated intakes of 0.011, 1.2, 0.61 and 100 
microgram/capita/day, respectively. These intakes are below the threshold values of 540 
microgram/person/day for structural class II. 
On the basis of the reported annual production in Europe (MSDI approach), the combined intake of 
the 37 of the candidate substances belonging to structural class I is approximately 1300 
microgram/capita/day. This value is lower than the threshold of concern for structural class I 
substances. Based on reported production volumes, European per capita intakes (MSDI) could be 
estimated for 76 of the 77 supporting substances. The total combined intakes of the candidate and 
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supporting substances are approximately 75000 and 7100 microgram/capita/day for structural class I 
and II, respectively, which exceed the thresholds of concern. However, the substances are expected to 
be efficiently metabolised and are not expected to saturate the metabolic pathways. 
For the substances in this group the available genotoxicity data do not preclude the evaluation of the 
candidate substances using the Procedure. 
It is anticipated that the candidate substances in FGE.20Rev3 would be metabolised to innocuous 
products. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present FGE using the Procedure. 
It is considered that on the basis of the default MSDI approach the 41 candidate substances would not 
give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 1400 to 120000 
microgram/person/day for the 37 flavouring substances from structural class I. The intakes were all 
above the threshold of concern for structural class I of 1800 microgram/person/day, except for five 
flavouring substances [FL-no: 05.129, 05.142, 05.153, 05.158 and 08.080]. The estimated intakes, 
based on the mTAMDI, of the four flavouring substances [FL-no: 02.205, 05.066, 05.221 and 06.104] 
assigned to structural class II were 3900, 1600, 7000 and 3900 microgram/person/day, respectively, 
which are above the threshold of concern for the structural class (540  microgram/person/day for 
structural class II). The five substances which have mTAMDI intake estimates below the threshold of 
concern for structural class I are also expected to be metabolised to innocuous products. Thus, on the 
basis of the mTAMDI, the estimated intakes for 36 of the 41 flavouring substances considered in this 
Opinion, exceed the relevant threshold for their structural class to which the flavouring substance has 
been assigned. Therefore, for these 36 substances more reliable exposure data are required. On the 
basis of such additional data, these flavouring substances should be re-evaluated using the Procedure. 
Subsequently, additional toxicological data might become necessary. 
In order to determine whether the conclusion for the 41 candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
the 41 flavouring substances. For these 41 flavouring substances the Panel concluded that they would 
present no safety concern at their estimated levels of intake based of the MSDI approach. 
 
KEYWORDS 
Flavourings, safety, benzyl alcohols, benzaldehydes, benzoic acids, esters, acetals, benzyl, benzoate, 
aliphatic, acyclic, alicyclic, FGE.20. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION 
The present flavouring group originally included two substances [FL-no: 09.693 and 09.696], which 
by hydrolysis and oxidation may be metabolised to alpha,beta-unsaturated aldehydes. As the 
alpha,beta-unsaturated aldehyde and ketone structures are considered a structural alerts for 
genotoxicity (EFSA, 2008b), they have been given special considerations in the Flavouring Group 
Evaluation 19 (FGE.19). The two substances [FL-no: 09.693 and 09.696] were considered with 
respect to genotoxicity in subgroup 1.1.3 of FGE.19 (FGE.202). 
FGE.19 contains 360 flavouring substances from the EU Register being alpha, beta-unsaturated 
aldehydes or ketones and precursors which could give rise to such carbonyl substances via hydrolysis 
and / or oxidation (EFSA, 2008b). The alpha, beta-unsaturated carbonyls were subdivided into 28 
subgroups on the basis of structural similarity (EFSA, 2008b). In an attempt to decide which of the 
substances could go through the Procedure, a (quantitative) structure-activity relationship (Q)SAR 
prediction of the genotoxicity of these substances was undertaken. The Panel took note of the (Q)SAR 
predictions by using two ISS Local Models (Benigni and Netzeva, 2007a; Benigni and Netzeva, 
2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the fact 
that there are available data on genotoxicity, in vitro and in vivo, as well as data on carcinogenicity for 
several substances. The Panel decided that 11 subgroups (1.1.2, 1.1.3, 1.1.4, 2.4, 2.6, 2.7, 3.1, 3.3, 4.1, 
4.2 and 4.4) (EFSA, 2008b) should be further examined to determine whether evaluation through the 
Procedure is feasible. Corresponding to these 11 subgroups 11 Flavouring Group Evaluations (FGEs) 
were established: FGE.201, 202, 203, 210, 212, 213, 214, 216, 217, 218 and 220. 
The revision 1 of FGE.20, FGE.20Rev1, included the assessment of one additional candidate 
substance, vanillin propylene glycol acetal [FL-no: 06.104]. For this substance there are 
hydrolysis data and for a related substance [FL-no: 02.248] in vitro genotoxicity data. Additional 
information for three substances [FL-no: 09.313, 09.317 and 09.852] has been made available 
since FGE.20 was published. Toxicity and metabolism data on a substance, vanillin 3-l-
menthoxypropane-1,2-diol acetal [FL-no: 02.248], related to the candidate substance vanillin 
propylene glycol acetal [FL-no:06.104], are included. 
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The revision 2 of FGE.20, FGE.20Rev2, included the assessment of five additional candidate 
substances [FL-no: 05.221, 08.132, 08.133, 09.693 and 09.696]. Toxicity data are available for four of 
the five substances. In vitro genotoxicity data are available for [FL-no: 05.221 and 08.133], long-term 
toxicity data are available for [FL-no: 08.133] and acute toxicity data are available for [FL-no: 08.133, 
09.693 and 09.696]. Two of the substances [FL-no: 09.693 and 09.696] were considered with respect 
to genotoxicity in FGE.202 in which the Panel concluded that the genotoxicity data available do not 
preclude their evaluation through the Procedure. So, [FL-no: 09.693 and 09.696] were evaluated 
through the Procedure in FGE.20Rev2. 
History of FGE.20: 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.20 7 December 2005 http://www.efsa.eu.int/science/afc/afc_opinions/1292_en.
html 
35 
FGE.20Rev1 29 November 2007 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902332837.htm 
36 
FGE.20Rev2 26 November 2009 http://www.efsa.europa.eu/en/efsajournal/pub/976.htm 41 
FGE.20Rev3 17 May 2011  41 
 
The present revision of FGE.20, FGE.20Rev3 includes the consideration of the SCF Opinion on 
benzoic acid (SCF, 2002c). Furthermore, the Industry has for two substances [FL-no: 06.104 and 
09.570] submitted information on the stereoisomeric composition, which was missing in the previous 
version of the FGE. Finally, the Industry has submitted new information to support the re-allocation of 
structural class to the candidate substance piperonyl alcohol [FL-no: 02.205].  
For piperonyl alcohol [FL-no: 02.205], the Flavouring Industry has submitted new information since 
the publication of FGE.20Rev2 that suggests that the natural occurrence in several food sources of 
closely structurally related substances, which are most likely metabolised to piperonyl alcohol. 
Therefore Flavouring Industry considered it correct to answer the question whether the substance 
occur naturally with a yes, and therefore the substance should be allocated to structural class II. The 
Panel agreed in this consideration and allocated [FL-no: 02.205] to structural class II.  
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a).  
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 20, Revision 3 
1.1. Description 
The present Flavouring Group Evaluation 20, Revision 3 (FGE.20Rev3), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in 
schematic form in Annex I of this FGE), deals with 41 benzyl alcohols, benzaldehydes, a related 
acetal, benzoic acids and related esters. These flavouring substances belong to chemical groups 23 and 
30, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
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The 41 candidate substances under consideration with their chemical Register names, FLAVIS-   (FL-
), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract 
Manufactures Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
This group of candidate substances includes 15 benzyl derivatives (subgroup 1), 25 hydroxy- and 
alkoxy-substituted benzyl derivatives (subgroup 2) and 1 hydroxy- and alkoxy-substituted biphenyl 
derivative (subgroup 3).  
• Subgroup 1 includes 14 alkyl esters of which nine are benzyl esters [FL-no: 09.152, 09.313, 
09.314, 09.315, 09.316, 09.317, 09.318, 09.611 and 09.835] and five are benzoic acid esters 
[FL-no: 09.631, 09.656, 09.693, 09.779 and 09.825]. Three of these candidate substances 
contain a double-bond in the alkyl side chain [FL-no: 09.314, 09.656 and 09.693] and two 
contain an alkyl substituent at the aromatic ring [FL-no: 09.631 and 09.611]. The remaining 
substance [FL-no: 06.017] is an acetal.  
• Subgroup 2 includes two benzyl alcohols [FL-no: 02.164, and the derivative piperonyl alcohol 
FL-no: 02.205], six benzaldehyde derivatives [FL-no: 05.066, 05.129, 05.142, 05.153, 05.158 
and 06.104], four benzoic acids [FL-no: 08.080, 08.087, 08.132 and 08.133] and 13 related 
esters [FL-no: 09.362, 09.363, 09.367, 09.560, 09.570, 09.581, 09.623, 09.696, 09.762, 
09.798, 09.799, 09.852 and 09.895]. One of the esters is a benzyl ester [FL-no: 09.895], all the 
others are benzoic acid esters. Three of the esters contain a double-bond in the alkyl side chain 
[FL-no: 09.560, 09.570 and 09.696].  
• Subgroup 3 contains one biphenyl [FL-no: 05.221]. 
The 41 flavouring substances (candidate substances) are closely related structurally to 77 flavouring 
substances (supporting substances) evaluated at the 46th and 57th JECFA meeting (JECFA, 1997a; 
JECFA, 2002b). The names and structures of the 77 supporting substances are listed in Table 3, 
together with their evaluation status (CoE, 1992; JECFA, 1997a; JECFA, 2002b; SCF, 1995). 
The 77 supporting substances include 34 benzyl derivatives (subgroup 1) and 43 hydroxy- and alkoxy-
substituted benzyl derivatives (subgroup 2).  
Two of the candidate substances [FL-no: 09.693 and 09.696] are alpha-beta unsaturated compounds 
and their possible genotoxicity has been evaluated in FGE.202 (EFSA, 2009ac). The Panel concluded 
that although the substances in FGE.202 have a structural alert for genotoxicity, the data available on 
one of the substances, citral [FL-no: 05.020], made it possible to conclude that there would be no 
safety concern with respect to genotoxicity for these substances and that they may be further evaluated 
through the Procedure.    
The hydrolysis products of the candidate esters are listed in Table 2b. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
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Three of the 41 flavouring substances possess one chiral centre [FL-no: 09.313, 09.317 and 09.852] 
and one flavouring substance possesses two chiral centres [FL-no: 06.104]. Due to the presence and 
the position of double bonds, three of the 41 candidate substances can exist as geometrical isomers 
[FL-no: 09.314, 09.560 and 09.570].  
Industry has for the two substances [FL-no: 06.104 and 09.570] submitted information on the 
stereoisomeric composition, which was missing in the previous version of the FGE. The candidate 
substance [FL-no: 06.104] consists of predominantly (up to 80 %) vanillin propylene glycol acetal, the 
parent compound, and up to 18 - 20 % vanillin. The candidate substance [FL-no: 09.570] has one 
double bond that exists in cis-form (Z). The Register name can thus be changed into (Z)-Hex-3-enyl 
salicylate (EFFA, 2010a) (See Table 1). 
1.3. Natural Occurrence in Food 
Twenty-two out of 41 candidate substances have been reported to occur in fruit (cherry, mango, 
papaya, bilberry, black currants, mulberry, sapodilla, cloudberry, pineapple, grape, cocoa), potato, 
coffee, beer, rum, sherry, whisky, wine, honey, spices, soybean, peanut, wort and pork. Quantitative 
data on the natural occurrence of these substances have been reported for the occurrence of 14 of these 
substances in food (TNO, 2000; EFFA, 2010a). These reports are: 
• 2-Methoxybenzaldehyde [FL-no: 05.129]: 7000 mg/kg in cassia leaf, up to 1500 mg/kg in 
cinnamon bark. 
• 3,4-Dihydroxybenzaldehyde [FL-no: 05.142]: up to 20 mg/kg in coffee, 313 mg/kg in 
bourbon vanilla.  
• 4-Hydroxy-3,5-dimethoxybenzaldehyde [FL-no: 05.153]: up to 0.7 mg/kg in beer, up to 9.2 
mg/kg in grape, up to 0.014 mg/kg in mango, 0.08 mg/kg in pineapple, 8.3 mg/kg in pork, up 
to 19.9 mg/kg in rum, 0.035 mg/kg in sherry, 1.9 mg/kg in bourbon vanilla, up to 8.7 mg/kg in 
whisky, up to 0.86 mg/kg in red wine, up to 0.04 mg/kg in wort.  
• 3-Methoxybenzaldehyde [FL-no: 05.158]: 3900 mg/kg in clove bud. 
• Gallic acid [FL-no: 08.080]: up to 0.6 mg/kg in beer, up to 7 mg/kg in cherry, up to 11 mg/kg 
in grape, up to 6.1 mg/kg in whisky, up to 35 mg/kg in wine. 
• 4-Hydroxy-3,5-dimethoxybenzoic acid [FL-no: 08.087]: up to 1.1 mg/kg in beer, 1.3 mg/kg in 
grape, up to 0.096 mg/kg in mango, up to 18 mg/kg in rum, up to 34 mg/kg in soybean, up to 
1.4 mg/kg in whisky, up to 10 mg/kg in wine. 
• 3-Hydroxybenzoic acid [FL-no: 08.132]: up to 2.7 mg/kg in honey. 
• 3,4-Dihydroxybenzoic acid [FL-no: 08.133]: up to 1.4 mg/kg in brandy, up to 0.4 mg/kg in 
beer, up to 52 mg/kg in black currants, up to 6.8 mg/kg in honey, 4.3 mg/kg in mulberry, 0.15 
mg/kg in rum, 10 mg/kg in soybean, up to 0.3 mg/kg in whisky, up to 10 mg/kg in wine. 
• Benzyl valerate [FL-no: 09.152]: 0.11 mg/kg in sea buckthorn. 
• Benzyl crotonate [FL-no: 09.314]: 0.0001 mg/kg in papaya. 
• Butyl benzoate [FL-no: 09.779]: 200 mg/kg in galanga, 2 mg/kg in hog plum, up to 0.05 
mg/kg in papaya. 
• Ethyl vanillate [FL-no: 09.798]: 0.3 mg/kg in rum, up to 113 mg/kg in red wine. 
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• Methyl vanillate [FL-no: 09.799]: 0.05 mg/kg in cloudberry, up to 214 mg/kg in red wine.  
• Pentyl benzoate [FL-no: 09.825]: 0.001 mg/kg in bilberry, trace amounts in sapodilla fruit. 
According to TNO the remaining 19 substances have not been reported to occur naturally in any food 
items (TNO, 2000). See Table 3.1 
Table 1.3: Substances for which no occurrence in food has been reported 
FL-no EU Register name 
02.164 4-Hydroxy-3,5-dimethoxybenzyl alcohol 
09.315 Benzyl dodecanoate 
09.317 Benzyl lactate 
09.318 Benzyl octanoate 
09.362 Ethyl 2-hydroxy-4-methylbenzoate 
09.560 Hex-3(cis)-enyl anisate 
09.581 Hexyl salicylate 
09.611 4-Isopropylbenzyl acetate 
09.623 Methyl 2,4-dihydroxy-3,6-dimethylbenzoate 
09.656 3-Methylbut-3-enyl benzoate 
09.693 Prenyl benzoate 
09.696 Prenyl salicylate 
09.762 Pentyl salicylate 
09.835 Benzyl decanoate 
09.852 2-Methylbutyl 2-hydroxybenzoate 
09.895 4-Methoxybenzyl-2-methylpropionate 
05.066 4-Ethoxy-3-methoxybenzaldehyde 
05.221 6,6'-Dihydroxy-5,5'-dimethoxy-biphenyl-3,3'-dicarbaldehyde 
06.104 Vanillin propylene glycol acetal 
 
2. Specifications 
Purity criteria for the 41 candidate substances have been provided by the Flavour Industry (EFFA, 
2003u; EFFA, 2004c; EFFA, 2007d; Flavour Industry, 2008c). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), this information is adequate for all the 41 substances (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
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Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The total annual volume of production of the 41 candidate substances in the present Flavouring Group 
Evaluation (FGE.20Rev3) from use as flavouring substances in Europe has been reported to be 
approximately 11200 kg (EFFA, 2003u; EFFA, 2004d; EFFA, 2007d; Flavour Industry, 2008c). For 
76 of the 77 supporting substances the total annual volume of production is approximately 660000 kg 
in Europe (vanillin [FL-no: 05.018] accounts for 390000 kg) (JECFA, 2002a). The annual volumes of 
production in Europe for 1 of the supporting substances [FL-no: 09.754] were not reported. 
On the basis of the annual volumes of production reported for the 41 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated. Approximately 97 % of the 
annual volume of production for the candidate substances is accounted for by three substances [FL-no: 
06.104, 08.132 and 08.133]. The estimated daily per capita intake of these three candidate substances 
from use as flavouring substances is 1320 microgram. For each of the remaining substances the 
estimated daily per capita intake is less than 10 microgram for each (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the 41 candidate substances information on food categories and normal and maximum use 
levels5,6,7 were submitted by the Flavour Industry(EFFA, 2003u; EFFA, 2004c; EFFA, 2007a; EFFA, 
2007d; Flavour Industry, 2008c). The 41 candidate substances are used in flavoured food products 
divided into the food categories, outlined in Annex III of the Commission Regulation (EC) No 
1565/2000 (EC, 2000a), as shown in Table 3.1. For the present calculation of mTAMDI, the reported 
normal use levels were used. In the case where different use levels were reported for different food 
categories the highest reported normal use level was used. 
Table 3.1 Use of Candidate Substances 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All 41 except [FL-no: 
08.132, 08.133] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 41 except [FL-no: 
08.132, 08.133] 
03.0 Edible ices, including sherbet and sorbet All 41 except [FL-no: 
08.132, 08.133] 
04.1 Processed fruits All 41 except [FL-no: 
05.221, 08.132, 08.133] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses 
and legumes), and nuts & seeds 
None 
05.0 Confectionery All 41 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, 
pulses & legumes, excluding bakery 
All 41 except [FL-no: 
05.221, 08.132, 08.133] 
07..0 Bakery wares All 41 except [FL-no 
05.129, 08.132, 08.133] 
08.0 Meat and meat products, including poultry and game All 41 except [FL-no: 
05.221, 08.132, 08.133] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms All 41 except [FL-no: 
05.221, 08.132, 08.133, 
09.825] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All 41 except [FL-no: 
08.132, 08.133] 
13.0 Foodstuffs intended for particular nutritional uses All 41 except [FL-no: 
05.221, 08.132, 08.133] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 41 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All 41 
15.0 Ready-to-eat savouries All 41 except [FL-no: 
08.132, 08.133, 09.693] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that 
could not be placed in categories 1 – 15 
All 41 except [FL-no: 
08.132, 08.133] 
 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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According to the Flavour Industry the normal use levels for the candidate substances are in the range 
of 1 - 500 mg/kg food, and the maximum use levels are in the range of 5 - 2000 mg/kg (EFFA, 2003u; 
EFFA, 2004c; EFFA, 2007a; EFFA, 2007d; Flavour Industry, 2008c). 
The mTAMDI value is 1400 - 120000 microgram/person/day for 37 of the 41 candidate substances 
from structural class I (see Section 5). For the candidate substances [FL-no: 02.205, 05.066, 05.221, 
and 06.104] from structural class II (see Section 5) the mTAMDIs are 3900, 1600, 7000 and 3900 
microgram/person/day, respectively. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
The 41 candidate substances are subdivided into three subgroups. Subgroup 1 includes 15 benzyl 
derivatives of which 14 are benzyl esters or benzoic acid esters and one is an acetal, [FL-no: 06.017] 
(diethoxymethyl)benzene. Subgroup 2 includes 25 hydroxy- and alkoxy-substituted benzyl derivatives 
of which 12 are benzyl alcohols, benzaldehydes or benzoic acids and 13 are related esters. Subgroup 3 
contains one derivative of biphenyl [FL-no: 05.221] (6,6’-dihydroxy-5,5’dimethoxy-biphenyl-3,3’-
dicarbaldehyde). 
It is expected that esters in subgroup 1 and 2 will be hydrolysed in vivo to their component alcohols 
and acids. Eight of the 14 esters from subgroup 1 will yield benzyl alcohol which has previously been 
evaluated by the JECFA (JECFA, 1996b) and SCF (SCF, 2002b). One candidate ester, 4-
isopropylbenzyl acetate [FL-no: 09.611] will yield 4-isopropyl benzyl alcohol. This substance has 
been previously evaluated by the JECFA (JECFA, 2002a). The benzyl alcohols are expected to be 
oxidised to corresponding benzoic acids, which will be conjugated with glycine and excreted as 
hippuric acids.  
Of the remaining five candidate esters in subgroup 1, four are expected to yield benzoic acid and 
simple aliphatic alcohols upon hydrolysis, 3-methylbut-3-enyl benzoate [FL-no: 09.656],  butyl 
benzoate [FL-no: 09.779], pentyl benzoate [FL-no: 09.825],  prenyl benzoate [FL-no: 09.693], and one 
ester, methyl 4-methylbenzoate [FL-no: 09.631] will yield 4-methylbenzoic acid upon hydrolysis. 
Benzoic acid will mainly be conjugated with glycine and excreted as hippuric acid. Conjugation with 
glycine may be a saturable process and glucuronide conjugates increase with increasing dose. 
One of the substances in subgroup 1 is an acetal, (diethoxymethyl)benzene [FL-no: 06.017]. This 
substance would be expected to yield benzaldehyde and ethanol upon hydrolysis. Benzaldehyde has 
been evaluated by the JECFA (JECFA, 1996b). Benzaldehyde is expected to be oxidized to benzoic 
acid.  
Subgroup 2 includes 13 esters of which one, 4-methoxybenzyl-2-methylpropionate [FL-no: 09.895] 
will yield 4-methoxybenzyl alcohol (p-anisyl alcohol) (supporting substance [FL-no: 02.128]) upon 
hydrolysis. This substance has been evaluated by the JECFA (JECFA, 2002a). 4-Methoxybenzyl 
alcohol is expected to be excreted in the urine either unchanged or as glucuronic acid, glycine or 
sulphate conjugate. The same metabolic pathway is proposed for the candidate benzyl alcohol 
derivative, 4-hydroxy-3,5-dimethoxybenzyl alcohol [FL-no: 02.164]. 
The remaining 12 esters in subgroup 2, ethyl 2-hydroxy-4-methylbenzoate [FL-no: 09.362], ethyl 2-
methoxybenzoate [FL-no: 09.363], ethyl 4-hydroxybenzoate [FL-no: 09.367], hex-3(cis)-enyl anisate 
[FL-no: 09.560] (hex-3(cis)-enyl 4-methoxybenzoate), hex-3-enyl salicylate [FL-no: 09.570] (hex-3-
enyl 2-hydroxybenzoate), hexyl salicylate [FL-no: 09.581] (hexyl 2-hydroxybenzoate), methyl 2,4-
dihydroxy-3,6-dimethylbenzoate [FL-no: 09.623], prenyl salicylate [FL-no: 09.696] (3-methylbut-2-
enyl 2-hydroxybenzoate), pentyl salicylate [FL-no: 09.762] (pentyl 2-hydroxybenzoate), ethyl 
vanillate [FL-no: 09.798] (ethyl 3-methoxy-4-hydroxybenzoate), methyl vanillate [FL-no: 09.799] 
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(methyl 3-methoxy-4-hydroxybenzoate), 2-methylbutyl 2-hydroxybenzoate [FL-no: 09.852] (2-
methylbutyl salicylate) will yield alkoxy- and/or hydroxy-substituted benzoic acids upon hydrolysis. 
The substituted benzoic acids that are hydrolysis products of candidate esters are expected to be 
excreted in the urine unchanged or as the glucuronic acid, glycine or sulphate conjugates. The same 
metabolic route is proposed for the candidate acids, 4-hydroxy-3,5-dimethoxybenzoic acid [FL-no: 
08.087], 3-hydroxybenzoic acid [FL-no: 08.132] and 3,4-dihydroxybenzoic acid [FL-no: 08.133]. 
The main metabolic pathway for the acetal, vanillin propylene glycol acetal [FL-no: 06.104], after 
hydrolysis to the aldehyde, and for the five candidate aldehydes in subgroup 2, 4-ethoxy-3-
methoxybenzaldehyde [FL-no: 05.066], 2-methoxybenzaldehyde [FL-no: 05.129], 3,4-
dihydroxybenzaldehyde [FL-no: 05.142], 4-hydroxy-3,5-dimethoxybenzaldehyde [FL-no: 05.153], 3-
methoxybenzaldehyde [FL-no: 05.158], is presumed to be oxidation of the aldehyde to the 
corresponding acids, followed by conjugation and excretion. The reduction to alcohols is a minor 
metabolic route and the oxidative pathway dominates clearly. To a minor extent O-demethylation 
followed by conjugation may occur. 
The candidate substance piperonyl alcohol [FL-no: 02.205] (3,4-methylenedioxybenzylalcohol) is 
expected to mainly undergo oxidation and conjugation of the side chain, and be excreted as glycine 
conjugate. Demethylenation of the methylenedioxy moiety is a very minor metabolic path for this 
compound. 
The main metabolite of gallic acid [FL-no: 08.080] (3,4,5-trihydroxybenzoic acid) is expected to be 4-
O-methyl gallic acid (3,5-dihydroxy-4-methoxybenzoic acid), the product of O-methylation. 
Decarboxylation to pyrogallol (1,2,3-trihydroxybenzene) may occur as a very minor pathway, but no 
further dehydroxylation to catechol has been observed. 
The biphenyl substance in subgroup 3 [FL-no: 05.221] is expected to be metabolised in a similar way 
to the benzaldehyde derivatives in subgroup 2. It is expected that the aldehyde group(s) will undergo 
oxidation to form the corresponding carboxylic acid which is likely to be conjugated and excreted. 
The reduction of the alcohol groups may again be a minor pathway, but some steric hindrance may 
occur making this less likely than for the benzaldehyde derivatives in subgroup 2.    
Based on experimental evidence and general knowledge of toxicokinetics of structurally related 
compounds, it is expected that, at the reported levels of intake as flavouring substances, the candidate 
substances are metabolised to innocuous products. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the 41 candidate substances from chemical groups 23 and 30 the 
Procedure as outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations 
of the substances are summarised in Table 2a. 
Step 1 
Thirty-seven of the flavouring substances are classified according to the decision tree approach by 
Cramer et al. (Cramer et al., 1978) into structural class I, four are classified into structural class II [FL-
no: 02.205, 05.066, 05.221 and 06.104].  
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Step 2 
Step 2 requires consideration of the metabolism of the candidate substances. It can be anticipated that 
at the estimated levels of intake all 41 candidate substances are expected to be metabolised to 
innocuous products. Accordingly, the evaluation of these 41 candidate substances proceeds via the A-
side of the Procedure scheme.  
Step A3 
The estimated levels of the European daily per capita intake (MSDI) for the 37 candidate substances 
classified into structural class I are in the range of 0.0012 to 610 micrograms. For the four candidate 
substances [FL-no: 02.205, 05.066, 05.221 and 06.104] classified into structural class II, the intakes 
are 0.011, 1.2, 0.61 and 100 micrograms, respectively (Table 2a). These intakes are below the 
thresholds of concern of 1800 and 540 microgram/person/day for structural class I and II, respectively. 
Based on results of the safety evaluation sequence of the Procedure, these 41 candidate substances, 
proceeding via the A-side of the Procedure scheme, do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for the 37 candidate substances in structural class I based on the mTAMDI 
range from 1400 to 120000 microgram/person/day. For five of the substances [FL-no: 05.129, 05.142, 
05.153, 05.158 and 08.080] the mTAMDI values are below the threshold of concern of 1800 
microgram/person/day for structural class I. For the remaining 32 of the 37 substances in class 1, the 
mTAMDI is above the threshold of concern.  
The estimated intake of the four candidate substances [FL-no: 02.205, 05.066, 05.221 and 06.104] 
assigned to structural class II, based on the mTAMDI, are 3900, 1600, 7000 and 3900 
microgram/person/day, respectively. These intakes are above the threshold of concern of 540 
microgram/person/day for structural classes II. 
Thus, for 36 candidate substances, for which the mTAMDI is above the threshold of concern, further 
information is required. This would include more reliable intake data and subsequently, if required, 
additional toxicological data. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 6.1. 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.164 4-Hydroxy-3,5-dimethoxybenzyl alcohol 0.037 3900 Class I 1800 
05.129 2-Methoxybenzaldehyde 0.16 1400 Class I 1800 
05.142 3,4-Dihydroxybenzaldehyde 8.5 1600 Class I 1800 
05.153 4-Hydroxy-3,5-dimethoxybenzaldehyde 0.74 1600 Class I 1800 
05.158 3-Methoxybenzaldehyde 0.011 1600 Class I 1800 
06.017 (Diethoxymethyl)benzene 1.7 3900 Class I 1800 
08.080 Gallic acid 0.011 1600 Class I 1800 
08.087 4-Hydroxy-3,5-dimethoxybenzoic acid 1.2 3200 Class I 1800 
08.132 3-Hydroxybenzoic acid 610 120000 Class I 1800 
08.133 3,4-Dihydroxybenzoic acid 610 120000 Class I 1800 
09.152 Benzyl valerate 1.7 3900 Class I 1800 
09.313 Benzyl 2-methylbutyrate 7.3 3900 Class I 1800 
09.314 Benzyl crotonate 0.37 3900 Class I 1800 
09.315 Benzyl dodecanoate 0.13 3900 Class I 1800 
09.316 Benzyl hexanoate 0.75 3900 Class I 1800 
Flavouring Group Evaluation 20, Revision 3 
 
 
15 EFSA Journal 2011; 9(7):2176 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
09.317 Benzyl lactate 0.91 3900 Class I 1800 
09.318 Benzyl octanoate 0.12 3900 Class I 1800 
09.362 Ethyl 2-hydroxy-4-methylbenzoate 0.0012 3900 Class I 1800 
09.363 Ethyl 2-methoxybenzoate 5.5 3900 Class I 1800 
09.367 Ethyl 4-hydroxybenzoate 10 3900 Class I 1800 
09.560 Hex-3(cis)-enyl anisate 0.12 3900 Class I 1800 
09.570 Hex-3-enyl salicylate 0.13 3900 Class I 1800 
09.581 Hexyl salicylate 0.018 3900 Class I 1800 
09.611 4-Isopropylbenzyl acetate 0.012 3900 Class I 1800 
09.623 Methyl 2,4-dihydroxy-3,6-dimethylbenzoate 0.012 3900 Class I 1800 
09.631 Methyl 4-methylbenzoate 0.0012 3900 Class I 1800 
09.656 3-Methylbut-3-enyl benzoate 0.12 3900 Class I 1800 
09.693 Prenyl benzoate 0.012 4900 Class I 1800 
09.696 Prenyl salicylate 0.011 3900 Class I 1800 
09.762 Pentyl salicylate 0.24 3900 Class I 1800 
09.779 Butyl benzoate 3.7 3900 Class I 1800 
09.798 Ethyl vanillate 0.024 3900 Class I 1800 
09.799 Methyl vanillate 0.011 3900 Class I 1800 
09.825 Pentyl benzoate 1.1 3900 Class I 1800 
09.835 Benzyl decanoate 0.35 3900 Class I 1800 
09.852 2-Methylbutyl 2-hydroxybenzoate 0.011 3900 Class I 1800 
09.895 4-Methoxybenzyl-2-methylpropionate 0.37 3900 Class I 1800 
02.205 Piperonyl alcohol 0.011 3900 Class II 540 
05.066 4-Ethoxy-3-methoxybenzaldehyde 1.2 1600 Class II 540 
05.221 6,6'-Dihydroxy-5,5'-dimethoxy-biphenyl-3,3'-
dicarbaldehyde 
0.61 7000 Class II 540 
06.104 Vanillin propylene glycol acetal 100 3900 Class II 540 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003u; EFFA, 2004d; 
EFFA, 2007d; Flavour Industry, 2008c) the combined estimated daily per capita intake as flavourings 
of the 37 candidate flavouring substances assigned to structural class I is 1300 microgram. This value 
does not exceed the threshold of concern for a substance belonging to structural class I of 1800 
microgram/person/day. 
The 41 candidate substances are structurally related to 77 supporting substances evaluated by JEFCA 
at its 46th and 57th meeting (JECFA, 1996b; JECFA, 2002a). Based on reported production volumes, 
European per capita intakes (MSDI) could be estimated for 76 of the 77 supporting substances. 
Production volumes in Europe were not reported for 1 of the supporting substances [FL-no: 09.754].  
The total combined intakes of the candidate and supporting substances are approximately 75000 and 
7100 microgram/capita/day for structural class I and II, respectively, which exceed the thresholds of 
concern of 1800 and 540 microgram/capita/day for structural classes I and II, respectively. However, 
the supporting substances were evaluated by the JECFA at the 46th and 57th meeting, where it was 
noted that although the combined intakes exceed the thresholds for the structural classes, the 
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substances are expected to be efficiently detoxicated and the available detoxication pathways would 
not be saturated. 
The Panel agreed with this view and concluded that the contributions to the total combined intakes of 
the candidate substances of about 1300 and 100 microgram/capita/day for structural class I and II, 
respectively, would not alter the JECFA conclusion based on combined intakes of approximately 
75000 and 7100 microgram/capita/day. The Panel noted that a considerable proportion of this 
combined intake is accounted for by the supporting substance vanillin [FL-no: 05.018] and for this 
compound the JECFA has allocated an Acceptable Daily Intake (ADI) of 0 - 10 mg/kg body weight 
(bw) (JECFA, 1967a; JECFA, 2002b). 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for 13 candidate substances and for 63 structurally related supporting substances 
evaluated by the JECFA (JECFA, 2002a). The LD50 values range from 500 to more than 5000 mg/kg 
body weight (bw) in four different animal species.  
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Benzyl Derivatives (Subgroup 1) 
There are no data available on short-term and long-term toxicity of candidate substances from 
subgroup 1 (benzyl derivatives). Data on benzyl derivatives are available for 10 supporting substances, 
which have been tested for subacute oral toxicity [FL-no: 05.110], for subchronic oral toxicity [FL-no: 
09.051, 09.725, 09.812, 09.803 and 05.027] and for chronic toxicity and carcinogenicity [FL-no: 
02.010, 09.014, 05.013 and 08.021]. 
Results from carcinogenicity studies on benzyl alcohol, benzyl acetate and benzaldehyde by dietary 
administration were negative and they were not genotoxic. These substances have been evaluated by 
the JECFA (JECFA, 1996b). The JECFA concluded that “the data reviewed for compounds in this 
group were sufficient to demonstrate the lack of teratogenic, reproductive or carcinogenic potential”. 
A group ADI of 0 – 5 mg/kg bw was allocated to these compounds. The SCF evaluated data on benzyl 
alcohol (SCF, 2002b) and concluded that it did not show compound-related effects with respect to 
carcinogenicity.  
Four candidate esters in subgroup 1, 3-methylbut-3-enyl benzoate [FL-no: 09.656], butyl benzoate 
[FL-no: 09.779], pentyl benzoate [FL-no: 09.825], prenyl benzoate [FL-no: 09.693], yield benzoic 
acid and simple aliphatic alcohols upon hydrolysis. One of the substances in subgroup 1 is an acetal, 
(diethoxymethyl)benzene [FL-no: 06.017], which would be expected to yield benzaldehyde and 
ethanol upon hydrolysis, and in turn benzaldehyde is expected to be oxidized to benzoic acid. The 
SCF (2002) has established a group ADI of 5 mg/kg bw for benzoic acid and its salts including benzyl 
alcohol and related benzyl derivatives used as flavourings, based on a developmental toxicity study in 
rats (SCF, 2002c)8. 
Hydroxy-/Alkoxy- Substituted Benzyl Derivatives (Subgroup 2) 
                                                     
 
8 The CEF panel is aware that the benzoic acid is currently under reviewing in the ANS Panel. 
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Short- and long-term toxicity data on hydroxy- and alkoxy-substituted benzyl derivatives (subgroup 2) 
are available for five candidate substances and eight supporting substances. The candidate substances 
have been tested for subacute oral toxicity [FL-no: 05.142, 08.080, 08.087 and 08.133] and for 
subchronic oral toxicity [FL-no: 08.080, 08.133 and 09.367]. There are data available on chronic 
toxicity and carcinogenicity for one candidate substance [FL-no: 08.133] in a study designed to 
evaluate incidences of lesions (hyperplasia, papillomas, squamous cell carcinoma and sarcoma 
incidence) in the forestomach in rats. No lesions developed in the forestomach of the rats. Other 
organs (oesophagus, stomach, intestines, liver and kidney) were inspected grossly. Mean body weight 
was not different from the control, but relative liver and kidney weight was significantly increased, but 
not further evaluated.  
For the supporting substances, data are available on subacute oral toxicity [FL-no: 09.796], on 
subchronic oral toxicity [FL-no: 05.015 and 09.751] and on chronic toxicity and carcinogenicity [FL-
no: 09.754, 05.018, 09.749, 05.019 and 05.016].  
Ethyl 4-hydroxybenzoate and other parabens were evaluated by SCF in 1994 (SCF, 1996). From 
subchronic and chronic toxicity tests conducted in rats, dogs and mice an overall NOAEL of 1000 
mg/kg bw/day was derived. This NOAEL value has been confirmed for ethyl- and methyl paraben by 
EFSA (EFSA, 2004b). 
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
There are data available for one candidate substance [FL-no: 09.367] (subgroup 2) and for 12 
supporting substances of which four belong to subgroup 1 [FL-no: 02.010, 05.013, 08.021 and 09.014] 
and eight to subgroup 2 [FL-no: 05.016, 05.017, 05.018, 05.019, 08.076, 08.112, 09.749 and 09.754]. 
For the candidate substance ethyl-4-hydroxybenzoate (ethyl paraben) [FL-no: 09.367] a NOAEL of 
2600 mg/kg bw/day has been reported for developmental toxicity in rats, while a NOAEL of 460 
mg/kg bw/day was found in the same study for maternal toxicity. From another study a NOAEL of 
1043 mg/kg bw/day is available for reproductive toxicity in male rats. Ethyl paraben has been 
evaluated as a food additive by the AFC panel, and the Panel considered 1000 mg/kg bw/day as the 
overall NOAEL, based on the absence of effects on sex hormones and on the male reproductive organs 
in juvenile rats at doses up to 1000 mg/kg bw/day in the above study (EFSA, 2004b). 
As there are valid and sufficient studies available on the candidate substance ethyl paraben the data on 
the supporting substance butyl paraben [FL-no: 09.754] were not considered for the evaluation of 
ethyl paraben. 
Developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Data from in vitro tests are available for 9 candidate substances [subgroup 1: FL-no: 09.631; subgroup 
2: FL-no: 09.367, 05.129, 05.158, 08.080, 05.153, 08.087 and 08.133; subgroup 3: FL-no: 05.221], 
and for 28 supporting substances (twelve from subgroup 1 and 16 from subgroup 2) and for one 
related substance (vanillin 3-(l-menthoxy)propane-1,2-diol acetal [FL-no: 02.248] related to subgroup 
2). Data from in vivo tests are available for two candidate substances from subgroup 2 [FL-no: 09.367 
and 08.080] and for 10 supporting substances (three from subgroup 1 and seven from subgroup 2). 
All the candidate substances [FL-no: 05.129, 05.153, 05.158, 05.221, 08.080, 08.087, 09.367 and 
09.631] tested for bacterial gene mutations gave negative results. For six candidate substances [FL-no: 
09.367, 05.129, 05.158, 08.080, 08.087 and 08.133] both positive and/or negative results were 
reported in various other in vitro test systems (Rec assay, chromosomal aberration test, sister 
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chromatid exchange (SCE) and mammalian cell gene mutation assay (mouse lymphoma tests)) for 
most of which the validity cannot be evaluated or are known to be of very limited relevance.  
The same situation was observed for the supporting substances. All the available bacterial gene 
mutation assays on supporting substances gave negative results. For 14 of these substances, both 
positive and negative results were reported in other in vitro test systems (Rec assay, chromosomal 
aberration test, sister chromatid exchange (SCE) and mammalian cell gene mutation assay) for most of 
which, however, the validity cannot be evaluated.  
The available in vivo studies on candidate substances reported negative results for ethyl 4-
hydroxybenzoate [FL-no: 09.367] in a chromosome aberration assay in rat bone marrow cells and for 
gallic acid [FL-no: 08.080] in a bioassay in the rat liver. However, due to very limited details on 
method and results the validity of these studies cannot be evaluated. 
The Panel noted that the supporting substance benzyl acetate [FL-no: 09.014] was positive in an in 
vivo Comet assay, which may indicate a genotoxic activity at high dose levels. The study was 
considered of limited validity. However, all other in vivo studies with benzyl acetate were negative 
and several of these studies, among which an unscheduled DNA synthesis (UDS) test in the liver and a 
mouse bone marrow micronucleus test were considered to be of good quality (NTP, 1993d). 
Additionally, in the long term carcinogenicity studies with benzyl acetate, no carcinogenic effects 
were observed in mice and rats after administration via the diet (NTP, 1993d). In a previous study by 
NTP (1986) in which this substance was administered by gavage in corn oil, concern was raised in 
particular about pancreatic tumours in rats, but for these tumours a confounding influence of the 
vehicle was suspected. In two other genotoxicity studies, specifically aiming at the determination of 
benzyl acetate-induced DNA damage (UDS test and alkaline elution assay) in rat pancreas, no 
indications of a genotoxic effect were obtained although these studies were of limited or inassessible 
validity. Taking all this information into account, the Panel considered the positive result from the in 
vivo Comet assay as insufficient grounds to preclude the evaluation of benzyl acetate via the 
Procedure.  
Furthermore, all the studies carried out with 10 different supporting substances among which were 
benzyl alcohol, benzyl acetate and benzaldehyde, give no indication of a genotoxic potential in vivo in 
several studies for different genetic endpoints and by different routes of administration. 
Conclusion on genotoxicity:  
While some of the in vitro studies indicated equivocal weak positive or positive results, considering 
the weight of evidence from candidate and supporting substances and the in vivo studies the Panel 
concluded there was no safety concern with respect to genotoxicity of the substances in the present 
flavouring group. 
Genotoxicity data are summaries in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The present revision of FGE.20, FGE.20Rev3 includes the consideration of the SCF opinion on 
benzoic acid (SCF, 2002c). Furthermore information on the stereoisomeric composition has become 
available for two substances [FL-no: 06.104 and 09.570] and new information to support the re-
allocation of structural class for the candidate substance piperonyl alcohol [FL-no: 02.205] has been 
submitted. The present FGE.20Rev3 deals in total with 41 benzyl alcohols, benzaldehydes, related 
acetals, benzoic acids and related esters and a hydroxy- and alkoxy-substituted biphenyl derivative. 
They belong to chemical groups 23 and 30. 
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Four of the 41 flavouring substances can exist as optical isomers [FL-no: 06.104, 09.313, 09.317 and 
09.852] and three of the 41 substances can exist as geometrical isomers [FL-no: 09.314, 09.560 and 
09.570].  
Thirty-seven candidate substances are classified into structural class I and four [FL-no: 02.205, 
05.066, 05.221 and 06.104] are classified into structural class II according to the decision tree 
approach presented by Cramer et al., 1978. 
Twenty-two of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
According to the default MSDI approach, the 37 flavouring substances allocated to structural class I 
have intakes in Europe from 0.001 to 610 microgram/capita/day, which are below the threshold of 
concern value for structural class I (1800 microgram/person/day). The four substances in structural 
class II [FL-no: 02.205, 05.066, 05.221 and 06.104] have estimated intakes of 0.011, 1.2, 0.61 and 100 
microgram/capita/day, respectively. These intakes are below the threshold values of 540 
microgram/person/day for structural class II. 
On the basis of the reported annual production in Europe (MSDI approach), the combined intake of 
the 37 of the candidate substances belonging to structural class I is approximately 1300 
microgram/capita/day. This value is lower than the threshold of concern for structural class I 
substances. Based on reported production volumes, European per capita intakes (MSDI) could be 
estimated for 76 of the 77 supporting substances. The total combined intakes of the candidate and 
supporting substances are approximately 75000 and 7100 microgram/capita/day for structural class I 
and II, respectively, which exceed the thresholds of concern. However, the substances are expected to 
be efficiently metabolised and are not expected to saturate the metabolic pathways. 
For the substances in this group the available genotoxicity data do not preclude the evaluation of the 
candidate substances using the Procedure. 
It is anticipated that the candidate substances in FGE.20Rev3 would be metabolised to innocuous 
products. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present FGE using the Procedure. 
It is considered that on the basis of the default MSDI approach the 41 candidate substances would not 
give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances. 
When the estimated intakes were based on the mTAMDI approach they ranged from 1400 to 120000 
microgram/person/day for the 37 flavouring substances from structural class I. The intakes were all 
above the threshold of concern for structural class I of 1800 microgram/person/day, except for five 
flavouring substances [FL-no: 05.129, 05.142, 05.153, 05.158 and 08.080]. The estimated intakes, 
based on the mTAMDI, of the four flavouring substances [FL-no: 02.205, 05.066, 05.221 and 06.104] 
assigned to structural class II were 3900, 1600, 7000 and 3900 microgram/person/day, respectively, 
which are above the threshold of concern for the structural class (540 microgram/person/day). The five 
substances which have mTAMDI intake estimates below the threshold of concern for structural class I 
are also expected to be metabolised to innocuous products. Thus, on the basis of the mTAMDI, the 
estimated intakes for 36 of the 41 flavouring substances considered in this Opinion, exceed the 
relevant threshold for their structural class to which the flavouring substance has been assigned. 
Therefore, for these 36 substances more reliable exposure data are required. On the basis of such 
additional data, these flavouring substances should be re-evaluated using the Procedure. Subsequently, 
additional toxicological data might become necessary. 
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In order to determine whether the conclusion for the 41 candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
the 41 flavouring substances. For these 41 flavouring substances the Panel concluded that they would 
present no safety concern at their estimated levels of intake based of the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 20, REVISION 3 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 20, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
02.164 
 
4-Hydroxy-3,5-dimethoxybenzyl 
alcohol 
O
HO
O
OH  
 
530-56-3 
Solid 
C9H12O4 
184.19 
Practically insoluble 
or insoluble 
Freely soluble 
387 
133 
MS 
95 % 
n.a. 
n.a. 
 
 
02.205 
 
Piperonyl alcohol OHO
O  
 
10306 
495-76-1 
Solid 
C8H8O3 
152.15 
Very slightly soluble 
Freely soluble 
161 (26 hPa) 
55 
MS 
95 % 
n.a. 
n.a. 
 
 
05.066 
 
4-Ethoxy-3-methoxybenzaldehyde 
O
O
O
 
 
703 
120-25-2 
Solid 
C10H12O3 
180.20 
Practically insoluble 
or insoluble 
Freely soluble 
168 (17 hPa) 
63 
MS 
95 % 
n.a. 
n.a. 
 
 
05.129 
 
2-Methoxybenzaldehyde 
O
O
 
4077 
10350 
135-02-4 
Solid 
C8H8O2 
136.15 
Practically insoluble 
or insoluble 
Freely soluble 
238 
38 
MS 
97 % 
1.556-1.562 
1.128-1.136 
 
 
05.142 
 
3,4-Dihydroxybenzaldehyde 
OH
HO
O  
10328 
139-85-5 
Solid 
C7H6O3 
138.12 
Slightly soluble 
Freely soluble 
323 
154 
MS 
98 % 
n.a. 
n.a. 
 
 
05.153 
1878 
4-Hydroxy-3,5-
dimethoxybenzaldehyde 
O
HO
O
O
 
10340 
134-96-3 
Solid 
C9H10O4 
182.18 
Practically insoluble 
or insoluble 
Freely soluble 
192 (19 hPa) 
113 
MS 
95 % 
n.a. 
n.a. 
 
 
05.158 
 
3-Methoxybenzaldehyde O O
 
 
10351 
591-31-1 
Liquid 
C8H8O2 
136.15 
Practically insoluble 
or insoluble 
Freely soluble 
230 
 
MS 
95 % 
1.549-1.555 
1.116-1.122 
 
 
05.221 
1881 
6,6'-Dihydroxy-5,5'-dimethoxy-
biphenyl-3,3'-dicarbaldehyde 
O
O
O
O
HO
OH  
 
2092-49-1 
Solid 
C16H14O6 
302.28 
Practically insoluble 
or insoluble 
Soluble 
 
315 
MS 
91.4 % 
n.a. 
n.a. 
 
 
06.017 
 
(Diethoxymethyl)benzene 
O
O
 
517 
774-48-1 
Liquid 
C11H16O2 
180.25 
Practically insoluble 
or insoluble 
Freely soluble 
222 
 
MS 
95 % 
1.475-1.481 
0.903-0.909 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 20, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
06.104 
1882 
Vanillin propylene glycol acetal 
HO
O
O
O 3905 
 
68527-74-2 
Liquid 
C11H14O4 
210.23 
Practically insoluble 
or insoluble 
Freely soluble 
154 (0.1 hPa) 
 
NMR 
97 % 
1.537-1.543 
1.190-1.206 
 
Commercial compound: 
Vanillin propylene glycol 
acetal up to 80 % and with 
18 - 20 % vanillin (EFFA, 
2010a). 
08.080 
 
Gallic acid 
HO
HO
O
OH
OH
 
10170 
149-91-7 
Solid 
C7H6O5 
170.12 
Sparingly soluble 
Freely soluble 
501 
242 
MS 
95 % 
n.a. 
n.a. 
 
 
08.087 
 
4-Hydroxy-3,5-dimethoxybenzoic 
acid 
O
HO
O
O
OH
 
10111 
530-57-4 
Solid 
C9H10O5 
198.18 
Sparingly soluble 
Freely soluble 
440 
206 
MS 
95 % 
n.a. 
n.a. 
 
 
08.132 
 
3-Hydroxybenzoic acid 
HO
O
OH
 
 
99-06-9 
Solid 
C7H6O3 
138.12 
Soluble 
Soluble 
 
202 
IR NMR MS 
>99% 
n.a. 
n.a. 
 
 
08.133 
 
3,4-Dihydroxybenzoic acid 
HO
O
OH
HO
 
 
99-50-3 
Solid 
C7H6O4 
154.12 
Soluble 
Soluble 
 
221 
IR NMR MS 
>99% 
n.a. 
n.a. 
 
 
09.152 
 
Benzyl valerate 
O
O  
470 
10361-39-4 
Liquid 
C12H16O2 
192.26 
Practically insoluble 
or insoluble 
Freely soluble 
236 
 
MS 
95 % 
1.487-1.493 
0.990-0.996 
 
 
09.313 
 
Benzyl 2-methylbutyrate 
O
O  
10523 
56423-40-6 
Liquid 
C12H16O2 
192.26 
Practically insoluble 
or insoluble 
Freely soluble 
248 
 
MS 
99 % 
1.486-1.495 
0.982-0.994 
 
Racemate. 
09.314 
 
Benzyl crotonate 
O
O  
 
65416-24-2 
Liquid 
C11H12O2 
176.21 
Practically insoluble 
or insoluble 
Freely soluble 
138 (16 hPa) 
 
MS 
95 % 
1.515-1.521 
1.029-1.035 
 
 
09.315 
 
Benzyl dodecanoate 
O
O  
 
140-25-0 
Liquid 
C19H30O2 
290.44 
Practically insoluble 
or insoluble 
Freely soluble 
210 (16 hPa) 
 
MS 
95 % 
1.479-1.485 
0.937-0.943 
 
 
09.316 
 
Benzyl hexanoate 
O
O  
10521 
6938-45-0 
Liquid 
C13H18O2 
206.28 
Practically insoluble 
or insoluble 
Freely soluble 
270 
 
MS 
99 % 
1.486-1.492 
0.978-0.985 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 20, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
09.317 
 
Benzyl lactate 
O
OH
O  
 
2051-96-9 
Liquid 
C10H12O3 
180.20 
Practically insoluble 
or insoluble 
Freely soluble 
134 (13 hPa) 
 
MS 
95 % 
1.512-1.518 
1.120-1.144 
 
Racemate. 
09.318 
 
Benzyl octanoate 
O
O  
 
10276-85-4 
Liquid 
C15H22O2 
234.34 
Practically insoluble 
or insoluble 
Freely soluble 
153 (8 hPa) 
 
MS 
95 % 
1.484-1.490 
0.960-0.966 
 
 
09.362 
 
Ethyl 2-hydroxy-4-methylbenzoate 
OH
O
O  
 
60770-00-5 
Liquid 
C10H12O3 
180.20 
Practically insoluble 
or insoluble 
Freely soluble 
254 
 
MS 
95 % 
1.514-1.520 
1.088-1.094 
 
 
09.363 
 
Ethyl 2-methoxybenzoate 
O
O
O  
 
7335-26-4 
Liquid 
C10H12O3 
180.20 
Practically insoluble 
or insoluble 
Freely soluble 
235 
 
MS 
95 % 
1.519-1.525 
1.109-1.115 
 
 
09.367 
 
Ethyl 4-hydroxybenzoate 
HO
O
O  
 
120-47-8 
Solid 
C9H10O3 
166.18 
Slightly soluble 
Freely soluble 
298 
118 
MS 
95 % 
n.a. 
n.a. 
 
 
09.560 
 
Hex-3(cis)-enyl anisate 
O
O
O
 
 
121432-33-5 
Solid 
C14H18O3 
234.29 
Practically insoluble 
or insoluble 
Freely soluble 
363 
73 
NMR 
95 % 
n.a. 
n.a. 
 
 
09.570 
 
Hex-3-enyl salicylate O
O
OH
(Z)-form shown
 
10685 
65405-77-8 
Solid 
C13H16O3 
220.26 
Practically insoluble 
or insoluble 
Freely soluble 
394 
139 
MS 
98 % 
1.518-1.522 
1.057-1.065 
 
Register name to be changed 
to (Z)-Hex-3-enyl salicylate 
(EFFA, 2010a). 
09.581 
 
Hexyl salicylate O
O
OH  
10695 
6259-76-3 
Liquid 
C13H18O3 
222.28 
Practically insoluble 
or insoluble 
Freely soluble 
290 
 
MS 
99 % 
1.501-1.507 
1.029-1.040 
 
 
09.611 
 
4-Isopropylbenzyl acetate 
O
O  
 
59230-57-8 
Liquid 
C12H16O2 
192.26 
Practically insoluble 
or insoluble 
Freely soluble 
250 
 
MS 
95 % 
1.494-1.500 
0.998-1.004 
 
 
09.623 
 
Methyl 2,4-dihydroxy-3,6-
dimethylbenzoate 
OH
O
O
HO
 
 
4707-47-5 
Solid 
C10H12O4 
196.20 
Slightly soluble 
Freely soluble 
246 
143 
MS 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 20, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
09.631 
 
Methyl 4-methylbenzoate O
O
 
 
99-75-2 
Solid 
C9H10O2 
150.18 
Practically insoluble 
or insoluble 
Freely soluble 
421 
33 
MS 
95 % 
n.a. 
n.a. 
 
 
09.656 
 
3-Methylbut-3-enyl benzoate 
O
O  
 
5205-12-9 
Liquid 
C12H14O2 
190.24 
Practically insoluble 
or insoluble 
Freely soluble 
60 (0.1 hPa) 
 
MS 
95 % 
1.499-1.505 
0.986-0.992 
 
 
09.693 
 
Prenyl benzoate 
O
O 4203 
 
5205-11-8 
Liquid 
C12H14O2 
190.24 
Practically insoluble 
or insoluble 
Freely soluble 
60 (0.1 hPa) 
 
MS 
95 % 
1.505-1.511 
0.982-0.988 
 
 
09.696 
 
Prenyl salicylate O
O
OH  
 
68555-58-8 
Solid 
C12H14O3 
206.24 
Practically insoluble 
or insoluble 
Freely soluble 
370 
113 
MS 
95 % 
n.a. 
n.a. 
 
 
09.762 
 
Pentyl salicylate O
O
OH  
613 
2050-08-0 
Liquid 
C12H16O3 
208.26 
Practically insoluble 
or insoluble 
Freely soluble 
268 
 
MS 
95 % 
1.533-1.539 
1.062-1.068 
 
 
09.779 
 
Butyl benzoate 
O
O  
740 
136-60-7 
Liquid 
C11H14O2 
178.23 
Practically insoluble 
or insoluble 
Freely soluble 
249 
 
MS 
95 % 
1.493-1.499 
1.003-1.009 
 
 
09.798 
 
Ethyl vanillate 
O
HO
O
O
 
2302 
617-05-0 
Solid 
C10H12O4 
196.20 
Practically insoluble 
or insoluble 
Freely soluble 
292 
44 
MS 
95 % 
n.a. 
n.a. 
 
 
09.799 
 
Methyl vanillate 
HO
O
O
O
 
2305 
3943-74-6 
Solid 
C9H10O4 
182.18 
Sparingly soluble 
Freely soluble 
286 
63 
MS 
95 % 
n.a. 
n.a. 
 
 
09.825 
 
Pentyl benzoate 
O
O  
2307 
2049-96-9 
Liquid 
C12H16O2 
192.26 
Practically insoluble 
or insoluble 
Freely soluble 
260 
 
MS 
95 % 
1.482-1.493 
0.989-0.993 
 
 
09.835 
 
Benzyl decanoate 
O
O  
 
42175-41-7 
Solid 
C17H26O2 
262.39 
Practically insoluble 
or insoluble 
Freely soluble 
400 
76 
MS 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 20, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
09.852 
 
2-Methylbutyl 2-hydroxybenzoate O
O
OH  
 
51115-63-0 
Solid 
C12H16O3 
208.26 
Practically insoluble 
or insoluble 
Freely soluble 
366 
117 
MS 
95 % 
n.a. 
n.a. 
 
Racemate. 
09.895 
 
4-Methoxybenzyl-2-
methylpropionate 
O
O
O  
 
 
Solid 
C12H16O3 
208.26 
Practically insoluble 
or insoluble 
Freely soluble 
287 
40 
MS 
95 % 
1.499-1.505 
1.057-1.063 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation remarks 
02.164 
 
4-Hydroxy-3,5-dimethoxybenzyl 
alcohol 
O
HO
O
OH 0.037 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.129 
 
2-Methoxybenzaldehyde 
O
O 0.16 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.142 
 
3,4-Dihydroxybenzaldehyde 
OH
HO
O 8.5 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.153 
1878 
4-Hydroxy-3,5-
dimethoxybenzaldehyde 
O
HO
O
O
0.74 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.158 
 
3-Methoxybenzaldehyde O O 0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
06.017 
 
(Diethoxymethyl)benzene 
O
O
1.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.080 
 
Gallic acid 
HO
HO
O
OH
OH
0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.087 
 
4-Hydroxy-3,5-
dimethoxybenzoic acid 
O
HO
O
O
OH
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.132 
 
3-Hydroxybenzoic acid 
HO
O
OH
610 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation remarks 
08.133 
 
3,4-Dihydroxybenzoic acid 
HO
O
OH
HO
610 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.152 
 
Benzyl valerate 
O
O 1.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.313 
 
Benzyl 2-methylbutyrate 
O
O 7.3 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.314 
 
Benzyl crotonate 
O
O 0.37 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.315 
 
Benzyl dodecanoate 
O
O 0.13 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.316 
 
Benzyl hexanoate 
O
O 0.75 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.317 
 
Benzyl lactate 
O
OH
O 0.91 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.318 
 
Benzyl octanoate 
O
O 0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.362 
 
Ethyl 2-hydroxy-4-
methylbenzoate 
OH
O
O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.363 
 
Ethyl 2-methoxybenzoate 
O
O
O 5.5 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.367 
 
Ethyl 4-hydroxybenzoate 
HO
O
O 10 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation remarks 
09.560 
 
Hex-3(cis)-enyl anisate 
O
O
O
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.570 
 
Hex-3-enyl salicylate O
O
OH
(Z)-form shown
0.13 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.581 
 
Hexyl salicylate O
O
OH 0.018 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.611 
 
4-Isopropylbenzyl acetate 
O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.623 
 
Methyl 2,4-dihydroxy-3,6-
dimethylbenzoate 
OH
O
O
HO
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.631 
 
Methyl 4-methylbenzoate O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.656 
 
3-Methylbut-3-enyl benzoate 
O
O 0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.693 
 
Prenyl benzoate 
O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.696 
 
Prenyl salicylate O
O
OH 0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.762 
 
Pentyl salicylate O
O
OH 0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation remarks 
09.779 
 
Butyl benzoate 
O
O 3.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.798 
 
Ethyl vanillate 
O
HO
O
O
0.024 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.799 
 
Methyl vanillate 
HO
O
O
O
0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.825 
 
Pentyl benzoate 
O
O 1.1 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.835 
 
Benzyl decanoate 
O
O 0.35 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.852 
 
2-Methylbutyl 2-
hydroxybenzoate 
O
O
OH 0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.895 
 
4-Methoxybenzyl-2-
methylpropionate 
O
O
O 0.37 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.205 
 
Piperonyl alcohol OHO
O
0.011 
 
Class II 
A3: Intake below threshold 
4) 6)  
05.066 
 
4-Ethoxy-3-
methoxybenzaldehyde 
O
O
O
1.2 
 
Class II 
A3: Intake below threshold 
4) 6)  
05.221 
1881 
6,6'-Dihydroxy-5,5'-dimethoxy-
biphenyl-3,3'-dicarbaldehyde 
O
O
O
O
HO
OH 0.61 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation remarks 
06.104 
1882 
Vanillin propylene glycol acetal 
HO
O
O
O 100 
 
Class II 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot.. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 4-Methylsalicylic acid 
OH
OOH
Not evaluated as flavouring substance  Not in EU-Register 
 o-Methoxybenzoic Acid 
O
OH
O
 
Evaluated as flavouring substance by JECFA 
(881) 
 Not in EU-Register 
 2,4-Dihydroxy-3,6-
dimethylbenzoic acid 
HO OH
OH
O Not evaluated as flavouring substance  Not in EU-Register 
 p-Toluic acid 
OHO  
Not evaluated as flavouring substance  Not in EU-Register 
 Methanol H
H
H
OH
 
Not evaluated as flavouring substance  Not in EU-Register 
 3,4-Dihydoxybenzyl alcohol HO
HO
OH
Not evaluated as flavouring substance  Not in EU-Register 
 Propylene glycol 
925 
OH
OH No evaluation 
Pending definition of “flavouring agent” 
 Not in EU-Register 
 Formaldehylde O
H H  
Not evaluated as flavouring substance  Not in EU-Register 
02.004 Butan-1-ol 
85 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.005 Hexan-1-ol 
91 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
02.010 Benzyl alcohol 
25 
OH
 
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.039 4-Isopropylbenzyl alcohol 
864 
OH
 
 
No safety concern d) 
Category B c) 
 
Class I 
A3: Intake below threshold 
 
02.040 Pentan-1-ol 
88 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
02.056 Hex-3(cis)-en-1-ol 
315 
OH  Category 1 a) 
No safety concern e) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: Not 
endogenous, A5: Adequate NOAEL exists 
 
02.076 2-Methylbutan-1-ol 
1199 
OH
 
Category 1 a) 
No safety concern f) 
Category B c) 
 
Class I 
A3: Intake below threshold 
 
02.078 Ethanol 
41 
OH  Category 1 a) 
No safety concern g) 
 
 
 
No evaluation 
At the forty-sixth JECFA meeting (JECFA, 
1997a), the Committee concluded that 
ethanol posed no safety concern at its 
current level of intake when ethyl esters are 
used as flavouring agents. 
02.109 3-Methylbut-2-en-1-ol 
1200 
OH  
 
No safety concern f) 
 
 
Class I 
A3: Intake below threshold 
This substance has been evaluated in 
FGE.202. it was concluded that there would 
be no safety concern with respect to 
genotoxicity or carcinogenicity. 
02.128 p-Anisyl alcohol 
871 
OH
O  
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
02.176 3-Methylbut-3-en-1-ol 
 
OH
 
 
 
 
FGE.06 
Class I 
A3: Intake below threshold 
 
05.013 Benzaldehyde 
22 
O
 
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
05.018 Vanillin 
889 
HO
O
O
 
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: Not 
endogenous, A5: Adequate NOAEL exists 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
08.002 Acetic acid 
81 
O
OH  
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.004 Lactic acid 
930 
OH
OH
O  
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.006 2-Methylpropionic acid 
253 
O
OH
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.007 Valeric acid 
90 
OH
O
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.009 Hexanoic acid 
93 
O
OH  
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.010 Octanoic acid 
99 
OH
O
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.011 Decanoic acid 
105 
OH
O
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.012 Dodecanoic acid 
111 
OH
O
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.021 Benzoic acid 
850 
OH
O
 
 
No safety concern h) 
Deleted c) 
 
Class I 
A3: Intake below threshold 
Substances for which CoE Committee of 
Experts had no information as to real use in 
foodstuffs and/or for which insufficient 
technicological and/or toxicological 
information was available (CoE, 1992).  
08.040 4-Hydroxybenzoic acid 
957 
HO
O
OH
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake below threshold 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
08.043 Vanillic acid 
959 
O
HO
O
OH
 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.046 2-Methylbutyric acid 
255 
O
OH
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.071 p-Anisic acid 
883 
O
OH
O  
No safety concern d) 
 
 
Class I 
A3: Intake below threshold 
 
08.072 But-2-enoic acid (cis and 
trans) 
 
OH
O
(E)-isomer shown  
 
 
 
FGE.05 
Class I 
A3: Intake below threshold 
 
08.112 Salicylic acid 
958 
O
OH
OH
 
 
No safety concern d) 
 
 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (SCF, 1995). 
b) (JECFA, 1999b). 
c) (CoE, 1992). 
d) (JECFA, 2002b). 
e) (JECFA, 2000a). 
f) (JECFA, 2004a). 
g) (JECFA, 1997a). 
h) (JECFA, 2002c). 
ND: Not detected. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.010 Benzyl alcohol OH
 
2137 
58 
100-51-6 
25 
JECFA specification (JECFA, 
2001c) 
13000  
No safety concern a) 
Category A b) 
GrADI: 0-5 (JECFA, 
1997a). 
02.039 4-Isopropylbenzyl alcohol OH 2933 
88 
536-60-7 
864 
JECFA specification (JECFA, 
2001c) 
0.24  
No safety concern a) 
Category B b) 
 
02.128 p-Anisyl alcohol OH
O  
2099 
66 
105-13-5 
871 
JECFA specification (JECFA, 
2001c) 
130  
No safety concern a) 
Category A b) 
 
02.165 4-Hydroxybenzyl alcohol 
HO
OH 3987 
 
623-05-2 
955 
JECFA specification (JECFA, 
2002d) 
5.2  
No safety concern a) 
 
 
02.213 Vanillyl alcohol 
HO
O
OH
3737 
690 
498-00-0 
886 
JECFA specification (JECFA, 
2001c) 
5.4  
No safety concern a) 
Category A b) 
 
04.093 Butyl vanillyl ether 
HO
O
O 3796 
 
82654-98-6 
888 
JECFA specification (JECFA, 
2001c) 
1.4  
No safety concern a) 
 
 
04.094 Ethyl 4-hydroxy-3-
methoxybenzyl ether 
HO
O
O 3815 
 
13184-86-6 
887 
JECFA specification (JECFA, 
2001c) 
20  
No safety concern a) 
 
 
05.013 Benzaldehyde O
 
2127 
101 
100-52-7 
22 
JECFA specification (JECFA, 
2001c) 
7900  
No safety concern a) 
Category A b) 
ADI: 0-5 (JECFA, 
1997a). 
05.015 4-Methoxybenzaldehyde 
O
O 2670 
103 
123-11-5 
878 
JECFA specification (JECFA, 
2001c) 
370  
No safety concern a) 
Category A b) 
 
05.016 Piperonal 
O
O
O
 
2911 
104 
120-57-0 
896 
JECFA specification (JECFA, 
2001c) 
1500  
No safety concern a) 
Category A b) 
ADI: 0-2.5 (JECFA, 
1968). 
05.017 Veratraldehyde O
O
O
3109 
106 
120-14-9 
877 
JECFA specification (JECFA, 
2001c) 
120  
No safety concern a) 
Category A b) 
 
05.018 Vanillin 
HO
O
O 3107 
107 
121-33-5 
889 
JECFA specification (JECFA, 
2001c) 
47000  
No safety concern a) 
Category A b) 
ADI: 0-10 (JECFA, 
1968). 
05.019 Ethyl vanillin O
HO
O
2464 
108 
121-32-4 
893 
JECFA specification (JECFA, 
2001c) 
5400  
No safety concern a) 
Category A b) 
ADI: 0-3 (JECFA, 
1995). 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
05.022 4-Isopropylbenzaldehyde O 2341 
111 
122-03-2 
868 
JECFA specification (JECFA, 
2001c) 
110  
No safety concern a) 
Category B b) 
 
05.027 Tolualdehyde 
O
O
O
3068 
115 
1334-78-7 
866 
JECFA specification (JECFA, 
2002d) 
230  
No safety concern a) 
Category A b) 
CASrn does not specify 
position of methyl 
substituent, 
"Incompletely Defined 
Substance". 
Composition of mixture 
to be specified. 
05.047 4-Hydroxybenzaldehyde 
HO
O
 
3984 
558 
123-08-0 
956 
JECFA specification (JECFA, 
2002d) 
55  
No safety concern a) 
Category B b) 
 
05.055 Salicylaldehyde 
OH
O
 
3004 
605 
90-02-8 
897 
JECFA specification (JECFA, 
2001c) 
84  
No safety concern a) 
Category B b) 
 
05.056 4-Ethoxybenzaldehyde 
O
O 2413 
626 
10031-82-0 
879 
JECFA specification (JECFA, 
2001c) 
0.073  
No safety concern a) 
Category B b) 
 
05.068 4-Ethylbenzaldehyde O 3756 
705 
4748-78-1 
865 
JECFA specification (JECFA, 
2001c) 
0.37  
No safety concern a) 
Category A b) 
 
05.091 2-Hydroxy-4-
methylbenzaldehyde 
OH
O 3697 
2130 
698-27-1 
898 
JECFA specification (JECFA, 
2001c) 
0.61  
No safety concern a) 
Category B b) 
 
05.110 2,4-Dimethylbenzaldehyde 
O
3427 
 
15764-16-6 
869 
JECFA specification (JECFA, 
2001c) 
0.37  
No safety concern a) 
 
 
06.002 5-Hydroxy-2-phenyl-1,3-
dioxane 
O
O OH
O
O
OH
 
2129 
36 
1319-88-6 
838 
JECFA specification (JECFA, 
2001c) 
13  
No safety concern a) 
Category A b) 
CASrn refers to 
benzaldehyde glyceryl 
acetate. Stereoisomeric 
composition and 
composition of mixture 
to be specified. 
06.003 alpha,alpha-Dimethoxytoluene 
O
O 2128 
37 
1125-88-8 
837 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern a) 
Category A b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
06.012 Tolualdehyde glyceryl acetal 
O
O OH
O
O
OH
CH3 CH3  
3067 
46 
1333-09-1 
867 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
Category A b) 
CASrn refers to named 
substance. 
Stereoisomeric 
composition and 
composition of mixture 
to be specified. 
06.019 1-Benzyloxy-1-(2-
methoxyethoxy)ethane 
O
O
O
 
2148 
523 
7492-39-9 
840 
JECFA specification (JECFA, 
2001c) 
1.2  
No safety concern a) 
Category B b) 
CASrn refers to the 
racemate, according to 
JECFA: Min. assay 
value is "98 (sum of 
named compound and 
starting materials)", 
composition of mixture 
to be specified. 
06.032 4-Methyl-2-phenyl-1,3-
dioxolane 
O
O
2130 
2226 
2568-25-4 
839 
JECFA specification (JECFA, 
2001c) 
0.037  
No safety concern a) 
Category A b) 
Stereoisomeric 
composition to be 
specified. 
06.132 Vanillin butan-2,3-diol acetal 
(mixture of stereo isomers) 
O
O
HO
O
4023 
 
63253-24-7 
960 
JECFA specification (JECFA, 
2002d) 
3.4  
No safety concern a) 
 
CASrn does not specify 
stereoisomers, 
stereoisomeric 
composition to be 
specified. 
08.021 Benzoic acid 
OH
O
 
2131 
21 
65-85-0 
850 
JECFA specification (JECFA, 
2001c) 
34  
No safety concern c) 
Deleted b) 
GrADI: 0-5 (JECFA, 
1997a). 
08.040 4-Hydroxybenzoic acid 
HO
O
OH
3986 
693 
99-96-7 
957 
JECFA specification (JECFA, 
2002d) 
16  
No safety concern a) 
Category A b) 
 
08.043 Vanillic acid 
O
HO
O
OH
3988 
697 
121-34-6 
959 
JECFA specification (JECFA, 
2002d) 
24  
No safety concern a) 
Category A b) 
 
08.071 p-Anisic acid 
O
OH
O 3945 
10077 
100-09-4 
883 
JECFA specification (JECFA, 
2001c) 
1.7  
No safety concern a) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
08.076 2,4-Dihydroxybenzoic acid 
HO
OH O
OH
3798 
 
89-86-1 
908 
JECFA specification (JECFA, 
2001c) 
5.5  
No safety concern a) 
 
 
08.092 3-Methoxybenzoic acid 
O
OH
O
 
3944 
 
586-38-9 
882 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
08.112 Salicylic acid O
OH
OH
 
3985 
10165 
69-72-7 
958 
JECFA specification (JECFA, 
2002d) 
0.024  
No safety concern a) 
 
 
09.014 Benzyl acetate 
O
O 2135 
204 
140-11-4 
23 
JECFA specification (JECFA, 
2001c) 
1200  
No safety concern a) 
Category B b) 
GrADI: 0-5 (JECFA, 
1997a). 
09.019 p-Anisyl acetate 
O
O
O 2098 
209 
104-21-2 
873 
JECFA specification (JECFA, 
2001c) 
50  
No safety concern a) 
Category B b) 
 
09.035 Vanillyl acetate O
O
O
O 3108 
225 
881-68-5 
890 
JECFA specification (JECFA, 
2001c) 
1.8  
No safety concern a) 
Category B b) 
 
09.051 Benzyl butyrate 
O
O 2140 
277 
103-37-7 
843 
JECFA specification (JECFA, 
2001c) 
100  
No safety concern a) 
Category A b) 
 
09.058 p-Anisyl butyrate 
O
O
O 2100 
286 
6963-56-0 
875 
JECFA specification (JECFA, 
2001c) 
29  
No safety concern a) 
Category B b) 
 
09.077 Benzyl formate 
O
O 2145 
344 
104-57-4 
841 
JECFA specification (JECFA, 
2001c) 
35  
No safety concern a) 
Category A b) 
 
09.087 p-Anisyl formate 
O
O
O 2101 
354 
122-91-8 
872 
JECFA specification (JECFA, 
2002d) 
39  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.132 Benzyl propionate 
O
O 2150 
413 
122-63-4 
842 
JECFA specification (JECFA, 
2001c) 
41  
No safety concern a) 
Category A b) 
 
09.145 p-Anisyl propionate 
O
O
O 2102 
426 
7549-33-9 
874 
JECFA specification (JECFA, 
2001c) 
0.42  
No safety concern a) 
Category B b) 
 
09.220 Piperonyl acetate 
O
O
O
O 2912 
2068 
326-61-4 
894 
JECFA specification (JECFA, 
2001c) 
34  
No safety concern a) 
Category B b) 
 
09.406 Benzyl 3-oxobutyrate 
O
O O 2136 
244 
5396-89-4 
848 
JECFA specification (JECFA, 
2001c) 
0.24  
No safety concern a) 
Category B b) 
 
09.426 Benzyl isobutyrate 
O
O 2141 
301 
103-28-6 
844 
JECFA specification (JECFA, 
2001c) 
13  
No safety concern a) 
Category B b) 
 
09.430 Piperonyl isobutyrate 
O
O
O
O 2913 
305 
5461-08-5 
895 
JECFA specification (JECFA, 
2001c) 
0.085  
No safety concern a) 
Category B b) 
 
09.458 Benzyl isovalerate 
O
O 2152 
453 
103-38-8 
845 
JECFA specification (JECFA, 
2001c) 
12  
No safety concern a) 
Category B b) 
 
09.494 Benzyl 2-methylcrotonate 
O
O 3330 
2184 
37526-88-8 
846 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
Category B b) 
 
09.508 Benzyl 2,3-dimethylcrotonate 
O
O 2143 
11868 
7492-69-5 
847 
JECFA specification (JECFA, 
2002d) 
0.012  
No safety concern a) 
 
 
09.705 Benzyl phenylacetate 
O
O 2149 
232 
102-16-9 
849 
JECFA specification (JECFA, 
2001c) 
4.3  
No safety concern a) 
Category B b) 
 
09.706 Anisyl phenylacetate 
O
O
O 3740 
233 
102-17-0 
876 
JECFA specification (JECFA, 
2001c) 
0.0024  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.713 Methyl 4-methoxybenzoate 
O
O
O 2679 
248 
121-98-2 
884 
JECFA specification (JECFA, 
2001c) 
0.97  
No safety concern a) 
Category B b) 
 
09.714 Ethyl 4-methoxybenzoate 
O
O
O
2420 
249 
94-30-4 
885 
JECFA specification (JECFA, 
2001c) 
9.1  
No safety concern a) 
Category B b) 
 
09.725 Methyl benzoate 
O
O 2683 
260 
93-58-3 
851 
JECFA specification (JECFA, 
2001c) 
40  
No safety concern a) 
Category B b) 
 
09.726 Ethyl benzoate 
O
O 2422 
261 
93-89-0 
852 
JECFA specification (JECFA, 
2001c) 
96  
No safety concern a) 
Category B b) 
 
09.727 Benzyl benzoate 
O
O 2138 
262 
120-51-4 
24 
JECFA specification (JECFA, 
2001c) 
1600  
No safety concern a) 
Category A b) 
GrADI: 0-5 (JECFA, 
1980a). 
09.748 Ethyl salicylate OH O
O
2458 
432 
118-61-6 
900 
JECFA specification (JECFA, 
2001c) 
27  
No safety concern a) 
Category B b) 
 
09.749 Methyl salicylate OH O
O
2745 
433 
119-36-8 
899 
JECFA specification (JECFA, 
2001c) 
410  
No safety concern a) 
Category A b) 
ADI: 0-0.5 (JECFA, 
1968). 
09.750 Isobutyl salicylate 
OH
O
O
2213 
434 
87-19-4 
902 
JECFA specification (JECFA, 
2001c) 
0.97  
No safety concern a) 
Category B b) 
 
09.751 Isopentyl salicylate 
OH
O
O
2084 
435 
87-20-7 
903 
JECFA specification (JECFA, 
2001c) 
41  
No safety concern a) 
Category B b) 
Composition of 
positional isomers to be 
identified. 
09.752 Benzyl salicylate 
OH
O
O
2151 
436 
118-58-1 
904 
JECFA specification (JECFA, 
2001c) 
26  
No safety concern a) 
Category B b) 
 
09.753 Phenethyl salicylate OH
O
O 2868 
437 
87-22-9 
905 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.754 Butyl 4-hydroxybenzoate 
HO
O
O
2203 
525 
94-26-8 
870 
JECFA specification (JECFA, 
2002d) 
ND  
No safety concern c) 
Deleted b) 
 
09.755 Isopentyl benzoate 
O
O 2058 
562 
94-46-2 
857 
JECFA specification (JECFA, 
2001c) 
96  
No safety concern a) 
Category B b) 
Composition of mixture 
to be specified. 
09.757 Isobutyl benzoate 
O
O 2185 
567 
120-50-3 
856 
JECFA specification (JECFA, 
2001c) 
0.37  
No safety concern a) 
Category B b) 
 
09.763 Butyl salicylate 
OH
O
O
3650 
614 
2052-14-4 
901 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
Category B b) 
 
09.768 Hexyl benzoate O
O
3691 
645 
6789-88-4 
854 
JECFA specification (JECFA, 
2001c) 
320  
No safety concern a) 
Category B b) 
 
09.770 Isopropyl benzoate 
O
O 2932 
652 
939-48-0 
855 
JECFA specification (JECFA, 
2001c) 
0.0037  
No safety concern a) 
Category B b) 
 
09.776 Propyl benzoate 
O
O 2931 
677 
2315-68-6 
853 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
Category B b) 
 
09.796 Methyl 2-methoxybenzoate O
O
O 2717 
2192 
606-45-1 
880 
JECFA specification (JECFA, 
2001c) 
49  
No safety concern a) 
Deleted b) 
 
09.803 Propylene glycol dibenzoate O
O
O
O
 
3419 
10890 
19224-26-1 
862 
JECFA specification (JECFA, 
2002d) 
13  
No safety concern c) 
 
CASrn refers to the 
racemate 
Stereoisomeric 
composition to be 
specified. 
09.806 Hex-3-enyl benzoate 
O
O
(Z)-isomer shown  
3688 
11778 
25152-85-6 
858 
JECFA specification (JECFA, 
2001c) 
6.7  
No safety concern a) 
 
CASrn refers to (Z)-
isomer 
Stereoisomeric 
composition and 
composition of mixture 
to be specified. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.807 o-Tolyl salicylate OH O
O
3734 
 
617-01-6 
907 
JECFA specification (JECFA, 
2001c) 
28  
No safety concern a) 
 
 
09.811 Vanillin isobutyrate O
O
O
O 3754 
 
20665-85-4 
891 
JECFA specification (JECFA, 
2001c) 
55  
No safety concern a) 
 
 
09.812 Glyceryl tribenzoate 
O
O
O
O
O
O
3398 
10656 
614-33-5 
861 
JECFA specification (JECFA, 
2002d) 
45  
No safety concern c) 
 
 
09.933 Ethyl vanillin isobutyrate 
O
O
O
O
3837 
 
188417-26-7 
953 
JECFA specification (JECFA, 
2001c)  
0.61  
No safety concern a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2002b). 
b) (CoE, 1992). 
c) (JECFA, 2002c). 
ND) No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products9 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous10 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
9 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
10 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the 41 candidate substances in the 
present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.20 (EFFA, 2003u; 
EFFA, 2004c; EFFA, 2007a; EFFA, 2007d; Flavour Industry, 2008c) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.164 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.205 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
05.066 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.129 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
5 
25 
2 
10 
- 
- 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
5 
25 
5 
25 
2 
10 
05.142 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.153 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.158 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.221 10 
40 
15 
20 
10 
20 
- 
- 
- 
- 
10 
20 
- 
- 
30 
50 
- 
- 
- 
- 
- 
- 
- 
- 
10 
30 
- 
- 
5 
15 
15 
30 
30 
50 
10 
20 
06.017 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.20 (EFFA, 2003u; 
EFFA, 2004c; EFFA, 2007a; EFFA, 2007d; Flavour Industry, 2008c) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
06.104 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
08.080 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
08.087 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.132 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
500 
2000 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
300 
500 
300 
500 
- 
- 
- 
- 
08.133 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
500 
2000 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
300 
500 
300 
500 
- 
- 
- 
- 
09.152 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.313 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.314 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.315 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.316 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.317 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.318 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.362 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.363 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.367 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.560 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.570 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.581 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.611 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.623 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.631 7 
34 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.656 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.693 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
20 
100 
5 
25 
10 
50 
- 
- 
5 
25 
09.696 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.762 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.779 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
11 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.798 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.799 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.825 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
- 
- 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.835 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.852 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.895 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the 41 flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2003u; EFFA, 2004c; EFFA, 
2007a; EFFA, 2007d; Flavour Industry, 2008c). The mTAMDI values are only given for the highest reported 
normal use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.164 4-Hydroxy-3,5-dimethoxybenzyl alcohol 3900 Class I 1800 
05.129 2-Methoxybenzaldehyde 1400 Class I 1800 
05.142 3,4-Dihydroxybenzaldehyde 1600 Class I 1800 
05.153 4-Hydroxy-3,5-dimethoxybenzaldehyde 1600 Class I 1800 
05.158 3-Methoxybenzaldehyde 1600 Class I 1800 
06.017 (Diethoxymethyl)benzene 3900 Class I 1800 
08.080 Gallic acid 1600 Class I 1800 
08.087 4-Hydroxy-3,5-dimethoxybenzoic acid 3200 Class I 1800 
08.132 3-Hydroxybenzoic acid 120000 Class I 1800 
08.133 3,4-Dihydroxybenzoic acid 120000 Class I 1800 
09.152 Benzyl valerate 3900 Class I 1800 
09.313 Benzyl 2-methylbutyrate 3900 Class I 1800 
09.314 Benzyl crotonate 3900 Class I 1800 
09.315 Benzyl dodecanoate 3900 Class I 1800 
09.316 Benzyl hexanoate 3900 Class I 1800 
09.317 Benzyl lactate 3900 Class I 1800 
09.318 Benzyl octanoate 3900 Class I 1800 
09.362 Ethyl 2-hydroxy-4-methylbenzoate 3900 Class I 1800 
09.363 Ethyl 2-methoxybenzoate 3900 Class I 1800 
09.367 Ethyl 4-hydroxybenzoate 3900 Class I 1800 
09.560 Hex-3(cis)-enyl anisate 3900 Class I 1800 
09.570 Hex-3-enyl salicylate 3900 Class I 1800 
09.581 Hexyl salicylate 3900 Class I 1800 
09.611 4-Isopropylbenzyl acetate 3900 Class I 1800 
09.623 Methyl 2,4-dihydroxy-3,6-dimethylbenzoate 3900 Class I 1800 
09.631 Methyl 4-methylbenzoate 3900 Class I 1800 
09.656 3-Methylbut-3-enyl benzoate 3900 Class I 1800 
09.693 Prenyl benzoate 4900 Class I 1800 
09.696 Prenyl salicylate 3900 Class I 1800 
09.762 Pentyl salicylate 3900 Class I 1800 
09.779 Butyl benzoate 3900 Class I 1800 
09.798 Ethyl vanillate 3900 Class I 1800 
09.799 Methyl vanillate 3900 Class I 1800 
09.825 Pentyl benzoate 3900 Class I 1800 
09.835 Benzyl decanoate 3900 Class I 1800 
09.852 2-Methylbutyl 2-hydroxybenzoate 3900 Class I 1800 
09.895 4-Methoxybenzyl-2-methylpropionate 3900 Class I 1800 
02.205 Piperonyl alcohol 3900 Class II 540 
05.066 4-Ethoxy-3-methoxybenzaldehyde 1600 Class II 540 
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TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
05.221 6,6'-Dihydroxy-5,5'-dimethoxy-biphenyl-3,3'-dicarbaldehyde 7000 Class II 540 
06.104 Vanillin propylene glycol acetal 3900 Class II 540 
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ANNEX III: METABOLISM 
III.1. Introduction 
The flavouring group consists of 41 substances out of which 15 are benzyl derivatives (subgroup 1) and 25 
are hydroxy- and alkoxy-substituted benzyl derivatives (subgroup 2) and 1 hydroxy- and alkoxy- substituted 
biphenyl derivative (subgroup 3). 
Subgroup 1 (benzyl derivatives) includes 14 alkyl esters of which eight contain benzyl alcohol in the alcohol 
moiety and straight or branched carboxylic acids as acid moiety [FL-no: 09.313 (benzyl 2-methylbutyrate; 
09.314 (benzyl crotonate); 09.315 (benzyl dodecanoate); 09.316 (benzyl hexanoate); 09.317 (benzyl lactate); 
09.318 (benzyl octanoate); 09.152 (benzyl valerate); 09.835 (benzyl decanoate)]. One of the esters contains 
isopropylbenzyl alcohol as alcohol moiety [FL-no: 09.611 (4-isopropylbenzyl acetate)]. Five of the esters 
contain benzoic acid in the acid moiety [FL-no: 09.631 (methyl 4-methylbenzoate); 09.656 (3-methylbut-3-
enyl benzoate); 09.693 (prenyl benzoate); 09.779 (butyl benzoate); 09.825 (pentyl benzoate)]. 
One substance in subgroup 1 is an acetal [FL-no: 06.017 ((diethoxymethyl)benzene)]. 
Two of the substances in subgroup 1 contain an alkyl substituent on the aromatic ring [FL-no: 09.611 (4-
isopropylbenzyl acetate); 09.631 (methyl 4-methylbenzoate)]. Three compounds contain a double bond in an 
alkyl chain [FL-no: 09.314 (benzyl crotonate); 09.656 (3-methylbut-3-enyl benzoate; 09.693 (prenyl 
benzoate)].  
Subgroup 2 (hydroxy- and alkoxy-substituted benzyl derivatives) includes two derivatives of benzyl alcohol 
[FL-no: 02.164 (4-hydroxy-3,5-dimethoxybenzyl alcohol) and 02.205 (piperonyl alcohol; 3,4-
methylenedioxybenzyl alcohol]. Piperonyl alcohol may also be considered as a cyclic acetal. 
Six substances are derivatives of benzaldehyde [FL-no: 05.066 (4-ethoxy-3-methoxybenzaldehyde); 05.129 
(2-methoxybenzaldehyde); 05.142 (3,4-dihydroxybenzaldehyde); 05.153 (4-hydroxy-3,5-
dimethoxybenzaldehyde); 05.158 (3-methoxybenzaldehyde) and 06.104 (vanillin propylene glycol acetal]. 
Four are derivatives of benzoic acid [FL-no: 08.080 (gallic acid; 3,4,5-trihydroxybenzoic acid); 08.087 (4-
hydroxy-3,5-dimethoxybenzoic acid); 08.132 (3-hydroxybenzoic acid) and 08.133 (3,4-dihydroxybenzoic 
acid)]. 
The remaining 13 substances are esters of which one is an ester with alkoxy substituted benzyl alcohol as the 
alcohol moiety [FL-no: 09.895 (4-methoxybenzyl-2-methylpropionate)] and 12 are esters with substituted 
benzoic acid as the acid moiety [FL-no: 09.362 (ethyl 2-hydroxy-4-methylbenzoate); 09.363 (ethyl 2-
methoxybenzoate); 09.367 (ethyl 4-hydroxybenzoate); 09.560 (hex-3(cis)-enyl anisate; hex-3(cis)-enyl-4-
methoxybenzoate); 09.570 (hex-3-enyl salicylate; hex-3-enyl 2-hydroxybenzoate); 09.581 (hexyl salicylate; 
hexyl 2-hydroxybenzoate); 09.623 (methyl 2,4-dihydroxy-3,6-dimethylbenzoate); 09.696 (prenyl salicylate; 
3-methyl-but-2-enyl 2-hydroxybenzoate); 09.762 (pentyl salicylate; pentyl 2-hydroxybenzoate); 09.798 
(ethyl vanillate; ethyl 3-methoxy-4-hydroxybenzoate); 09.799 (methyl vanillate; methyl 3-methoxy-4-
hydroxybenzoate); 09.852 (2-methylbutyl 2-hydroxybenzoate; 2-methylbutyl salicylate)]. 
Three of the esters in subgroup 2 contain a double bond in an alkyl chain [FL-no: 09.560 (hex-3(cis)-enyl 
anisate); 09.570 (hex-3-enyl salicylate; 09.696 (prenyl salicylate)]. 
Subgroup 3 (biphenyl) contains one derivative of biphenyl [FL-no: 05.221 (6,6’-dihydroxy-5,5’dimethoxy-
biphenyl-3,3’-dicarbaldehyde)]. 
Flavouring Group Evaluation 20, Revision 3 
 
 
51 EFSA Journal 2011; 9(7):2176 
 
III.2. Absorption, Distribution and Elimination 
Subgroup 1 (benzyl derivatives) 
Candidate substances from subgroup 1 
There are no studies submitted on the candidate substances from subgroup 1. 
Supporting substances from subgroup 1 
Several studies have been submitted demonstrating efficient absorption, metabolism and excretion of the 
supporting substances benzyl alcohol [FL-no: 02.010], benzaldehyde [FL-no: 05.013], benzoic acid [FL-no: 
08.021], and benzyl acetate [FL-no: 09.014].  
Benzyl alcohol [FL-no: 02.010] 
Similar intravenous doses (range 0.036 to 0.222 micromole/kg bw) of benzyl alcohol were given via 
medications to 14 term and nine pre-term infants, in order to estimate plasma levels of benzoic and hippuric 
acids. The mean peak concentrations of benzoic acid in the plasma of pre-term babies were almost 10 times 
higher than in full-term newborns. In the urine of pre-term infants a larger proportion of benzyl alcohol was 
found as benzoic acid and a smaller proportion as hippuric acid than in full-term infants (% of dose excreted 
in urine in 24 hours: pre-term: benzoic acid 75 %, hippuric acid 64 %; full-term: benzoic acid 38 %, hippuric 
acid 82 %). The results suggest that humans metabolise benzyl alcohol to both benzoic acid and hippuric 
acid but hippuric acid formation is deficient in pre-term newborns (LeBel et al., 1988). 
Five minutes after single intraperitoneal doses of 500 - 1100 mg/kg bw of benzyl alcohol administered to 
CD1 mice, benzyl alcohol was detected in plasma (McCloskey et al., 1986). 
Benzaldehyde [FL-no: 05.013] 
In the rabbit, approximately 83 % of single oral doses of 350 or 750 mg/kg bw given orally of benzaldehyde 
was absorbed, since it was found in the urine of both dose groups. The aldehyde was oxidised mainly to 
benzoic acid and excreted predominantly as hippuric acid (approximately 68 %). Other urinary metabolites 
detected were benzoylglucuronic acid (10 %), benzoyl glucuronide (3 %), free benzoic acid (1.5 %) and trace 
amounts of benzyl mercapturic acid (Laham et al., 1988). 
Benzoic acid [FL-no: 08.021] 
Following administration of 375 mg [carboxyl-14C]-benzoic acid/kg bw to rats (orally) and mice 
intraperitonelly (i.p.), 88 - 89 % of the radioactivity was recovered in the urine of rats within 24 hours with 
91 - 94 % recovery after 72 hours, and only 1 - 6 % was present in the faeces. In mice, 92 - 98 % of the 
radioactivity was recovered in the urine of rats within 24 hours and only 1 - 10 % was present in the faeces. 
It was possible to conclude that after both route of administration more than 95 % of benzoic acid is 
absorbed, metabolised and rapidly excreted. The following metabolites were identified: hippuric acid (70.2 - 
84.2 %), benzoyl glucuronide (0.7 - 1.8 %), benzoic acid (0.4 - 12.8 %) and 3-hydroxy-3-phenyl propionic 
acid (0.1 - 0.2 %) (Nutley, 1990).  
Benzyl acetate [FL-no: 09.014] 
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A study on benzyl acetate metabolism in male Fischer 344 rats and male B6C3F1 mice was performed. Ring-
labelled 14C-benzyl acetate was used for single dose studies and unlabelled benzyl acetate was used for 
repeated dose studies. For intravenous administration of single doses three rats were injected with 5 mg 14C-
benzyl acetate in the tail vein and three mice were similarly injected with 10 mg. For the single oral dose 
study, groups of three rats were given  5, 50 or 500 mg/kg bw and groups of three mice were given 10, 100 
or 1000 mg/kg bw in corn oil by gavage. For the repeated dose studies, three rats and three mice were given 
unlabelled benzyl acetate in corn oil by gavage at 500 or 1000 mg/kg bw, respectively, once a day, 5 days a 
week for 2 weeks. Metabolites in urine were determined by High Performance Liquid Chromatography 
(HPLC). After administration of the radioactive compound, rats and mice were housed in metabolism cages 
and urine and faeces were collected during 24 hours. After intravenous administration CO2 and volatiles 
were collected.  
Benzyl acetate was rapidly and almost completely absorbed, based on the high recovery of radioactivity 
(nearly 90 % of the dose) in the urine in 24 hours, following both intravenous or oral dosing in rats and mice. 
Little radioactivity (0.3 - 1.3 % of the dose) was recovered in the faeces. Elimination as CO2 or volatiles was 
minimal following intravenous administration and was not determined after oral dosing. This clearance 
pattern was not affected by repeated oral dosing, indicating no potential for bioacumulation, as supported 
also by the absence of radioactivity in tissues analysed at 24 hours after dosing. The major metabolite of 
benzyl acetate in the urine of rats and mice was hippuric acid, accounting for more than 90 % of the total 
metabolites excreted in urine of all dose groups. Mercapturic acid was detected as a minor metabolite in the 
urine of rats and mice (less than 1 %), but was not found in all dose groups and not in all animals of the dose 
groups where it was detected. Small amounts of unidentified metabolites were also present. The absorption, 
routes of metabolism and excretion of benzyl acetate were apparently unaffected by the size or number of 
doses administered in the metabolism study. There was no evidence to indicate a reduction or saturation of 
the metabolic capacity in tested animals in the tested dose range (Abdo et al., 1985). 
Subgroup 2 (hydroxy- and alkoxy-substituted benzyl derivatives) 
Candidate substances from subgroup 2  
Piperonyl alcohol (1-hydroxymethyl-3,4-methylenedioxybenzene) [FL-no: 02.205] 
In a study of several methylenedioxyphenyl (MDP) compounds, male Swiss-Webster mice were 
administered a dimethyl sulphoxide (DMSO) solution of radiolabelled piperonyl alcohol (1-hydroxymethyl-
3,4-methylene-14C-dioxybenzene) by oral gavage at a dose of 0.76 mg/kg bw. Total radiocarbon 
determinations were made on expired 14CO2 at 0.5, 1, 2, 4 and 6 hours after dosing and at each six-hours 
interval thereafter; on urine and faeces samples taken at 12, 24 and 48 hours after treatment; on selected 
organs removed from the animals and the remaining carcass at 48 hours after treatment. Only the 12-hours 
samples were used for separation and characterisation of metabolites. Forty-eight hours after treatment, the 
distribution of radioactivity was as follows (averages of four experiments): CO2, 3.0 %; urine, 93.3 %; 
faeces, 8.5 %; intestine, 0.2 %; liver, 0.1 %; and carcass, 0.3 %. These data indicate that piperonyl alcohol is 
almost completely absorbed in the gastrointestinal (GI) tract, then metabolised and rapidly and almost 
completely excreted, mostly via the urine. Less than 10 % was excreted in the faeces. In all cases, the major 
metabolite was the glycine conjugate of piperonylic acid. Free piperonylic acid was not detected. Minor 
amounts of two unidentified metabolites were also present (Klungsoeyr and Scheline, 1984). 
Gallic acid (3,4,5-trihydroxybenzoic acid [FL-no: 08.080] 
Gallic acid [FL-no: 08.080] was given orally to six week old male Wistar rats in order to determine the 
metabolic fate of the substance. After oral administration of 100 mg/kg bw, gallic acid was absorbed fairly 
quickly and reached the maximum concentration at 15 minutes in portal blood. The concentration was halved 
by 30 minutes and gallic acid had almost disappeared after six hours. The metabolite 4-O-methyl gallic acid 
also reached peak values within 15 minutes, and then decreased slowly. In the inferior vena cava, gallic acid 
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and its metabolite were detected in approximately equal proportions and both reached peak values at 30 
minutes after oral administration and decreased gradually until six hours after administration. The main 
metabolite in urine was 4-O-methyl gallic acid, but unchanged gallic acid was also found in urine. The ratio 
of 4-O-methyl gallic acid to total gallic acid metabolites in urine ranged from 0.55 to 0.76, indicating that a 
significant amount of gallic acid was excreted without being metabolised (Zong et al., 1999). 
Ethyl 4-hydroxybenzoate (ethyl paraben) [FL-no: 09.367] 
Ethyl paraben [FL-no: 09.367] was given orally in capsules at a dose of 1 g/kg bw to groups of three fasted 
dogs and blood and urine were analysed at frequent predetermined intervals until 48 hours after dosing. 
Metabolites were detectable in the blood up to 24 hours post-ingestion. Recovery as urine metabolites was 66 
% of the administered dose at 48 hours. Dogs were also administered a 100 mg/kg bw dose of ethyl paraben 
intravenously and then killed to determine the distribution of the parent material and its metabolites. The 
ester was detected only in the brain and pancreas, whereas high concentrations of metabolites were detected 
in the liver and kidneys (Jones et al., 1956). 
Absorption, distribution, metabolism and excretion of ethylparaben [FL-no: 09.367] were investigated in 
Wistar rats administered 100 mg by oral gavage. Animals were held in metabolism cages for the collection of 
urine (at approximately 15, 30, 60, 75, 90, 120, 150 and 210 minutes) and blood (at approximately 30, 60, 
90, 120, 180, 240 and 360 minutes), and samples were analysed to establish the excretion kinetics. 
Metabolites were detected in the urine starting at 30 minutes after dosing, and their concentration increased 
steadily during the next three to six hours. Absorption of ethylparaben was followed by metabolism and 
excretion of mainly free 4-hydroxybenzoic acid and its glucuronic and glycine conjugates. A small portion of 
the dose was excreted as sulphate conjugate (Derache and Gourdon, 1963). 
14C-labelled ethyl 4-hydroxybenzoate was orally given to four male cats in the diet at a single dose of 156 
mg/kg bw. Essentially all (mean = 96.0 %) of the radioactiviy was excreted in urine within 72 hours as p-
hydroxyhippuric acid and 4-hydroxybenzoic acid (Phillips et al., 1978). 
Supporting substances from subgroup 2 
3,4-Methylenedioxybenzaldehyde (piperonal) [FL-no: 05.016] 
In male rats a 150 mg/kg bw dose of piperonal in propylene glycol was administered by gavage. Urine 
samples were collected at 24 and 48 hours. Recovery of urine metabolites made up 90 % of the given dose, 
and metabolite excretion occurred mainly within 24 hours. No unchanged compound was detected in the 
urine (Klungsoeyr and Scheline, 1984). 
Veratraldehyde (3,4-dimethoxybenzaldehyde) [FL-no: 05.017] 
A 1 g/kg bw oral dose of veratraldehyde was administered to rabbits by gavage and urine was collected for 
24 hours. At least approximately 70 % of the aldehyde was absorbed as it was present in the urine mainly as 
the corresponding acid and its conjugates (Scheline, 1972). 
Vanillin (4-hydroxy-3-methoxybenzaldehyde) [FL-no: 05.018] 
Oral dosage of 100 mg/kg bw of vanillin to male albino rats resulted in an urinary excretion of most 
metabolites within 24 hours, mainly as glucuronide and sulphate conjugates, although vanillic acid was also 
excreted as free acid and as glycine conjugate. After 48 hours 94 % of the dose was excreted as different 
metabolites (Strand and Sheline, 1975). 
A 100 mg dose of vanillin dissolved in water was given to an adult human and the urine was collected for 24 
hours. During this period an increase, from a background level, in the vanillic acid output in the urine level 
was measured, accounting for approximately 94% of the vanillin dose (Dirscherl and Wirtzfeld, 1964). 
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4-Hydroxybenzoic acid [FL-no: 08.040] 
Groups of four to eight rabbits were administered 100, 250, 500, 1000 or 1500 mg 4-hydroxybenzoic acid/kg 
bw by gavage. Urine was collected continuously and analysed for metabolites. Based on the total urinary 
recovery of the test material (84 to 104 %) the compound was almost completely absorbed, metabolised and 
excreted (Bray et al., 1947). 
Concluding remarks on absorption, distribution and excretion 
The results of these studies indicate that the benzyl derivatives in subgroup 1 as well as the hydroxy- and 
alkoxy-substituted benzyl derivatives in subgroup 2 are expected to be rapidly absorbed, metabolised and 
excreted mainly in the urine. 
III.3. Metabolism 
III.3.1. Hydrolysis of Esters and Acetals 
In general, esters containing an aromatic ring system are expected to be hydrolysed in vivo to the component 
acid and alcohol through the catalytic activity of carboxylesterases or esterases. In mammals, esterases occur 
in most tissues throughout the body but predominate in the hepatocytes (Heymann, 1980). 
Subgroup 1 (benzyl derivatives) 
Candidate substances from subgroup 1  
There are no studies submitted on the candidate substances from subgroup 1. 
Supporting substances from subgroup 1 
Benzyl acetate [FL-no: 09.014] 
Neat benzyl acetate was spiked into control rat plasma (1 microlitre/0.5 ml), vortexed and incubated at room 
temperature for 0.5 – 36 minutes. Incubation was terminated by addition of acetonitrile. The plasma was 
centrifuged to precipitate plasma proteins and the clear plasma was analysed by (High Performance Liquid 
Chromatography) HPLC to determine benzyl acetate and benzyl alcohol. Benzyl acetate was found to be 
rapidly hydrolysed to benzyl alcohol. The half-life of benzyl acetate was about 4 minutes and 24 minutes 
after spiking virtually all benzyl acetate was hydrolysed to benzyl alcohol. Hydrolysis was partially inhibited 
by the esterase inhibitor sodium fluoride, which suggests that plasma esterases contribute to the rapid 
hydrolysis. When benzyl acetate was administered to rats and mice in gavage and dosed feed studies, benzyl 
acetate was not detected in any plasma samples collected (Yuan et al., 1995). 
In vivo metabolism studies in mice and rats clearly indicate that radiolabelled benzyl acetate is readily 
hydrolysed, since more than 90 % of the radioactivity is demonstrated in the urine as benzoic or hippuric 
acid (Abdo et al., 1985). 
Benzyl acetate was hydrolysed in pig liver homogenate. At pH 7.4 and 25° C the velocity was calculated to 
27 micromole/min/mg, Km 0.55 mM. (Greenzaid & Jenks, 1971 referred in (Heymann, 1980)).  
Alkyl- and aryl-benzoates 
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The plasma half-lives (t½) for the in vitro hydrolysis by plasma enzymes of a series of four alkyl benzoates 
(including supporting chemicals methyl benzoate [FL-no: 09.725], ethyl benzoate [FL-no: 09.726] and 
propyl benzoate [FL-no: 09.776]) and two aryl benzoates (including supporting substance benzyl benzoate 
[FL-no: 09.727]) in 80 % human blood plasma ranged from 24 to 210 minutes for the alkyl benzoates. By 
increasing chain length an increasing enzymatic degradation was seen, except when going from methyl to 
ethyl. The butyl ester was the least resistant (t½ 24 minutes), while the ethyl ester was the most resistant to 
hydrolysis (t½ 210 minutes). The plasma half-lives were 19 and 15 minutes for phenyl benzoate and benzyl 
benzoate, respectively (Nielsen and Bundgaard, 1987). 
An in vitro hydrolysis study demonstrated that benzyl phenylacetate was 100 % hydrolysed within two hours 
of incubation with a pancreatin solution, whereas the supporting substance benzylacetate [FL-no: 09.014] 
was only 50 % hydrolysed after 2 hours incubation. Benzyl cinnamate and methyl phenylacetate were 80 and 
70 % hydrolysed, respectively (Leegwater and Straten, 1974a). 
Other related substances:  
4-Methyl-2-phenyl-1,3-dioxolane (benzaldehyde propylene glycol acetal) 
Benzaldehyde-related acetals readily hydrolyse to their component alcohols and benzaldehyde under acidic 
conditions. Hydrolysis of acetals in simulated gastric juice (pH 1.2) and simulated intestinal fluid (pH 7.5) 
was monitored by the formation rate of aldehyde liberated during treatment. Data show that non-cyclic 
acetals are completely hydrolysed at pH 1.2 but that hardly any hydrolysis occurs at pH 7.5. Benzaldehyde–
propylene–glycol acetal (4-methyl-2-phenyl-1,3-dioxolane, MPD), a cyclic acetal, was hydrolysed to an 
extent of around 50 % after one hour in simulated gastric juice and no further hydrolysis was observed after 
five hours. Reflux of MPD for five hours in 0.1 N HCl also resulted in hydrolysis to an extent of 50 % of the 
theoretical maximum. Due to the same poor hydrolysis of MPD (to around 50 %) even after five hours reflux 
in 0.1 N HCl the author questioned the chemical identity of the substance (Morgareidge, 1962a). The result 
of this study on hydrolysis of a cyclic benzaldehyde acetal is inconclusive. 
Subgroup 2 (hydroxy- and alkoxy-substituted benzylderivatives) 
Candidate substances from subgroup 2  
Benzyl 2-methylbutyrate (benzyl 2-methylbutanoate) [FL-no: 09.313] 
Benzyl 2-methylbutyrate at a concentration of 40 microlitre/l (0.21 mM)was incubated in 0.5 M phosphate 
buffer at pH 7.5 and 37°C with a preparation of pancreatin for two hours. The extent of hydrolysis was 100 
% as determined by gas-liquid chromatography. The supporting substance benzyl acetate [FL-no: 09.014] at 
a concentration of 70 microlitre/l (0.49 mM) was 50 % hydrolysed after 2 hours (Grundschober, 1977). 
Ethyl 4-hydroxybenzoate (ethyl paraben) [FL-no: 09.367]  
An in vitro assay demonstrated that ethylparaben is efficiently hydrolysed by the liver and kidney esterases: 
96 % hydrolysis was measured after three minutes in dog liver tissue suspension and 100% hydrolysis after 
30 minutes in dog kidney suspension (Jones et al., 1956). 
Ethylparaben [FL-no: 09.367] was 80 % hydrolysed to free 4-hydroxybenzoic acid within 60 minutes in 
perfused mouse liver, only 2.3 % intact ester was recovered. Ethyl paraben was not detected in the blood of 
six humans 1-4½ hours after oral intake of 10 to 20 mg/kg bw. When given orally to dogs at doses between 
25 and 500 mg/kg bw, high serum concentrations of 4-hydroxybenzoic acid were reported and no ethyl 
paraben was detected in the blood except for the 500 mg/kg bw dose (Heim et al., 1957). 
Studies were conducted with methyl, ethyl [FL-no: 09.367], propyl and butyl 4-hydroxybenzoate [FL-no: 
09.754] (supporting substance) in dogs. The results showed significantly higher rates of test material 
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recovery in the urine of dogs dosed orally 1 g/kg bw orally or 50 mg/kg bw by the intravenously route for 
the methyl, ethyl and propyl esters (% of dose excreted within 48 hours, oral: 89.0 and 66.0 and 57.6%, 
respectively; i.v. 85, 70 and 94 %, respectively) as compared to the butyl ester (oral 48.2 %; i.v. 40.1 %). 
The methyl, ethyl and propyl esters showed 100 % hydrolysis within 3 minutes when incubated with liver 
homogenate, whereas the butyl ester was completely hydrolysed only after 30-60 minutes. This finding 
suggests that an increase in the alkyl chain length in the homologous series of alkyl esters make the esters 
more resistant to hydrolysis (Jones et al., 1956). 
Vanillin propylene glycol acetal [FL-no: 06.104] 
Under acidic conditions, pH 2.6, vanillin propylene glycol acetal [FL-no: 06.104] began to hydrolyse 
immediately with approximately 3 % of the acetal disappearing and 92 % hydrolysed within two hours. At 
pH 1.8, approximately 90 % of vanillin propylene glycol acetal hydrolysed immediately and 93 % 
hydrolysed within five minutes (Bennett, 1997). 
Supporting substances from subgroup 2 
Methyl-2-hydroxybenzoate (methyl salicylate) [FL-no: 09.749] 
An oral dose of methyl salicylate equivalent to 500 mg/kg bw of salicylic acid was dissolved in 2 % methyl 
cellulose and administered to male rats. The plasma levels measured within 20 minutes of dosing showed 
complete hydrolysis of methyl salicylate. A similar experiment was conducted with male dogs. Capsules 
containing 320 mg methyl salicylate/kg bw were given orally to three fasted dogs in five repeated 
experiments. Blood drawn 1 and 4 hours after dosing showed 95 % hydrolysis of methyl salicylate to 
salicylic acid at both time intervals. Six humans were given a 0.42 ml dose of methyl salicylate administered 
in ginger ale. Blood was drawn by venipuncture 15 and 90 minutes later. In contrast to the other two species 
an appreciable portion of unhydrolysed methyl salicylate was found, 39 % after 15 minutes and 21 % after 
90 minutes (Davison et al., 1961). 
Other related substances  
At low pH similar to that found in the stomach, a structurally related substance, vanillin 3-(l-
menthoxy)propane-1,2-diol acetal [FL-no: 02.248], is readily hydrolysed. In a hydrolysis study, 12-39 mM 
vanillin 3-l-menthoxypropane-1,2-diol acetal underwent 91 % hydrolysis at pH 2 within 45 minutes. At pH 
3, approximately 86 % of vanillin 3-l-menthoxypropane-1,2-diol acetal was hydrolysed within 90 minutes. 
At pH 4, approximately 92 % of the acetal was hydrolysed within eight hours. At pH 5, approximately 12 % 
of the flavouring substance was hydrolysed within eight hours (Reitz, 1995). 
Concluding remarks on hydrolysis 
There is some information about hydrolysis of esters in in vivo as well as in vitro systems for some 
supporting substances in subgroup 1 and for some supporting and candidate substances in subgroup 2.  
It is expected that esters in subgroup 1 and 2 will be hydrolysed in vivo. Eight of the candidate substances in 
subgroup 1 [FL-no: 09.313 (benzyl 2-methylbutyrate); 09.314 (benzyl crotonate); 09.315 (benzyl 
dodecanoate); 09.316 (benzyl hexanoate); 09.317 (benzyl lactate); 09.318 (benzyl octanoate); 09.152 (benzyl 
valerate); 09.835 (benzyl decanoate)] will yield benzyl alcohol and simple aliphatic carboxylic acids upon 
hydrolysis. One ester, 4-isopropylbenzyl acetate [FL-no: 09.611] will yield 4-isopropylbenzyl alcohol and 
acetic acid. 
The acetal in subgroup 1, (diethoxymethyl)benzene [FL-no: 06.017], is expected to be efficiently hydrolysed 
to yield benzaldehyde and ethanol.  
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Four of the remaining esters in subgroup 1 are expected to yield benzoic acid and simple aliphatic alcohols 
upon hydrolysis, [FL-no: 09.656 (3-methylbut-3-enyl benzoate), 09.693 (prenyl benzoate), 09.779 (butyl 
benzoate), 09.825 (pentyl benzoate)]. One ester, [FL-no: 09.631] (methyl 4-methylbenzoate), will yield 4-
methylbenzoic acid upon hydrolysis. The alcohol part of the candidate substance, [FL-no: 09.656] (3-
methylbut-3-enyl benzoate), includes a terminal double bond.  
Of the 13 esters in subgroup 2, one ester, [FL-no: 09.895 (4-methoxybenzyl-2-methylpropionate), will yield 
4-methoxybenzyl alcohol (p-anisyl alcohol) [FL-no: 02.128] upon hydrolysis. The remaining 12 esters in 
subgroup 2, [FL-no: 09.362 (ethyl 2-hydroxy-4-methylbenzoate), 09.363 (ethyl 2-methoxybenzoate), 09.367 
(ethyl 4-hydroxybenzoate), 09.560 (hex-3(cis)-enyl anisate, ((hex-3(cis)-enyl 4-methoxybenzoate)), 09.570 
(hex-3-enyl salicylate), 09.581 (hexyl salicylate), 09.623 (methyl 2,4-dihydroxy-3,6-dimethylbenzoate), 
09.696 (prenyl salicylate), 09.762 (pentyl salicylate), 09.798 (ethyl vanillate), 09.799 (methyl vanillate) and 
09.852 (2-methylbutyl 2-hydroxybenzoate)], will yield hydroxy and/or alkoxy-substituted benzoic acid upon 
hydrolysis.  
III.3.2  Metabolism Studies 
Subgroup 1 (benzyl derivatives) 
Candidate substances from subgroup 1 
There are no metabolism studies submitted for the candidate substances belonging to subgroup 1.   
Supporting substances from subgroup 1 
Benzyl alcohol [FL-no: 02.010] 
Five minutes after single intraperitoneal doses of 500 – 1100 mg/kg bw of benzyl alcohol administered to 
CD1 mice, benzyl alcohol was detected in plasma. At doses of 700 – 1100 mg/kg bw, plasma also contained 
measurable concentrations of benzaldehyde. Animals pre-treated with an alcohol dehydrogenase inhibitor 
(pyrazole) showed a 200 % increase in plasma benzyl alcohol levels, whereas pre-treatment with an aldehyde 
dehydrogenase inhibitor (disulphiram) resulted in a 368 % increase in plasma benzaldehyde levels as 
compared to control values (McCloskey et al., 1986). 
Benzaldehyde [FL-no: 05.013] 
The metabolism of benzaldehyde was investigated in Sprague Dawley rats (5/group/sex) which were 
administered single oral doses of 400, 750 or 1000 mg/kg bw of pure benzaldehyde by gavage once daily for 
13 consecutive days. Urine was collected for 24 hours after the 2nd, the 8th and the 13th dose and analysed for 
the presence of metabolites. The major metabolites were benzoic acid acid conjugates and benzylmercapturic 
acid.  Although females in the mid- and high-dose groups exhibited a slight decrease in excretion of 
benzylmercapturic acid after the 8th dose, all groups showed increased urinary levels after the 13th doses. An 
increase in dose from 400 to 1000 mg/kg bw/day resulted in a 7- to 8-fold increase in benzylmercapturic acid 
excretion. The amount of benzylmercapturic acid excreted in urine collected for 24 hours ranged between 
0.13-2.05 mg/rat, the higher amounts collected from the rats in the highest dose groups. Benzaldehyde is 
reduced to benzyl alcohol only to a minor extent; the alcohol sulphate conjugate may further react with 
glutathione to form benzyl mercapturic acid (Laham and Potvin, 1987). 
In the rabbits orally dosed with 350 or 750 mg/kg bw, the aldehyde was oxidised mainly to benzoic acid and 
excreted predominantly as hippuric acid (approximately 68 % of the administered dose). Other urinary 
metabolites detected were benzoylglucuronic acid (10 %), benzoyl glucuronide (3 %), free benzoic acid (1.5 
%), and trace amounts of benzylmercapturic acid (Laham et al., 1988). 
4-Isopropylbenzaldehyde (cuminaldehyde) [FL-no: 05.022] 
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High doses (2000 mg) of p-isopropylbenzaldehyde were given orally to male rabbits. Urine was collected for 
three days post-treatment. The yield of urinary oxidation metabolites was higher than that of reduction 
metabolites. This was in contrast to o-isopropylbenzaldehyde, the reduction of which was more extensive 
and the corresponding acids were not found. p-Isopropylbenzaldehyde mainly undergoes a combination of 
oxidation of the aldehyde function and the oxidation of the alkyl-side chain to yield 9-hydroxycuminic acid 
and 8-hydroxycuminic acid. Cumyl alcohol (cuminyl alcohol, 4-isopropylbenzyl alcohol) and 2-
carboxyphenylpropionic acid were minor urinary metabolites. It was concluded that oxidation or reduction 
was controlled by the position of substituents, in that oxidation occurs with the p-isomer and reduction 
occurs with the o-isomer. In addition, stereoselective oxidation was found in the aromatic isopropyl group of 
the p-isomer (Ishida et al., 1989b). 
Benzoic acid [FL-no: 08.021] 
Ring labelled 14C-benzoic acid was given orally at doses in the range of 1 – 400 mg/kg bw to various species 
including primates, pigs, rabbits, rodents, cats, dogs, hedgehogs, bats, birds and reptiles. Hippuric acid was 
the primary urinary metabolite in most species. The ornithine conjugate of benzoic acid, ornithic acid, was 
the major urinary metabolite excreted within 24 hours in chickens and reptiles. Benzoyl glucuronide was 
predominant in bats. In humans, more than 99 % of 14C was excreted as hippuric acid within 24 hours 
(Bridges et al., 1970). 
Following oral administration of 375 mg [14C]-benzoic acid/kg bw to rats, 91 – 94 % of the radioactivity was 
recovered in the urine of rats after 72 hours, whereas only 1 – 6 % was present in the faeces. The following 
metabolites were identified: hippuric acid (70.2 – 84.2 %), benzoyl glucuronide (0.7 – 1.8 %), benzoic acid 
(0.4 – 12.8 %) and 3-hydroxy-3-phenyl propionic acid (0.1 – 0.2 %) (Nutley, 1990). 
Urinary hippuric acid is used as a biologial marker of toluene exposure. In order to investigate the types and 
quantities of beverages that increase urinary hippuric acid excretion, 137 healthy students were recruited and 
divided into quintiles based on their consumption of non-alcoholic beverages containing benzoic acid. HPLC 
was used to determine benzoic acid intake from beverages and urinary hippuric acid before, and 1.5 and 3 
hours after consumption of various beverages. The range of benzoic acid in 13 beverages was 0 – 1.02 
mg/ml and the benzoic acid intakes from the beverages for groups 1 – 5, respectively, were: 0.4 mg ± 0.5; 
23.4 mg ± 9.8; 55.2 mg ± 2.3; 76.3 mg ± 4.0; and 116.5 mg ± 16.5. Urinary hippuric acid geometric mean 
concentrations before consuming beverages in the five groups, respectively, were 0.276, 0.270, 0.207, 0.262 
and 0.316 g/l; 1.5 hours after beverage consumption they were 0.210, 0.603, 1.026, 1.066 and 1.688 g/l and 
significantly increased (p<0.001) after adjustment for urinary hippuric acid before ingestion. Three hours 
after beverage consumption, urinary hippuric acid geometric mean concentrations in the five groups, 
respectively, were 0.160, 0.232, 0.306, 0.287 and 0.337 g/l (p<0.001). The authors concluded that beverages 
containing more than 100 mg benzoic acid may increase urinary hippuric acid significantly (Chang et al., 
2000). 
Benzyl acetate [FL-no: 09.014] 
Following gavage administration of [methylene-14C]-benzyl acetate to groups of three or more male Fischer 
344 rats at a dose of 5, 250 or 500 mg/kg bw as the substance alone, in corn oil, or in propylene glycol, 70 – 
89 % of the dose was excreted in the urine within 24 hours. Approximately 4 % of the radioactivity was 
detected in the faeces after 72 hours and about 1 % in the carcass after 72 hours. The elimination of benzyl 
acetate and metabolites, regardless of vehicle, was largely complete after three days. Urine was collected and 
urinary metabolites were assayed by Thin Layer Chromatography (TLC) and HPLC. In other animals 14C 
plasma levels were measured, and variation of metabolites in plasma were assayed. No benzyl acetate was 
detected in the plasma or urine at any time point. Small amounts of benzyl alcohol were detected in the 
plasma at early time points after administration of the neat substance or dissolved in propylene glycol. After 
administration of 500 and 250 mg/kg bw, unconjugated benzoic acid was the major plasma metabolite. After 
the 5 mg/kg bw dose, hippuric acid was the major plasma metabolite. At the higher dose levels small 
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amounts of radioactivity (< 5 % of total plasma 14C) was present as unknown metabolites of high and 
moderate polarity, but not in all samples. At the 5 mg/kg bw dose, 20 % of plasma 14C was present as the 
unknown polar metabolite, although this became less important with time. When propylene glycol was used 
as vehicle, benzylmercapturic acid was detected in plasma, but only at the 5 mg/kg bw dose. Hippuric acid 
was always the major urinary metabolite but the proportion of dose present as benzoyl glucuronide increased 
with dose. Low levels (1.0 – 3.6 %) of benzoic acid and benzyl mercapturic acid (1.0 - 1.9 %) excreted in 
urine were not significantly affected by dose or vehicle (Chidgey and Caldwell, 1986). 
Chidgey et al. (1986) suggest that formation of benzyl mercapturic acid occurs via formation of benzyl 
sulphate. In a study designed to define the route of metabolism of benzyl acetate leading to the formation of 
benzyl mercapturic acid, male Fischer 344 rats were dosed by gavage with [methylene-14C]benzyl acetate 
(500 mg/kg bw) alone or together with pyrazole (200 mg/kg), pentachlorphenol (10 mg/kg bw) or both. 
Urine and faeces were collected and urinary metabolites were assayed by radio-TLC and HPLC. The 
excretion of 14C was rapid in all cases, with most of the dose being excreted in urine within 24 hours. Co-
administration of benzyl acetate with pyrazole, an inhibitor of alcohol dehydrogenase, caused an 11-fold 
increase in the excretion of benzyl mercapturic acid and halved the percentage of the dose excreted as 
benzoyl glucuronide. Pretreatment with pentachlorophenol, an inhibitor of sulphotransferase activity in vivo, 
abolished the excretion of benzyl mercapturic acid, while excretion of the mercapturate following treatment 
with both pyrazole and pentachlorophenol was higher than in control or pentacholorophenol treated rats, but 
much lower than in the animals given pyrazole alone. Taken together, these results suggest that the formation 
of benzyl mercapturic acid involves the sulphate ester of benzyl alcohol as an obligatory intermediate and 
that formation of reactive metabolites of toxicological significance is unlikely (Chidgey et al., 1986). 
Fischer 344 rats and C57BL/6N mice were administered [ring-UL-14C]benzyl acetate at single oral doses of 5 
or 500 mg/kg bw in rats or 10 mg/kg bw in mice, and urine and faeces were collected for 96 hours to 
determine the effects of age on disposition of benzyl acetate. Age groups studied were 3 to 4, 9 and 25 
month-old rats and 2, 13 and 25 month-old mice. In rats, approximately 80 % of radioactivity was recovered 
in the urine in the first 24 hours for all age groups. The major urinary metabolite was hippuric acid (> 90 % 
of total urinary radioactivity) and benzyl mercapturic acid (1-2 %) was the only other metabolite detected in 
the urine of rats. There were no age differences in the percentage of [14C]benzyl acetate excreted as hippuric 
acid, but the amount of excreted benzyl mercapturic acid increased slightly in the 25 month-old rats as 
compared to younger rats. The percentage of radioactivity excreted in the faeces was slightly decreased in 
the 25 months old group. In mice, hippuric acid was the major urinary metabolite, constituting 93 – 96 % of 
the total dose after 96 hours. Less radioactivity was excreted in the urine of 25 month-old mice than in the 
younger groups. Faecal excretion was a minor route and the amount was similar for all age groups. The 
authors concluded that formation of hippuric acid is not affected by age, but aging does affect the minor 
routes of metabolism and excretion of benzyl acetate in rats and mice (McMahon et al., 1989). 
Benzyl acetate was administered to rats and mice in gavage and dosed feed studies. For gavage study groups 
of six male F344/N rats and twelve male B6C3F1 mice were administered benzyl acetate in corn oil at 500 
mg/kg (rat) and 1000 mg/kg (mouse). Blood samples were collected 5 min – 24 hours after dosing. For dosed 
feed studies groups of ten rats and ten mice, of the same strains as in the gavage study, were dosed with 
benzyl acetate in feed (10,800 ppm for rats and 2700 ppm for mice) ad libitum during the study. The 
concentrations in feed were estimated to provide a daily benzyl acetate dose of 648 mg/kg for rats and 900 
mg/kg for mice. At day 7 and 8 blood samples were collected at five time points during 15 hours, with two 
animals from each species sampled at each time point. Benzyl acetate was not detected in any plasma 
samples collected in the studies. Except for the 5 and 10 minutes rat plasma samples and the 5 minutes mice 
plasma samples in the gavage study, no benzyl alcohol was detected in plasma. Concentrations of benzoic 
acid and hippuric acid in plasma rapidly increased to peak concentrations within 3 hours after gavage with 
the peak benzoic acid concentrations being much higher (about 10- to 20-fold) than the peak hippuric acid 
concentrations. Plasma concentrations of benzoic acid in the dosed feed studies were much lower (more than 
100-fold) than the concentrations in the gavage studies, consistently with the mode of administration (bolus 
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dose with gavage). Plasma concentrations of hippuric acid were comparable in both studies. The absence of 
benzyl acetate in plasma shows that benzyl acetate is rapidly hydrolysed to benzyl alcohol. The major 
metabolite of benzyl acetate, benzoic acid, is mainly dependent on the conjugation pathway involving 
Coenzyme A (CoA). This pathway would be saturated when plasma concentrations of benzoic acid are very 
high or when the CoA is depleted. Such conditions appear to have occurred after a bolus gavage dose of 
benzyl acetate to result in a brief peak in the plasma concentration of benzoic acid. When benzyl acetate was 
administered to rats and mice in dosed feed, it appears that the CoA conjugation pathway was never saturated 
and plasma concentration of benzoic acid remained low (Yuan et al., 1995). 
Other related substances 
Sodium benzoate 
Male volunteers were given oral doses of 2000 to 5000 mg sodium benzoate. The 5000 mg dose group was 
given a 5000 mg dose of glycine one hour later and 2000 mg doses every two hours thereafter. Benzoate was 
excreted mainly as hippuric acid. No free benzoic acid was detected. Minor amounts of benzoyl glucuronide 
were detected at both doses. Co-administration of glycine with benzoate increased the rate of hippuric acid 
excretion, indicating that at high dose levels, glycine is rate limiting for formation of hippuric acid (Amsel 
and Levy, 1969). 
After administration of oral doses of 40, 80 and 160 mg/kg bw of sodium benzoate to humans, the mean 
plasma Area Under Curves (AUCs) of benzoic acid increased disproportionately to the dose, 3.7 and 12.0 
times greater, respectively, for the higher dosages than for the lowest dose, while the mean AUCs for 
hippuric acid was proportional to dose. Peak plasma concentrations of benzoic acid increased with increasing 
dose, while peak hippuric acid concentrations did not change. The data suggest that the conjugation with 
glycine to form hippuric acid is a saturable process in humans (Kubota et al., 1988; Kubota and Ishizaki, 
1991). 
Subgroup 2 (hydroxy- and alkoxy-substituted benzyl derivatives) 
Candidate substances from subgroup 2 
Piperonyl alcohol (3,4-methylenedioxybenzyl alcohol ) [FL-no: 02.205] 
The metabolism of piperonyl alcohol [FL-no: 02.205] and piperonal (3,4-methylenedioxybenzaldehyde) [FL-
no: 05.016] (supporting substance) was studied in male Wistar rats. Piperonyl alcohol dissolved in propylene 
glycol was administered by oral gavage at a dose of 1 mmol/kg bw (corresponding to 152 mg/kg bw) and 
urine samples were taken at 24 and 48 hours. Recovery of urinary metabolites were 90 %, and metabolite 
excretion occurred mainly within 24 hours. Piperonyl glycine was identified as the major metabolite (70 ± 5 
%; 24-hours analysis expressed as a percent of administered dose) and piperonylic acid (17 ± 3 %) was the 
other important metabolite. Demethylenation of the methylenedioxy moiety led to the excretion of three 
cathecol derivatives, which accounted for 0.7 % of the dose, protocatechuic acid (0.4 ± 0.1 %), 
protocatechuyl alcohol (0.3 ± 0.1 %). Other minor metabolites were piperonyl alcohol (1.4 ± 0.5  %) and 
vanillyl alcohol (0.05 ± 0.03 %) (Klungsoeyr and Scheline, 1984). 
In a study of several methylenedioxyphenyl (MDP) compounds, radiolabelled piperonyl alcohol (1-
hydroxymethyl-3,4-methylene-14C-dioxybenzene) was administered to male Swiss-Webster mice in a DMSO 
solution by oral gavage at a dose of 0.76 mg/kg bw. Total radiocarbon determinations were made on expired 
14CO2 at 0.5, 1, 2, 4 and 6 hours after dosing and at each 6-hours interval thereafter. Urine and faeces 
samples were taken at 12, 24 and 48 hours after treatment. The 12-hours urine samples were used for 
separation and characterisation of metabolites. At the end of the experiment, 14CO2 excretion amounted to 3 
% of the dose, indicating that demethylenation of piperonyl alcohol only occurs as a minor metabolic 
pathway. The major part of radioactivity was retrieved in urine, 93.3 %, and less than 10 % in faeces. The 
major urinary metabolite after administration of piperonyl alcohol was piperonyl glycine. Other MDP 
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substances studied were safrole, dihydrosafrole, myristicin, Tropital, piperonyl butoxide, piperonal and 
piperonylic acid. The major metabolic pathway for piperonyl butoxide, safrole, dihydrosafrole and myristicin 
was demethylenation of the methylenedioxy moiety. As for piperonyl alcohol, oxidation and conjugation of 
the side chain is the major metabolic pathway for Tropital, piperonal and piperonylic acid. The authors 
discussed that the polar nature of these compounds or their ease of conversion to polar products may 
minimise their entrance to the lipid components of the microsomal enzymes so that no extensive 
demethylenation would occur (Kamienski and Casida, 1970). 
Gallic acid (3,4,5-trihydroxybenzoic acid) [FL-no: 08.080] 
Following administration of gallic acid [FL-no: 08.080] to rats either in the diet at a concentration of 0.5 % 
or in single doses of 100 mg/rat via oral gavage, the major urinary excretion products were the unchanged 
parent substance and one metabolite which was concluded to be 4-O-methyl gallic acid. A minor metabolite, 
2-O-methylpyrogallol, was excreted mainly as an acid-labile conjugate. When the same compound was given 
at 100 mg/rat as intraperitoneal injection the results were similar to those obtained when the substance was 
given orally, however, a minor metabolite identified as pyrogallol was also present along with a trace of 2-O-
methyl pyrogallol. Rabbits administered a diet containing 0.5 % gallic acid also excreted 4-O-methyl gallic 
acid, pyrogallol, and possibly also 2-O-methyl pyrogallol. The data indicated that mostly free benzoic acid 
derivatives were excreted, although rabbits excreted an acid-labile conjugate of 4-O-methyl gallic acid. The 
results indicate that O-methylation and decarboxylation are the reactions involved in the metabolic 
conversion of gallic acid. The authors stated that this selective O-methylation would prevent the formation of 
the catechol configurations (Booth et al., 1959). 
Scheline (1966a) reported that rats that were administered 100 mg/kg bw of gallic acid [FL-no: 08.080] by 
oral gavage excreted the parent substance and the free and acid-labile conjugates of its 4-O-methyl ether. 
Pyrogallol and 2-O-methyl pyrogallol, the decarboxylated metabolites, were excreted in their conjugated 
forms. Dosing with 30 and 300 mg gallic acid/kg bw showed that excretion of decarboxylated metabolites 
increased with increasing dose. Intraperitoneal injection of gallic acid in four rats resulted in the urinary 
excretion of gallic acid and 3,5-dihydroxy-4-methoxybenzoic acid, but neither pyrogallol or 2-O-methyl 
pyrogallol were detected in these urines. A study of the ability of rat intestinal contents to metabolise gallic 
acid showed that it was decarboxylated to pyrogallol when test substance was added to medium containing 
extracts of caecal or colon contents. Test substance was recovered essentially unchanged when small 
intestine contents were used (Scheline, 1966a). 
In order to examine decarboxylation and demethylation of some phenolic benzoic acid derivatives by rat 
caecal contents, test substances were incubated for 22 hours in medium containing ceacal contents. Solutions 
together with appropriate standards were then examined by TLC. Gallic acid [FL-no: 08.080] gave rise to 
pyrogallol which was present in five out of eight samples. When pyrogallol was absent after incubation large 
amounts of resorcinol were observed on the chromatograms. Dehydroxylation to resorcinol was also seen 
when pyrogallol itself was incubated with caecal extract. Unchanged gallic acid was found in 4 out of 8 
samples. Pyrogallol was not dehydroxylated to catechol in these experiments. The main findings of the study 
that covered 27 phenolic benzoic acid derivatives was that decarboxylation only occurred when a free 
hydroxyl group was present in the para position (Scheline, 1966b). 
The metabolic fate of gallic acid [FL-no: 08.080] in peripheral blood, liver and urine after oral administration 
was studied in six-week-old male Wistar rats in order to determine the most appropriate route of 
administration for the treatment of liver cancer, i.e. the route that gives the highest concentration of gallic 
acid in liver. Gallic acid was given orally to the rats at 50, 100 or 500 mg/kg bw  (The number of animals is 
not reported, but results from the 100 mg/kg bw group are shown as the mean of 4-6 animals). Blood 
samples were taken from the portal vein and the inferior vena cava at 5, 15, 30, 60, 180 and 360 minutes 
after administration and urine was collected at the same time points. Intestinal contents were collected and, in 
order to avoid contamination due to enterohepatic circulation, bile duct was ligated before oral 
administration of 100 mg/kg bw. Animals were sacrificed, and the entire intestinal contents were collected. 
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The liver was removed from terminated animals after perfusion with saline to eliminate blood contamination. 
For analysis, samples from serum, urine and liver were processed and then analysed by HPLC. Gallic acid 
reached its peak concentration in the portal vein 15 minutes after oral administration of 100 mg/kg bw. After 
30 minutes it had decreased to half the concentration and had almost disappeared after 6 hours. The only 
metabolite detected in the blood and urine was identified as 4-O-methyl gallic acid. 4-O-Methyl gallic acid 
also reached peak concentration in the portal vein after 15 minutes, and then decreased slowly. In the inferior 
vena cava both gallic acid and 4-O-methyl gallic acid reached peak concentration at 30 minutes after oral 
administration of 100 mg gallic acid/kg bw. In the portal vein, gallic acid was detected at about twice the 
concentration of 4-O-methyl gallic acid. In the inferior vena cava, 4-O-methyl gallic acid and gallic acid 
were detected in approximately equal proportions and in about the same amount as 4-O-methyl gallic acid in 
the portal vein. 4-O-Methyl gallic acid, but not gallic acid was found in the liver homogenate prepared after 
thorough perfusion with saline. The main metabolite of gallic acid in urine was 4-O-methyl gallic acid and 
its concentration was about 100 times higher than in the inferior vena cava. Gallic acid was also found in 
urine at a higher concentration than in the inferior vena cava, but at lower concentration than 4-O-methyl 
gallic acid in urine. In contrast to previously published studies (Booth et al., 1959; Scheline, 1966a), this 
study did not detect pyrogallol as a metabolite in blood or urine. The authors attribute this discrepancy to the 
earlier studies using TLC for determination of metabolites, but without proper determination of structures, 
and also comment that the time for collecting urine under unstable conditions may have led to the 
decomposition of gallic acid to pyrogallol (Zong et al., 1999). 
Ethyl 4-hydroxybenzoate (ethyl paraben) [FL-no: 09.367] 
Absorption, distribution, metabolism and excretion of ethylparaben [FL-no: 09.367] were investigated in 
Wistar rats administered 100 mg by oral gavage. Animals were held in metabolism cages for the collection of 
urine (at approximately 15, 30, 60, 75, 90, 120, 150 and 210 minutes) and blood (at approximately 30, 60, 
90, 120, 180, 240 and 360 minutes), and samples were analysed to establish the excretion kinetics. 
Metabolites were detected in the urine starting at 30 minutes after dosing, but no unchanged ethyl paraben 
was identified by this time. p-Hydroxyhippuric acid appeared in the urine 30 minutes after dosing and its 
concentration increased steadily during the next three hours. The glucuronide and ethereal sulphate 
metabolites only appeared between 30 and 75 minutes post-ingestion. A continuous increase of free 4-
hydroxybenzoic acid in the blood occurred during the first hour post-dosing, but its concentration then 
decreased over the next hour and plateaued for the remaining four hours of sample collection. Maximum 
urinary excretion of free 4-hydroxybenzoic acid occurred at 90 minutes post-dosing, whereas excretion of 
the glucuronic and glycine conjugates increased until the end of the collection period at 210 minutes post-
dosing. In summary, absorption of ethylparaben was followed by metabolism and excretion of mainly free 4-
hydroxybenzoic acid and its glucuronic and glycine conjugates. A small portion of the dose was excreted as 
sulphate conjugate (Derache and Gourdon, 1963). 
The 14C-labelled ethyl 4-hydroxybenzoate was orally given to four male cats in the diet at a concentration 
that provided a single dose of 156 mg/kg bw, equivalent to 130 mg/kg bw of the parent acid. Urine was 
collected at 24-, 48- and 72-hours intervals, total faeces were collected at 72-hours, and all samples were 
assayed for total radioactivity. The radioactive metabolites present in the 24-hours samples were isolated and 
identified. Essentially, all (mean = 96.0 %) of the radioactiviy was excreted within 72 hours with the 
breakdown expressed as mean values for the four animals as follows: 24-hours urine, 85.8 %; 48-hours urine, 
3.6 %; 72-hours urine, 0.8 %; 72-hours faeces, 5.8 %. The 24-hours urine samples revealed two metabolites. 
Metabolite I contained between 54 and 69 % of the administered radioactivity and had a similar retention 
volume as p-hydroxyhippuric acid. Metabolite II contained between 31 and 46 % of the administered 
radioactivity and had a similar retention volume as 4-hydroxybenzoic acid. Additional evaluations confirmed 
the identity of the suggested metabolites (Phillips et al., 1978). 
Ethyl 4-hydroxybenzoate (ethylparaben) [FL-no: 09.367] and supporting substances 4-hydroxy benzoic acid 
[FL-no 08.040] and butyl 4-hydroxybenzoate (butylparaben) [FL-no: 09.754] 
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Groups of three fasted dogs were administered single doses of 1 g/kg bw of 4-hydroxybenzoic acid 
(supporting substance [FL-no 08.040]) or its methyl, ethyl (candidate substance [FL-no: 09.367]), propyl and 
butyl (supporting substance [FL-no: 09.754]) esters orally or 50 mg/kg bw by intravenous injection. Blood 
and urine samples were collected at fixed intervals until 48 hours. Recovery of total test material as 
metabolites in urine after the oral and intravenous doses was 60 - 95 % for the acid and the methyl, ethyl and 
propyl esters. For the candidate substance ethyl 4-hydroxybenzoate [FL-no: 09.367] recovery of total 
material was 66 % of the oral and 70 % of the intravenous dose. Metabolites were detectable in the blood up 
to 24 hours post-ingestion. Of the dose 12.3 % was excreted as free acid and 32.5 % as the glucuronic acid 
conjugate. Recovery of the butyl ester was 48 % after oral and 40 % after intravenous dosing. After oral 
dosing about 5 % of the butyl ester was excreted as free 4-hydroxybenzoic acid and 27.5 % as the glucuronic 
acid conjugate. Other conjugates were not determined. After intravenous dosing 11.3 % of the given dose 
was recovered as free acid in urine and 20.1 % as the glucuronic acid conjugate. The test material was 
mainly excreted within 24 hours after dosing. The low rate of recovery seen with both dosing methods was 
attributed to incomplete hydrolysis of the butyl ester in the body. In vitro incubation of the butyl ester with 
freshly prepared liver homogenate showed complete hydrolysis within 30 – 60 minutes. Studies conducted 
with related benzoate esters, methyl and ethyl p-hydroxybenzoate, showed significantly higher rates of test 
material recovery when given to dogs by the oral and intravenous route, and showed 100 % hydrolysis 
within 3 minutes when incubated with liver homogenate. This finding suggests that an increase in the length 
of the alkyl rest in the homologous series of alkyl esters make the esters more resistant to hydrolysis and may 
result in the activation of other metabolic and excretion pathways (Jones et al., 1956). 
Supporting substances from subgroup 2 
4-Methoxybenzylalcohol (p-anisyl alcohol) [FL-no: 02.128] 
In an in vitro study, 4-methoxybenzylalcohol (p-anisyl alcohol) [FL-no: 02.128] was incubated with rat 
caecal extract. Analysis after approximately 46 hours showed the presence of unchanged compound and 
anisic acid. No observation of O-demethylation was observed (Scheline, 1972). 
Vanillyl alcohol (4-hydroxy-3-methoxy benzylalcohol) [FL-no: 02.213] and vanillin (4-hydroxy-3-
methoxybenzaldehyde) [FL-no: 05.018] 
In an in vivo study conducted in male albino rats, vanillyl alcohol [FL-no: 02.213] and vanillin [FL-no: 
05.018] were administered by gavage in doses of 100 or 300 mg/kg bw. Urinary metabolites were collected 
over the first 24 - 48 hours period and analysed qualitatively. Vanillyl alcohol was mainly excreted as 
vanillyl alcohol or vanillic acid and related conjugates. The aldehyde intermediate was also detected. 
Conjugated fractions of vanillin, guaiacol, catechol, 4-methylguaiacol and 4-methylcatechol were also 
identified in smaller quantities. Oral dosage of 100 mg/kg bw of vanillin resulted in an urinary excretion of 
most metabolites within 24 hours, mainly as glucuronide and sulphate conjugates although vanillic acid was 
also excreted as free acid and as glycine conjugate. After 48 hours 94 % of the dose was accounted for as 
follows: vanillin 7 %, vanillyl alcohol 19 %, vanillic acid 47 %, vanilloylglycine 10 %, catechol 8 %, 4-
methyl catechol 2 %, guaiacol 0.5 % and 4-methyl guaiacol 0.6 %. Vanillin and its primary reduction and 
oxidation metabolites were also excreted in appreciable amounts in the bile. Bile collected five hours after 
two rats were given 100 and 300 mg/kg bw oral doses of vanillin contained glucuronide conjugates of 
vanillin (6 %), vanillyl alcohol (8 %) and vanillic acid (9 %). The results show that both oxidative and 
reductive pathways exist for the metabolism of vanillin, although the oxidative metabolism dominates. At a 
dose level of 100 mg/kg bw, 57 % of the dose of vanillin was excreted as free vanillic acid or its conjugates 
and in total oxidation products amounted to approximately 65-70 % of the dose. The reduction pathway 
accounted for a little more than 20 % of the dose (Strand and Sheline, 1975). 
In Sprague-Dawley albino rats 100 mg vanillin [FL-no: 05.018]/kg bw was given by intraperitoneal injection 
and 24-hours urine was collected and analysed. The main urinary metabolite was conjugated vanillic acid 
which accounted for 41 % of the administered dose, while free vanillic acid accounted for 6 %. In addition, 
there was a trace of catechol. Vanillyl alcohol, a reductive product, represented 10 % of the administered 
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dose. The presence of the urinary glycine conjugate of vanillic acid was not reported in this study. The 
oxidative path of metabolism was found to predominate, however, the importance of the minor reductive 
pathway may be magnified by inhibition of the oxidative process, as was achieved by administration of 
disulphiram in the study (Wong and Sourkes, 1966). 
An experiment was conducted with the aim to determine whether man is capable of oxidising vanillin to 
vanillic acid. A 100 mg dose of vanillin dissolved in water was given to an adult human and the urine 
collected for 24 hours. Examination revealed an increase in the vanillic acid output in the urine from a 
background level of 0.3 mg/24 hours to 96 mg/24 hours. The observed increase accounted for approximately 
94 % of the vanillin dose (Dirscherl and Wirtzfeld, 1964). 
Veratraldehyde (3,4-dimethoxybenzaldehyde) [FL-no: 05.017] 
A 1 g/kg bw oral dose of veratraldehyde (3,4-dimethoxybenzaldehyde) was administered to rabbits by 
gavage and urine was collected for 24 hours. Approximately 70 % of the aldehyde was accounted for in 
urine mainly as the corresponding acid, veratric acid (28 %) and its glucuronic acid (38 %) or sulphate (3-7 
%) conjugate. To a small extent, veratric acid was decarboxylated and O-demethylated to yield catechol 
(Sammons and Williams, 1941). Presumably, veratric acid may enter the enterohepatic circulation where gut 
microflora decarboxylate the acid to yield catechol (o-hydroxyphenol). The observation that catechol was 
formed as a minor metabolite when veratraldehyde was incubated with rat caecal extract illustrates this 
decarboxylation pathway in gut bacteria (Scheline, 1972). 
4-Hydroxybenzaldehyde [FL-no:05.047] and salicylaldehyde (2-hydroxybenzaldehyde) [FL-no: 05.055] 
In rabbits, 96 % of a single oral dose of 400 mg/kg bw 4-hydroxybenzaldehyde was excreted in the urine 
within 24 hours as 4-hydroxybenzoic acid and its glycine, glucuronic acid and sulphate conjugates (Bray et 
al., 1952b). 
A single dose of 400 mg)/kg bw 2-hydroxybenzaldehyde (salicylaldehyde was administered to a fasted rabbit 
in three or six experiments. Approximately 75 % of the dose was excreted as ether soluble acids in the urine 
collected over 24 hours, and 27 % and 3 % accounted for as glucuronic acid and sulphate conjugates, 
respectively (Bray et al., 1952b). 
In a corresponding study, approximately 94 % of a single oral dose of 250 or 500 mg/kg bw salicylaldehyde 
administered to two groups of four rabbits was excreted unchanged or as the glucuronic acid and sulphate 
conjugates, while the major part was excreted as the unchanged acid (Bray et al., 1948). 
Veratraldehyde (3,4-dimethoxybenzaldehyde) [FL-no: 05.017], vanillin (4-hydroxy-3-
methoxybenzaldehyde) [FL-no: 05.018] and vanillic acid (4-hydroxy-3-methoxy benzoic acid) [FL-no: 
08.043] 
Veratraldehyde [FL-no: 05.017], vanillin [FL-no: 05.018] or vanillic acid [FL-no: 08.043] were given orally 
by gavage to six rabbits at a dose of approximately 1 g/kg bw. Urine was collected for 5 hours. After 
administration of veratraldehyde approximately 70 % of the material was recovered in the urine as free 
corresponding acid (28 %) and its glucuronic acid (38 %) or sulphate (3 - 7 %) conjugate. Approximately 69 
% of vanillin was oxidised to vanillic acid, of which 44 % was recovered as free acid and 25 % conjugated 
acid. About 14 % of the dose was excreted as the glucuronic acid conjugate of vanillin. In the case of vanillic 
acid, 56 % was excreted as free vanilllic acid and 27 % as conjugated, as glucuronide conjugate or ethereal 
sulphate. Less than 5 % was demethylated (Sammons and Williams, 1941). 
4-Hydroxybenzoic acid [FL-no: 08.040] 
Groups of four to eight rabbits were administered doses of 100, 250, 500, 1000 or 1500 mg/kg bw 4-
hydroxybenzoic acid by gavage. Urine was collected continuously and analysed for metabolites. Total 
urinary recovery of the test material was in the range of 84 to 104 %, with ether soluble acids comprising 64 
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to 75 % of the total. Glucuronic acid and sulphate conjugates were also detected in the urine at 10 to 35 % 
and 4 to 7 %, respectively. The levels of all the metabolites returned to background levels within 24 hours 
after dosing (Bray et al., 1947). 
Results from four experiments showed that between 2.2 and 5.4 % was excreted in the urine within 24 hours 
as the corresponding hippurate of a 0.41 mmole 4-hydroxybenzoic acid dose was administered by 
intraperitoneal injection to female albino rats (Teuchy et al., 1971). 
Other related substances 
Methyl 4-hydroxybenzoate (methyl paraben)  
Methyl 4-hydroxybenzoate (methylparaben) was administered to three male rabbits by oral gavage at 800 
mg/kg bw as a 12 % natrium salt solution, and the 24-hours urine was analysed. Three major metabolites, 4-
hydroxybenzoic acid, p-hydroxyhippuric acid and p-carboxyphenyl glucuronide, as well as two minor 
metabolites, p-hydroxybenzoyl glucuronide and p-carboxyphenyl sulphate, were identified (Tsukamoto and 
Terada, 1962). 
Concluding remarks on metabolism 
The esters in subgroup 1 will upon hydrolysis yield benzyl alcohol or benzoic acid along with alkyl 
carboxylic acids or alcohols. The metabolic fate of alkyl carboxylic acids and alcohols has been discussed in 
previous FGEs, and will not be discussed further in this evaluation. Benzyl alcohol, benzylaldehyde and 
benzoic acid have been evaluated by the JECFA (JECFA, 1996b), as has 4-isopropylbenzyl alcohol (JECFA, 
2002a), which is the alcohol moiety of candidate substance [FL-no: 09.611] (4-isopropylbenzyl acetate). 
Benzaldehyde and the benzyl alcohols are expected to be oxidized to corresponding benzoic acids, which 
will be conjugated with glycine and excreted as hippuric acids.  
The candidate substance [FL-no: 09.314 (benzyl crotonate)] will yield crotonic acid as acid moiety, this 
substance has been discussed in the previous FGE.05Rev1. In addition, crotonic acid has been evaluated by 
the SCF (SCF, 2002a). 
The alcohol part of the candidate substance [FL-no: 09.656] (3-methylbut-3-enyl benzoate) includes a 
terminal double bond, a structure that has been discussed in FGE.06Rev1 and will not be further discussed in 
this FGE. 
The candidate substance (diethoxymethyl)benzene [FL-no: 06.017] is an acetal. This substance would be 
expected to yield benzaldehyde and ethanol upon hydrolysis. Benzaldehyde is expected to be oxidized to 
benzoic acid.  
Subgroup 2, hydroxy- and alkoxy-substituted benzyl derivatives, includes 13 esters of which one [FL-no: 
09.895] (4-methoxybenzyl-2-methylpropionate) will yield 4-methoxy-benzyl alcohol (p-anisyl alcohol) [FL-
no: 02.128] upon hydrolysis. This substance has been evaluated by the JECFA (JECFA, 2002a). 4-Methoxy-
benzyl alcohol is expected to be excreted in the urine either unchanged or as glucuronic acid, glycine or 
sulphate conjugate. The same metabolic pathway is proposed for the candidate benzyl alcohol derivative 
[FL-no: 02.164] (4-hydroxy-3,5-dimethoxy benzylalcohol). 
The remaining 12 esters in subgroup 2 will yield hydroxy- and/or alkoxy-substituted benzoic acids upon 
hydrolysis. The substituted benzoic acids that are hydrolysis products of candidate esters are expected to be 
excreted in the urine as the glucuronic acid, glycine or sulphate conjugate or at a minor extent unchanged. 
The same metabolic route is proposed for the candidate acid [FL-no: 08.087] (4-hydroxy-3,5-
dimethoxybenzoic acid), [FL-no: 08.132] (3-hydroxybenzoic acid) and [FL-no: 08.133] (3,4-
dihydroxybenzoic acid).  
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The candidate substance piperonyl alcohol  [FL-no: 02.205] (3,4-methylenedioxybenzylalcohol) is expected 
to mainly undergo oxidation and conjugation of the side chain, and be excreted as a glycine conjugate. 
Demethylenation of the methylenedioxy moiety does seem to be only a very minor metabolic path for this 
compound. 
For the six candidate aldehydes in subgroup 2 the main metabolic pathway is presumed to be oxidation to the 
corresponding acids, followed by glycine and glucuronic acid conjugation and excretion. The reduction to 
alcohols is a minor metabolic route and the oxidative pathway clearly dominates. To a minor extent O-
demethylation followed by conjugation may occur.  
The main metabolite of gallic acid (3,4,5-trihydroxy-benzoic acid) [FL-no: 08.080] is expected to be 4-O-
methyl gallic acid, i.e. the product of O-methylation. Decarboxylation to pyrogallol (1,2,3-
trihydroxybenzene) may occur as a very minor pathway, but no further dehydroxylation to catechol has been 
observed. 
III.4. Summary and Conclusions 
It is expected that esters in subgroup 1 and 2 will be hydrolysed in vivo to their component alcohols and 
acids. Eight of the 14 esters from subgroup 1 (benzyl derivatives) will yield benzyl alcohol which has 
previously been evaluated by the JECFA (JECFA, 1996b) and SCF (SCF, 2002b). One candidate ester [FL-
no: 09.611] (4-isopropylbenzyl acetate) will yield 4-isopropyl benzyl alcohol. This substance has been 
previously evaluated by the JECFA (JECFA, 2002a). The benzyl alcohols are expected to be oxidized to 
corresponding benzoic acids, which will be conjugated with glycine and excreted as hippuric acids.  
Of the remaining five candidate esters in subgroup 1, four are expected to yield benzoic acid and simple 
aliphatic alcohols upon hydrolysis [FL-no: 09.656 (3-methylbut-3-enyl benzoate); 09.779 (butyl benzoate); 
09.825 (pentyl benzoate); 09.693 (prenyl benzoate)] and one ester [FL-no: 09.631 (methyl 4-methyl 
benzoate)] will yield 4-methyl-benzoic acid upon hydrolysis. Benzoic acid will mainly be conjugated with 
glycine and excreted as hippuric acid. Conjugation with glycine may be a saturable process and glucuronide 
conjugates increase with increasing dose. 
One of the substances, [FL-no: 06.017] ((diethoxymethyl)benzene), in subgroup 1 is an acetal. This 
substance would be expected to yield benzaldehyde and ethanol upon hydrolysis. Benzaldehyde has been 
evaluated by the JECFA (JECFA, 1996b). Benzaldehyde is expected to be oxidized to benzoic acid.  
Subgroup 2 (hydroxy- and alkoxy-substituted benzyl derivatives) includes 13 esters of which one [FL-no: 
09.895](4-methoxybenzyl-2-methylpropionate) will yield 4-methoxybenzyl alcohol (p-anisyl alcohol) 
(supporting substance [FL-no: 02.128]) upon hydrolysis. This substance has been evaluated by the JECFA 
(JECFA, 2002a). 4-Methoxy-benzyl alcohol is expected to be excreted in the urine either unchanged or as a 
glucuronic acid, glycine or sulphate conjugate. The same metabolic pathway is proposed for the candidate 
benzyl alcohol derivative [FL-no: 02.164] (4-hydroxy-3,5-dimethoxybenzyl alcohol). 
The remaining 12 esters in subgroup 2 [FL-no: 09.362 (ethyl 2-hydroxy-4-methylbenzoate); 09.363 (ethyl 2-
methoxybenzoate); 09.367 (ethyl 4-hydroxybenzoate); 09.560 (hex-3(cis)-enyl anisate; hex-3(cis)-enyl-4-
methoxybenzoate); 09.570 (hex-3-enyl salicylate; hex-3-enyl-2-hydroxybenzoate); 09.581 (hexyl salicylate; 
hexyl 2-hydroxybenzoate); 09.623 (methyl 2,4-dihydroxy-3,6-dimethylbenzoate); 09.696 (prenyl salicylate; 
3-methyl-but-2-enyl 2-hydroxybenzoate); 09.762 (pentyl salicylate; pentyl 2-hydroxybenzoate); 09.798 
(ethyl vanillate; ethyl 3-methoxy-4-hydroxybenzoate); 09.799 (methyl vanillate; methyl 3-methoxy-4-
hydroxybenzoate); 09.852 (2-methylbutyl 2-hydroxybenzoate; 2-methylbutyl salicylate)] will yield hydroxy- 
and/or alkoxy-substituted benzoic acids upon hydrolysis. The substituted benzoic acids that are hydrolysis 
products of candidate esters are expected to be excreted in the urine unchanged or as the glucuronic acid, 
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glycine or sulphate conjugate. The same metabolic route is proposed for the candidate acids [FL-no: 08.087] 
(4-hydroxy-3,5-dimethoxybenzoic acid), [FL-no: 08.132 (3-hydroxybenzoic acid)] and [FL-no: 08.133] (3,4-
dihydroxybenzoic acid). 
The main metabolic pathway for the acetal [FL-no: 06.104 (vanillin propylene glycol acetal)], after 
hydrolysis to the aldehyde and for the five candidate aldehydes in subgroup 2 [FL-no: 05.066 (4-ethoxy-3-
methoxybenzaldehyde); 05.129 (2-methoxybenzaldehyde); 05.142 (3,4-dihydroxybenzaldehyde); 05.153 (4-
hydroxy-3,5-dimethoxybenzaldehyde); 05.158 (3-methoxybenzaldehyde)] is presumed to be oxidation to the 
corresponding acids, followed by conjugation and excretion. The reduction to alcohols is a minor metabolic 
route and the oxidative pathway dominates clearly. To a minor extent O-demethylation followed by 
conjugation may occur.  
The candidate substance piperonyl alcohol (3,4-methylenedioxybenzyl alcohol) [FL-no: 02.205] is expected 
to mainly undergo oxidation and conjugation of the side chain, and be excreted as glycine conjugate. 
Demethylenation of the methylenedioxy moiety is a very minor metabolic path for this compound, according 
to published literature.  
The main metabolite of gallic acid (3,4,5-trihydroxy-benzoic acid) [FL-no: 08.080] is expected to be 4-O-
methyl gallic acid the product of O-methylation. Decarboxilation to pyrogallol (1,2,3-trihydroxybenzene) 
may occur as a very minor pathway, but no further dehydroxylation to catechol has been observed.  
The substance in subgroup 3 is expected to be metabolised in a similar way to the benzaldehyde derivatives 
in subgroup 2. It is expected that the aldehyde group(s) will undergo oxidation to form the corresponding 
carboxylic acid which is likely to be conjugated and excreted. The reduction of the alcohol groups may again 
be a minor pathway, but some steric hindrance may occur making this less likely than for the benzaldehyde 
derivatives in subgroup 2. 
Based on experimental evidence and general knowledge of toxicokinetics of structurally related compounds 
it is expected that at the reported levels of intake as flavouring substances the candidate substances in 
FGE.20Rev3 would be rapidly and efficiently absorbed, metabolised to innocuous products and excreted. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for 13 candidate substances of the present flavouring group evaluation from chemical groups 23 and 30, and for 63 
supporting substances evaluated by the JECFA at the 57th meeting (JECFA, 2002a). The supporting substances are listed in brackets. 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Benzyl alcohol [02.010]) Rabbit NR Oral 1040 (Graham and Kuizenga, 
1945) 
 
Rat NR Oral 2979 (Ciba-Geigy Corp., 1945)  
Rat NR Oral 2080 (Graham and Kuizenga, 
1945) 
 
Rat M, F Gavage 1230 (Jenner et al., 1964)  
Rat M, F Oral 1570 (Damment, 1980)  
Rat NR Oral 3100 (Smyth et al., 1951a)  
Mouse NR Gavage 1580 (Jenner et al., 1964)  
Mouse NR Oral 1150 (Carter et al., 1958)  
(Benzyl formate [09.077]) Rat M, F Gavage 1.7 (1.4-2.1) ml/kg bw (1840; 1510-
2270)10 
(Shelanski and 
Moldovan, 1971d) 
 
(Benzyl acetate [09.014]) Rabbit NR Oral 2640 (Graham and Kuizenga, 
1945) 
 
Rat M, F Gavage 2490 (Jenner et al., 1964)  
Rat NR Oral 3690 (Graham and Kuizenga, 
1945) 
 
(Benzyl propionate [09.132]) Rat NR Oral 3300 (Moreno, 1973u)  
(Benzyl butyrate [09.051]) Rat NR Oral 1850 (Moreno, 1973v)  
Rat M, F Gavage 2330 (Jenner et al., 1964)  
(Benzyl isobutyrate [09.426]) Rat M, F Oral 2850 (Owen, 1971)  
(Benzyl isovalerate [09.458]) Rat NR Oral 5000 (Moreno, 1974j)  
Benzyl dodecanoate [09.315] Rat NR Oral > 5000 (Moreno, 1975m)   
(Benzyl 2-methylcrotonate [09.494]) Rat NR Oral > 5000 (Moreno, 1979d)  
(Benzyl benzoate [09.727]) Cat NR Oral 2240 (Graham and Kuizenga, 
1945) 
 
Rabbit NR Oral 2016 (Draize et al., 1948)  
Rabbit NR Oral 1680 (Graham and Kuizenga, 
1945) 
 
Rabbit NR Oral 1800 (Lehman, 1955)  
Guinea pig NR Oral 1120 (Draize et al., 1948)  
Guinea pig NR Oral 1000 (Lehman, 1955)  
Rat NR Oral 1904 (Draize et al., 1948)  
Rat NR Oral 2800 (Graham and Kuizenga, 
1945) 
 
Rat NR Oral 1700 (Lehman, 1955)  
Mouse NR Oral 1568 (Draize et al., 1948)  
Mouse NR Oral 1400 (Lehman, 1955)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Benzyl phenylacetate [09.705]) Rat M, F Oral > 5000 (Owen, 1971)  
(Benzaldehyde [05.013]) Guinea pig M, F Gavage 1000 (Jenner et al., 1964)  
Rat M, F Gavage 1300 (Jenner et al., 1964)  
Rat NR Oral 2850 (Sporn et al., 1967)  
Rat M, F Gavage 1300 (Taylor et al., 1964)  
Mouse NR Diet 1250 (Schafer and Bowles, 
1985) 
 
(alpha,alpha- Dimethoxytoluene [06.003]) Rat NR Oral 1220 (Moreno, 1977z)  
(5-Hydroxy-2-phenyl-1,3-dioxane [06.002]) Rat NR Oral 3749 (Levenstein, 1974g)  
Rat NR Oral 2750 (Moreno, 1980k)  
(4-Methyl-2-phenyl-1,3-dioxolane [06.032]) Rat M, F Gavage 3000 (Lewis and Palanker, 
1979b) 
 
(Benzoic acid [08.021]) Mouse NR Oral 1250 (Schafer and Bowles, 
1985) 
 
Mouse NR Oral 1996 (Sado, 1973)  
Mouse NR Gavage 1950 (Shell Oil Company, 
1982) 
 
(Methyl benzoate [09.725]) Rabbit NR Oral 2170 (Graham and Kuizenga, 
1945) 
 
Guinea pig NR Gavage 4100 (Kravets-Bekker and 
Ivanova, 1970) 
 
Rat NR Oral 2170 (Graham and Kuizenga, 
1945) 
 
Rat M, F Gavage 1350 (Jenner et al., 1964)  
Rat NR Gavage 3500 (Kravets-Bekker and 
Ivanova, 1970) 
 
Rat M, F Oral 3420 (Smyth et al., 1954)  
Mouse NR Gavage 3330 (Jenner et al., 1964)  
Mouse NR Gavage 3000 (Kravets-Bekker and 
Ivanova, 1970) 
 
Methyl 4-methylbenzoate [09.631] Rat M Gavage 2987 (Dashiell and Hinckle, 
1981) 
 
Rat NR Oral 3300 (Moreno, 1977aa)  
(Ethyl benzoate [09.726]) Rabbit NR Oral 2630 (Graham and Kuizenga, 
1945) 
 
Rat NR Oral 2100 (Graham and Kuizenga, 
1945) 
 
Rat M, F Oral 6480 (Smyth et al., 1954)  
Butyl benzoate [09.779] Mouse M, F Gavage 3450 (Bier, 1979)  
Rat M, F Gavage 51401 (Smyth et al., 1954)  
(Hexyl benzoate [09.768]) Rat NR Oral 12300 (Smyth et al., 1951a)  
(Isopropyl benzoate [09.770]) Rat NR Oral 3730 (Smyth et al., 1951a)  
(Isobutyl benzoate [09.757]) Rat M, F Gavage 3685 (Levenstein, 1973e)  
(Isopentyl benzoate [09.755]) Rat NR Oral 6330 (Weir and Wong, 1971b)  
(Hex-3-enyl benzoate [09.806]) Rat NR Oral > 5000 (Moreno, 1976u)  
(4-Isopropylbenzyl alcohol [02.039]) Rat NR Oral 1020 (Moreno, 1973z)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
4-Isopropylbenzyl acetate [09.611] Rat NR Oral 1450 (Moreno, 1978i)  
(4-Ethylbenzaldehyde [05.068]) Rat M, F Oral 1970 (Costello, 1984)  
(Tolualdehydes (mixed o, m, p) [05.027]) Rat NR Oral 2250 (Moreno, 1973w)  
(Tolualdehyde glyceryl acetal [06.012]) Rat NR Oral 3400 (Moreno, 1972i)  
(4-Isopropylbenzaldehyde [05.022]) Rat M, F Gavage 1390 (Jenner et al., 1964)  
(2,4-Dimethylbenzaldehyde [05.110]) Rat M, F Gavage between 1750 and 5000 (deGroot et al., 1974) Death of 3/5 male and 3/5 female rats after single 
dose of 5000 mg/kg bw. No death after repeated 
doses of 1750 mg/kg bw in 5 male and 5 female 
rats. 
(4-Hydroxybenzaldehyde [05.047]) Rat NR Oral 3980 (Dow Chemical 
Company, 1992b) 
 
(4-Hydroxybenzoic acid [08.040]) Mouse NR Oral 2200 (Sokol, 1952)  
(Salicylic acid [08.112]) Mouse NR Oral 908 (Sado, 1973)  
Rat NR Gavage 1050 (Hasegawa et al., 1989)  
Ethyl 4-hydroxybenzoate [09.367] Rat F Gavage 4300 (CTFA, 1980b)  
Mouse NR Oral 8000 (Sokol, 1952)  
Mouse NR Oral 6008 (Sado, 1973)  
Rabbit NR2 Oral 5000 (Sabalitschka and 
Neufeld-Crzellitzer, 
1954) 
 
Dog NR2 Oral 5000 (Sabalitschka and 
Neufeld-Crzellitzer, 
1954) 
 
(Butyl 4-hydroxybenzoate [09.754]) Mouse NR Oral 13200 (Sado, 1973)  
Mouse NR Oral > 5000 (Sokol, 1952)  
(p-Anisyl alcohol [02.128]) Mouse NR Oral 1780 (Draize et al., 1948)  
Rat NR Oral 1340 (Draize et al., 1948)  
(Anisyl formate [09.087]) Rat NR Oral 1770 (Levenstein, 1975j)  
(Anisyl acetate [09.019]) Rat M, F Oral 2250 (Weir and Wong, 1971b)  
(p-Anisyl propionate [09.145]) Rat NR Oral 3330 (Wohl, 1974d)  
(p-Anisyl butyrate [09.058]) Rat NR Oral 3400 (Moreno, 1976v)  
(Anisyl phenylacetate [09.706]) Rat M, F Gavage M: 5417  
F: 4641 
(Reagan and Becci, 
1984d) 
 
Rat NR Oral > 5000 (Moreno, 1977ab)  
(Veratraldehyde [05.017]) Rat NR Oral 2000 (Moreno, 1974k)  
Rat M Oral 2040 (Field, 1979a)  
Mouse M Oral 3200 (Field, 1979b)  
(4-Methoxybenzaldehyde [05.015]) Rat NR Oral 3210 (BASF, 1981)  
Rat M, F Gavage 1510 (Jenner et al., 1964)  
Guinea pig M, F Gavage 1260 (Jenner et al., 1964)  
Rat M, F Gavage 1510 (Taylor et al., 1964)  
2-Methoxybenzaldehyde [05.129] Rat M Gavage 2.4 –2.8 ml/kg 
(2705 –3156)3 
(Field, 1979b)  
Rat NR Oral 2500 (Moreno, 1977ac)  
Mouse M Gavage 2.4 ml/kg 
(2705)3 
(Field, 1979b)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(4-Ethoxybenzaldehyde [05.056]) Rat NR Oral 2100 (Moreno, 1977ad)  
(Methyl 2-methoxybenzoate [09.796]) Rat NR Oral 3800 (Moreno, 1982l)  
(Methyl 4-methoxybenzoate [09.713]) Rat NR Oral > 5000 (Levenstein, 1975k)  
(Ethyl 4-methoxybenzoate [09.714]) Rat NR Oral 2240 (Levenstein, 1975l)  
Gallic acid [08.080] Mouse M, F Oral > 5000 (Rajalakshsmi et al., 
2001) 
 
Rabbit NR Gavage 50004 (Dollahite et al., 1962)  
(Vanillin [05.018]) Mouse M Gavage 1000 (Inouye et al., 1988)  
Rabbit NR Gavage 2600 (Deichmann and 
Kitzmiller, 1940) 
 
Rat M, F Gavage 1580 (Taylor et al., 1964)  
Rat M, F Gavage 1580 (Jenner et al., 1964)  
Rat M, F Gavage 39785
39256 
(Lheritier, 1992)  
Rat M Gavage 3830 (Monsanto Co., 1955b)  
Rat M, F Oral 3300 (Monsanto Co., 1976)  
Rat NR Oral 4370 (Makaruk, 1980)  
Guinea 
pig 
M, F Gavage 1400 (Jenner et al., 1964)  
(Vanillin isobutyrate [09.811]) Rat M, F Gavage 4755 (Mallory et al., 1983)  
(Salicylaldehyde [05.055]) Rat NR Oral 520 (Moreno, 1977af)  
Rat M Gavage 566 (Eastman Kodak Co., 
1991b) 
 
Mouse M Gavage 504 (Eastman Kodak Co., 
1991b) 
 
(2-Hydroxy-4-methylbenzaldehyde [05.091]) Rat M, F Gavage 1520 (Mondino, 1982)  
Rat M, F Oral 1520 (Peano and Berruto, 
1982) 
 
(Methyl salicylate [09.749]) Mouse M Gavage 1390 (Ohsumi et al., 1984)  
Rat NR Gavage 1250 (Giroux et al., 1954b)  
Rat M, F Oral M: 3049  
F: 2642 
(Hazleton Laboratories, 
1982c) 
 
Rat M, F Gavage 887 (Jenner et al., 1964)  
Rat NR Oral 1220 (Nivikov et al., 1994)  
Mouse M Oral 1110 (Davison et al., 1961)  
Guinea pig M, F Gavage 1060 (Jenner et al., 1964)  
Mouse M, F Gavage 1440 (NTP, 1984a)  
(Ethyl salicylate [09.748]) Rat NR Oral 1320 (Moreno, 1976x)  
(Butyl salicylate [09.763]) Rat NR Oral 1836 (Levenstein, 1975m)  
(Isobutyl salicylate [09.750]) Rat NR Oral 1560 (Moreno, 1973aa)  
(Isopentyl salicylate [09.751]) Rat NR Oral 4100 (Moreno, 1982m)  
Rat M, F Oral > 5000 (Hazleton Laboratories, 
1982c) 
 
Hexyl salicylate [09.581] Rat NR Oral > 5000 (Moreno, 1975n)  
Hex-3-enyl salicylate [09.570] Rat NR Oral 5000 (Moreno, 1975o)  
Prenyl salicylate [09.696] Rat NR Oral 3200 (Moreno, 1978k)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Benzyl salicylate [09.752]) Rat M Gavage 2227 (Fogleman and Margolin, 
1970) 
 
(Phenethyl salicylate [09.753]) Rat NR Oral > 5000 (Moreno, 1973ab)  
(o-Tolyl salicylate [09.807]) Rat M, F Oral 1.81 ml/kg 
(1810)7 
(Sterner and Chibanguza, 
1983) 
 
(2,4-Dihydroxybenzoic acid [08.076]) Mouse NR Intraperitonel > 800 (Grady et al., 1976) Highest dose applied was not lethal. 
(Ethyl 4-hydroxy-3-methoxybenzyl ether [04.094]) Rat M, F Oral > 2000 (Dufour, 1994)  
(Butyl vanillyl ether [04.093]) Rat M, F Gavage M: 5104 
F: 4734 
(Buch, 1989)  
(Ethyl vanillin [05.019]) Rat M, F Gavage > 2000 (Jenner et al., 1964)  
Rat M Gavage 4470 (Rhone-Poulenc Inc., 
1992b) 
 
Rat M, F Oral 35008 (Monsanto Co., 1991a)  
Rat M, F Oral 35009 (Monsanto Co., 1991b)  
Rabbit NR Gavage 2000 (Deichmann and 
Kitzmiller, 1940) 
 
(Ethyl vanillin isobutyrate [09.933]) Rat M, F Oral > 2000 (Sanders and Crowther, 
1997) 
 
(Piperonyl acetate [09.220]) Rat NR Oral 2100 (Moreno, 1973ac)  
(Piperonal [05.016]) Rat M, F Gavage 2700 (Jenner et al., 1964)  
Rat M, F Gavage 2700 (Taylor et al., 1964)  
Rat M, F Gavage 2700 (Hagan et al., 1965)  
Prenyl benzoate [09.693] Rat NR Oral 4700 (Moreno, 1978j)  
Prenyl salicylate [09.696] Rat NR Oral 3200 (Moreno, 1978k)  
3,4-Dihydroxybenzoic acid [08.133] Mice NR Oral > 800 (Grady et al., 1976)  
' NR: Not Reported 
1 Dose range-finding study. 
2 Article published in German. Data point not verified.  
3 Calculation based on a specific gravity of 1.127 g/ml. 
4 Dosed as a 10 % solution.  
5 Calculated using Bliss’ method.  
6 Calculated using Litchfield and Wilcox’s method.  
7 Calculation based on an assumed specific gravity of 1.0 g/ml.  
8 Administered as a 10 % solution in corn oil.  
9 Administered as a 20 % solution-suspension in corn oil. 
10 Calculated based on a specific gravity of 1.081 g/ml 
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Subacute / Subchronic / Chronic / Carcinogenic toxicity data are available for five candidate substances of the present flavouring group evaluation from 
chemical group 23 and 30, and for 18 supporting substances evaluated by the JECFA at the 46th and 57th meeting (JECFA, 1996b; JECFA, 2002a). The 
supporting substances are listed in brackets. 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Benzyl alcohol [02.010]) Rat; M, F 
20 
Gavage 0, 50, 100, 200, 
400, 800 mg/kg 
bw/day 
13 weeks 100 (NTP, 1989a) Fully described NTP study. Reduced relative 
weight gain in females at 200 mg/kg bw/day and 
more, and at 800 mg/kg bw/day in males. 
Rat; M, F 
100 
Gavage 0, 200, 400 mg/kg 
bw/day 
103 weeks ND7 (NTP, 1989a) Fully described NTP study. Survival in both dose 
group of females was 50 % that of controls. This 
was, as concluded by NTP, primarily due to an 
increased number of gavage-related deaths. NTP 
conclusion on carcinogenicity: no evidence of 
carcinogenic activity.  
Mouse; M, F 
20 
Gavage 0, 50, 100, 200, 
400, 800 mg/kg 
bw/day 
13 weeks 100 (NTP, 1989a) Fully described NTP study. Reduced relative 
weight gain in females at 200 mg/kg bw/day and 
more, and at 400 and 800 mg/kg bw/day in 
males. 
Mouse; M, F 
100 
Gavage 0, 100, 200 mg/kg 
bw/day 
103 weeks 200 (NTP, 1989a) Fully described NTP study. NTP conclusion on 
carcinogenicity: no evidence of carcinogenic 
activity. 
(Benzyl acetate [09.014]) Rat; M, F 
20 
Gavage 0, 62.5, 125, 250, 
500, 1000 mg/kg 
bw/day 
13 weeks 250 (NTP, 1986c) Fully described NTP study. Clinical signs of 
toxicity in females at 500 mg/kg and in males 
and females at 1000 mg/kg. Decreased body 
weight in males at 1000 mg/kg. Deaths at highest 
dose (1 F/2 M). At necropsy thickened stomach 
walls in surviving animals (2/8 M, 4/9 F). 
Hippocampal necrosis in both sexes at 1000 
mg/kg (8/8 M, 4/9 F).  
Rat; M 
30 
Oral 0, 20000, 35000, 
50000 mg/kg in 
the diet (0, 1500, 
2700, 3800 mg/kg 
bw/day)25, 26 
 
13 weeks  ND7 (Abdo et al., 1998) Published non-GLP study of good quality. 
Benzyl acetate caused an increase in mortality, 
incidence of abnormal neural behavioral signs 
along with astrocyte hypertrophy and neuronal 
necrosis in the cerebellum, hippocampus and 
pyriform cortex of the brain at 35000 mg/kg feed 
and more. Body weight was statistically 
significant reduced from 20000 mg/kg feed. 
These effects were reduced significantly by 
glycine but not by L-alanine.  
Rat; M, F 
20 
Oral 0, 3130, 6250, 
12500, 25000, 
50000 mg/kg in 
the diet 
(equivalent to 0, 
230, 460, 900, 
1750, 3900 mg/kg 
bw/day for males 
13 weeks 460 (NTP, 1993d) Fully described NTP study. High mortality at 
highest dose (9/10 F, 9/10 M). Statistically 
significant decreases in final body weights (over 
10 %) observed at 25000 mg/kg feed. Clinical 
signs of intoxication at 50000 mg/kg feed. At the 
highest dose level degeneration and necrosis of 
neurons and glial cells in the cerebellum and 
hippocampus, renal tubular degeneration and 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
0, 240, 480, 930, 
1870, 4500 mg/kg 
bw/day for 
females) 
histopathological changes in skeletal thigh 
muscles. Testicular tubular atrophy in a few 
males at 12500 mg/kg feed. 
Rat; M, F 
120 
Oral 0, 3000, 6000, 
12000 mg/kg in 
the diet (equal to 
0, 130, 260, 510 
mg/kg bw/day in 
males and 0, 145, 
290, 575 mg/kg 
bw/day in 
females) 
103 weeks 260 (NTP, 1993d) Fully described NTP study. Slightly reduced 
mean body weight and feed consumption at the 
highest dose. NTP conclusion on 
carcinogenicity: No evidence of carcinogenic 
activity in male and female Fischer 344/N rats. 
Rat; M, F 
100 
Gavage 0, 250, 500 mg/kg 
bw/day 
103 weeks ND7 (NTP, 1986c) Fully described NTP study. No observable 
adverse effects on mean body weight gain and 
survival. NTP conclusion on carcinogenicity: 
Benzyl acetate increased the incidence of acinar-
cell adenomas of the endocrine pancreas in male 
F344/N rats; the gavage vehicle may have been a 
contributing factor. No evidence of carcinogenic 
activity for female rats. 
Mouse; M, F 
20 
Gavage 0,  125, 250, 500, 
1000, 2000 mg/kg 
bw/day for 
females and 
0, 62.5, 125, 250, 
500, 1000 mg/kg 
bw/day for males 
13 weeks 500 (NTP, 1986c) Fully described NTP study. High mortality (8/10) 
in females at 2000 mg/kg due to gavage error. 
Clinical signs of toxicity were observed at 1000 
mg/kg bw/day. Hippocampal necrosis in one 
female at 1000 mg/kg. 
Mouse; M, F 
20 
Oral 0, 3130, 6250, 
12500, 25000, 
50000 mg/kg in 
the diet (equal to 
0, 425, 1000, 
2000, 3700, 7900 
mg/kg bw/day for 
males and 0, 650, 
1280, 2980, 4300, 
9400 mg/kg 
bw/day for 
females) 
13 weeks ND7 (NTP, 1993d) Fully described NTP study. Statistically 
significant, dose-related decreases in final body 
weights (over 10 %) observed in all treated 
animals. Hippocampal necrosis in one male and 
three females of highest dose group. 
Mouse; M, F 
120 
Oral 0, 330, 1000, 
3000 mg/kg in the 
diet (equal to 0, 
37, 112, 346 
mg/kg bw/day in 
males and 0, 42, 
132, 382 mg/kg 
bw/day in 
103 weeks ND7 (NTP, 1993d) Fully described NTP study. Decreased mean 
body weights (9-13 %) in all treated mice except 
for females at 330 mg/kg feed (statistics not 
reported). Statistically significant, dose-related 
incidence and severity of non-neoplastic lesions 
of the nasal mucosa and glands in all treated 
animals. NTP conclusion on carcinogenicity: No 
evidence of carcinogenic activity in male and 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
females) female B6C3F1 mice. 
Mouse; M, F 
100 
Gavage 0, 500, 1000 
mg/kg bw/day 
103 weeks ND7 (NTP, 1986c) Fully described NTP study. No observable 
adverse effects on mean body weight gain and 
survival. NTP conclusion on carcinogenicity: For 
male and female B6C3F1 mice there was 
evidence of carcinogenicity, in that benzyl 
acetate caused an increased incidence of 
hepatocellular neoplasms particularly adenoma, 
and squamous cell neoplasms (papillomas) of the 
forestomach. 
(Benzyl butyrate [09.051]) Rat; M, F 
12 
Oral1 0, 26.5 mg/kg 
bw/day24 
12 weeks 26.5 (Oser, 1957) Unpublished non-GLP study.with limited details 
on study protocol and results. 
(Benzaldehyde [05.013]) Rat; M, F 
20 
Gavage 0, 50, 100, 200, 
400, 800 mg/kg 
bw/day 
13 weeks 200 (Kluwe et al., 
1983; NTP, 1990c) 
Fully described NTP study. High mortality in 
males (6/10) and death of three females in the 
highest group. Death of one female at 400 
mg/kg. Reduced terminal body weights (26 %) in 
males at highest dose. Treatment-related lesions 
in the brain, forestomach, liver and kidney in 
both sexes at 800 mg/kg including necrosis and 
degeneration of cerebellum, necrosis of neurons 
of the hippocampus, hyperplasia and/or 
hyperkeratosis of sqamous epithelium of the 
forestomach, degeneration and/or necrosis of 
liver and kidney. 
Rat; M, F 
10 
Oral 0, 1% in the diet 
(0, 500 mg/kg 
bw/day)21 
16 weeks 5002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
10 
Oral 0, 0.1% in the diet 
(0, 50 mg/kg 
bw/day)21 
27 - 28 weeks 502 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
100 
Gavage 0, 200, 400 mg/kg 
bw/day 
103 weeks ND7 (NTP, 1990c) Fully described NTP study. Significantly reduced 
survival of the high dose group rats after one 
year and significant dose-related trend to reduced 
survival in the treated groups of males. Body 
weight not affected. NTP conclusion on 
carcinogenicity: No evidence of carcinogenic 
activity for male or female F344/N rats. 
Mouse; 
M, F 
20 
Gavage 0, 75, 150, 300, 
600, 1200 mg/kg 
bw/day 
13 weeks 300 (Kluwe et al., 
1983; NTP, 1990c) 
Fully described NTP study. High mortality in 
males (9/10) and death of one female in the 
highest group. Reduced mean body weight at 600 
mg/kg in males, but not in females. Mild to 
moderate renal tubular degeneration in all males 
at 1200 mg/kg and in one male at 600 mg/kg. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
Mouse; M, F Gavage 0, 200, 400 mg/kg 
bw/day for males,  
0, 300, 600 mg/kg 
bw/day for 
females 
103 weeks ND7 (NTP, 1990c) Fully described NTP study. No significant 
effects on body weight and survival observed in 
any group. Increased incidences of .squamous 
cell papillomas of the forestomach in both 
exposure groups with dose-related increased 
incidences in forestomach hyperplasia. NTP 
conclusion on carcinogenicity: Some evidence of 
carcinogenic activity for male or female B6C3F1 
mice. 
(Methyl benzoate [09.725]) Rat; NR 
13 
Gavage 0, 0.005, 0.05 
mg/kg bw/day 
6 months 0.005 (Kravets-Bekker 
and Ivanova, 1970) 
Published non-GLP study of limited quality. 
Unusual study design and parameters analysed. 
Limited report of  experimental details and 
results. 
(Benzoic acid [08.021]) Mouse; M, F 
100 
Gavage 0, 80 mg/kg 
bw/day 
3 months ND7 (Shtenberg and 
Ignat’ev, 1970) 
Published non-GLP study of limited quality. 
Insufficient details on methods and results 
provided. Reduced weight gain with normal food 
intake in treated animals. 
Mouse; M, F 
50 
oral (paste) 0, 40 mg/kg 
bw/day 
17 months 402 (Shtenberg and 
Ignat’ev, 1970) 
Published non-GLP study of limited quality. 
Insufficient details on methods and results 
provided. 
(Glyceryl tribenzoate [09.812]) Rat; M, F 
30 
Oral 0, 120, 600, 2600 
mg/kg bw/day 
90 days 600 (Carson, 1972a) Unpublished non-GLP study carried out in 
accordance with OECD guideline 408. 
Decreased body weight gain (by 23 %) in high 
dose males with normal food intake. 
(Propylene glycol dibenzoate 
[09.803]) 
Rat; M, F 
30 
Oral 0, 130, 630, 2500 
mg/kg bw/day 
90 days 25002 (Carson, 1972b) Unpublished non-GLP study carried out in 
accordance with OECD guideline 408. 
(Tolualdehydes (mixed o, m, p) 
[05.027]) 
Rat; M, F 
30 
Oral 36 mg/kg bw/day 
for males,  
43 mg/kg bw/day 
for females 
90 days 362 (Oser et al., 1965) Published non-GLP study. Very limited details 
provided. 
Rat; M, F 
30  
Gavage 0, 50, 250, 500 
mg/kg bw/day 
13 weeks 250 (Brantom et al., 
1972) 
Published non-GLP study of good quality, 
carried out in accordance to OECD guideline 
408. Decreased relative pituitary weight in 
females at 500 mg/kg bw/day. Reduced weight 
and relative weight of small intestine in all 
treated groups. However, this effect was not 
dose-related and not reproduced in a second 
study. 
(2,4-Dimethylbenzaldehyde 
[05.110]) 
Rat; M, F 
10 
Gavage 0, 0.175, 1.75 
mg/kg bw/day 
2 weeks 1.752 (deGroot et al., 
1974) 
Unpublished non-GLP study with limited 
parameters analysed and limited report of results. 
Increased relative liver weight in high-dose 
males without histopathological changes. 
Ethyl 4-hydroxybenzoate 
[09.367] 
Rat; M, F 
24 
Oral 0, 2, 8 % in the 
diet 
(0, 1050, 5700 
mg/kg bw/day) 
12 weeks 1050 (Matthews et al., 
1956) 
Published non-GLP study of very limited quality. 
Insufficient endpoints analysed. High mortality 
at highest dose. 
Rat; NR Oral 0, 0.2, 1, 2 % in 25 weeks 1000 (Sado, 1973) Published non-GLP study of limited quality. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
10 or 11 the diet 
(0, 100, 500, 1000 
mg/kg bw/day)18 
Experimental details and results insufficiently 
reported. 
(Butyl 4-hydroxybenzoate 
[09.754]) 
Rat; NR 
10 or 183 
Gavage 0, 0.25, 50 mg/kg 
bw/day 
13 - 15 weeks 502 (Ikeda and Yokoi, 
1950) 
Published non-GLP study in Japanese with 
English translation. Validity cannot be evaluated 
due to incomplete report of data.  
Rat; M, F 
24 
Oral 0, 2, 8 % in the 
diet 
(0, 1050, 5700 
mg/kg bw/day) 
12 weeks 1050 (Matthews et al., 
1956) 
Published non-GLP study of very limited quality. 
Insufficient endpoints analysed. High  mortality 
(100 % in males) at highest dose. 
Mouse; M, F 
20 
Oral 0, 0.6, 1.25, 2.5, 
5, 10 % in the diet 
(0, 900, 1850, 
3750, 7500, 
15000 mg/kg 
bw/day) 
6 weeks 900 (Inai et al., 1985) Published non-GLP study of limited quality. 
Experimental details and results insufficiently 
reported. Copy partly unreadable. 
Mouse; M, F 
100 
Oral 0, 0.15, 0.3, 0.6 % 
in the diet 
(0, 225, 450, 900 
mg/kg bw/day) 
102 weeks 9002 (Inai et al., 1985) Published non-GLP study of limited quality. 
Experimental details and results insufficiently 
reported. Copy partly unreadable. 
(4-Methoxybenzaldehyde 
[05.015]) 
Rat; M, F 
20 
Oral 0, 7.3 mg/kg 
bw/day 
12 weeks 7.34, 2 (Trubek 
Laboratories Inc., 
1958f) 
Unpublished study of poor quality with 
insufficient study protocol and report of data; 
Eugenol: JECFA evaluation; NOAEL 250 mg/kg 
bw/day in rat (diet), ADI 2.5 mg/kg bw. 
Rat; M, F 
10 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
16 weeks 5002 (FDA, 1954) Unpublished study of limited quality. 
Insufficient study protocol and report of data; 
part of screening of 50 flavouring substances. 
Rat; M, F 
10 
Oral 0, 0.1 % in the 
diet 
(0, 50 mg/kg 
bw/day)21 
28 weeks 502 (FDA, 1954) Unpublished study of limited quality. 
Insufficient study protocol and report of data; 
part of screening of 50 flavouring substances. 
Rat; M, F 
10 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
15 weeks 5002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
10 
Oral 0, 0.1 % in the 
diet 
(0, 50 mg/kg 
bw/day)21 
27 - 28 weeks 502 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
(Methyl 2-methoxybenzoate 
[09.796]) 
Rat; M, F 
10 
Oral 0, 94 mg/kg 
bw/day 
14 days 942 (Van Miller and 
Weaver, 1987) 
Unpublished GLP-study. 
3,4-Dihydroxybenzaldehyde 
[05.142]  
Rat; M, F 
10 
Oral 0, 1.5 % in the 
diet 
(0, 1500 mg/kg 
bw/day)16 
4 weeks 150015 (Shibata et al., 
1990) 
Published non-GLP study of limited quality. 
Experimental details and results insufficiently 
reported. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
Gallic acid [08.080] Rat; M, F 
20 
Oral 0, 0.2, 0.6, 1.7, 5 
% in the diet 
13 weeks 0.6 % in the diet 
(M: 119 
F: 128)17 
(Niho et al., 2001) Published non-GLP study of good quality. 
Centrilobular liver cell hypertrophy, reflected in 
a significant increase in liver weight, was 
observed in animals of both sexes from 1.7 %. 
Rat; M 
5 
Oral 0, 2 % in the diet 
(0, 2000 mg/kg 
bw/day)16 
4 weeks 20002, 6 (Hirose et al., 
1987) 
Published non-GLP study of limited quality. 
Experimental details and results insufficiently 
reported. 
Mouse; M, F 
12 
Oral 0, 1000 mg/kg 
bw/day 
28 days 10002 (Rajalakshsmi et 
al., 2001) 
Published non-GLP study of acceptable quality.  
(Vanillin [05.018]) Rat; M, F 
10 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
16 weeks 5002 (FDA, 1954) Unpublished study of limited quality. 
Insufficient study protocol and report of data; 
part of screening of 50 flavouring substances. 
Rat; M, F  
10 
Oral 0, 0.1 % in the 
diet 
(0, 50 mg/kg 
bw/day)21 
27 - 28 weeks 502 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M 
5 
Oral 0, 2, 5 % in the 
diet 
(0, 1000, 2500 
mg/kg bw/day)21 
1 year 25002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; NR 
8 
Oral 64 mg/kg bw/day 70 days ND (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. No NOAEL could be 
derived. 
Rat; NR 
8 
Oral 20 mg/kg bw/day 126 days 202 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. 
Rat; M, F 
10 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
16 weeks 5002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
24 
Oral 0, 0.5, 1, 2 % in 
the diet 
(0, 250, 500, 1000 
mg/kg bw/day)21 
2 years 10002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
10 
Oral 0, 0.1 % in the 
diet 
(0, 50 mg/kg 
bw/day)21 
28 weeks 502 (FDA, 1954) Unpublished study of limited quality. 
Insufficient study protocol and report of data; 
part of screening of 50 flavouring substances. 
Rat; NR 
12 
Gavage 300 mg/kg bw 
twice a week 
14 weeks 3002, 5 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. 
Rat; M Oral 0, 0.1, 0.5, 1.0 % 26 weeks 4372 (Monsanto Co., Unpublished non-GLP study of limited quality. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
10 in the diet 
(0, 40, 214, 437 
mg/kg bw/day)20 
1955a) Insufficient analysis of clinical-chemical 
parameters. Results of microscopic examination 
not reported. 
Rabbit; NR 
3 
Oral 240 mg/kg 
bw/day 
56 or 126 days19 2402 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. 
Rabbit; NR 
1 
Oral 83 mg/kg bw/day 
for 14 days 
103 mg/kg 
bw/day for 61 
days 
14 or 61 days ND (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. The animal treated with 83 
mg/kg bw/day died due to glycerol poisoning 
(solvent), the animal treated with 103 mg/kg 
bw/day suffered from anemia, diarrea and 
showed a reduced wt gain. 
Dog; M, F 
2 
Capsule 0, 25, 100 mg/kg 
bw/day 
26 weeks 100 (Monsanto Co., 
1955a) 
Unpublished non-GLP study of limited quality. 
Insufficient analysis of clinical-chemical 
parameters. Results of microscopic examination 
not reported. 
4-Hydroxy-3,5-
dimethoxybenzoic acid [08.087] 
Rat; M 
5 
Oral 0, 2 % in the diet 
(0, 2000 mg/kg 
bw/day) 16 
4 weeks 20002, 6 (Hirose et al., 
1987) 
Published non-GLP study of limited quality. 
Experimental details and results insufficiently 
reported. 
(Methyl salicylate [09.749]) Rat; M, F 
20 
Oral 0, 0.1, 1.0 % in 
the diet 
(0, 50, 500 mg/kg 
bw/day)21 
17 weeks 5002 (Webb and 
Hansen, 1963) 
Published non-GLP FDA-study of good quality. 
Preliminary study in extensive toxicological 
evaluation. Study protocols fully described, 
results not reported in detail but only 
summarised in text. 
Rat; M, F 
6 
Oral 0, 2 % in the diet 
(0, 1000 mg/kg 
bw/day)21 
Up to 71 days 10007 (Webb and 
Hansen, 1963) 
Published non-GLP FDA-study of good quality. 
Supplemental study in extensive toxicological 
evaluation to analyse bone effects. Study 
protocols fully described, results not reported in 
detail but only summarised in text. 
Rat; NR Oral 1.12, 2 % in the 
diet 
(560, 1000 mg/kg 
bw/day)21, 23  
10 weeks < 560 (Harrison et al., 
1963) 
Only abstract available. No details reported. 
Study carried out to further investigate the 
increase of cancellous bone reported by Webb & 
Hansen, 1963). Effects confirmed at levels of 2 
% and 1.12 % but not at lower (unspecified) 
levels. 
Rat; M, F 
10 
Oral 0, 0.2, 0.36, 0.63, 
1.13, 2.0 % in the 
diet 
(0, 100, 180, 320, 
560, 1000 mg/kg 
bw/day)21 
11 weeks 180 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. Decreased weight gain at 320 mg/kg, 
decreased weight gain and increased bone 
density from 560 mg/kg. 
Rat; M 
5 
Oral 0.6, 2.0 % in the 
diet 
(300, 1000 mg/kg 
bw/day)21 
12 weeks 300 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. No control animals used. 100 % 
mortality in high dose group after 6 weeks with 
bone lesions. No such effects at 300 mg/kg. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
Rat; M, F 
15 
Oral 0, 2.0 % in the 
diet 
(0, 1000 mg/kg 
bw/day)21 
11 weeks ND7 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. Changes in bone density and 20 % 
mortality in treated animals. No such effects in 
controls. 
Rat; M 
108 
Oral 0, 0.6, 2.0 % in 
the diet 
(0, 300, 1000 
mg/kg bw/day)21 
6 weeks ND9 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. Deaths occurred among the rats at 
the high dose ad libitum and in all members of 
the pair-fed groups (incl. controls). 
Rat; M, F 
20 
Oral 0, 0.6., 0.9, 1.2, 
2.0 % in the diet  
(0, 300, 450, 600, 
1000 mg/kg 
bw/day)21 
11 weeks 450 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. Weekly X-ray evaluation of animals 
for progression of bone changes. Bone changes 
at 1000 mg/kg from week 2, at 600 mg/kg from 
week 5. 
Dog; M, F 
2 
Oral 50, 100, 250, 500, 
800, 1200 mg/kg 
bw 
Up to 59 days 250 (Webb and 
Hansen, 1963) 
Published non-GLP FDA-study of good quality. 
Preliminary study in extensive toxicological 
evaluation. Study protocols fully described, 
results not reported in detail but only 
summarised in text. 
Dog; M, F 
6 
Oral 0, 150, 300, 500, 
800 mg/kg 
bw/day22 
7.5 months10 ND7 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. 100 % mortality at highest dose, only 
2 surviving animals at 500 mg/kg. At lower 
doses no effects on body weight and 
hematological parameters. Increased liver and 
kidney weight at all doses but not after recovery 
diet. No NOEL could be derived. 
Dog; M, F 
8, 1211 
Oral 0, 50, 100, 170 
mg/kg bw/day 
6 months12 1702 (Abbott and 
Harrison, 1978) 
Unpublished non-GLP study of limited quality. 
Insufficient report of experimental details and 
results. Very limited number of analysed 
parameters. No adverse effects at any dose. 
Rat; M, F 
50 
Oral 0, 0.1, 0.5, 1.0, 
2.0 % in the diet 
(0, 50, 250, 500, 
1000 mg/kg 
bw/day)21 
2 years 50 (Webb and 
Hansen, 1963) 
Published non-GLP FDA-study of good quality. 
Study protocols fully described, results not 
reported in detail but only summarised in text. 
Rat; M, F 
50 
Oral 0.07, 0.21 % in 
the diet 
(0, 35 100)21 
2 years 1002 (Packman et al., 
1961) 
Only abstract available with very limited report 
of study details and results. 
Dog; M, F 
4 
Oral 0, 50,150, 350 
mg/kg bw/day 
2 years 50 (Webb and 
Hansen, 1963) 
Published non-GLP FDA-study of good quality. 
Study protocols fully described, results not 
reported in detail but only summarised in text. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Isopentyl salicylate [09.751]) Rat; M, F 
30 
Oral 0, 0.005, 0.05, 0.5 
% in the diet 
(0, 4.7, 46, 420 
mg/kg bw/day in 
males and 0, 4.8, 
47, 480 mg/kg 
bw/day in 
females) 
13 weeks 5 (Drake et al., 
1975) 
Published non-GLP study of good quality. 
Reduced body weight gain at 0.5 % associated 
with reduced food intake. Increased relative 
kidney weight without any histophathological 
changes at 0.05 and 0.5 % in the diet. 
Rat; M, F 
10 
Oral 0. 0.5 % in the 
diet 
(0, 420 mg/kg 
bw/day in males 
and 0, 480 mg/kg 
bw/day in 
females)13 
98 days 420 (Drake et al., 
1975) 
Published non-GLP study of good quality. 
Reduced body weight gain at 0.5 % associated 
with reduced food intake. Only body weight gain 
analysed. 
(Ethyl vanillin [05.019]) Rat; M 
5 
Oral 0, 2, 5 % in the 
diet 
(0, 1000, 2500 
mg/kg bw/day)21 
1 year 25002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; NR 
8 
Oral 64 mg/kg bw/day 70 days 642 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of 
data.. No adequate controls. No NOAEL could 
be derived. 
Rat; NR 
8 
Oral 20 mg/kg bw/day 126 days 202 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. 
Rat; NR 
12 
Gavage 300 mg/kg bw 
twice a week 
14 weeks 3002, 5 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. 
Rat; M, F 
40 
Oral 0, 500, 1000, 
2000 mg/kg 
bw/day 
13 weeks 500 (Hooks et al., 
1992) 
Unpublished report summarised by the JECFA 
(1996a). Study has been reported to be designed 
in accordance with toxicological principles for 
the safety assessement of food additives 
established by the US FDA in 1982. Limited 
report of experimental details and results. 
Rat; M, F 
24 
Oral 0, 0.5, 1, 2 % in 
the diet 
(0, 250, 500, 1000 
mg/kg bw/day)21 
2 years 10002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rabbit; NR 
3 
Oral 240 mg/kg 
bw/day 
56 or 126 days19 2402 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. 
Rabbit; NR 
1 
Oral 15-49 mg/kg 
bw/day 
(15, 15, 32, 41, 49 
mg/kg day for 15, 
15 - 49 days 412 (Deichmann and 
Kitzmiller, 1940) 
Published non-GLP study with insufficient 
quality of experimental design and report of data. 
No adequate controls. The animal treated with 15 
mg/kg bw/day for 15 days died due to glycerol 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
31, 17, 31, 49 
days, 
respectively) 
poisoning (solvent), the animal treated with 49 
mg/kg bw/day for 49 days suffered from anemia, 
diarrea and showed a reduced wt gain. 
(Piperonal [05.016]) Rat; M, F 
20 
Oral 0, 16 mg/kg bw 12 weeks 1614, 2 (Trubek 
Laboratories Inc., 
1958f) 
Unpublished study of poor quality with 
insufficient study protocol and report of data; 
Eugenol: JECFA evaluation; NOAEL 250 mg/kg 
bw/day in rat (diet), ADI 2.5 mg/kg bw. 
Rat; M, F 
10 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
16 weeks 5002 (FDA, 1954) Unpublished study of limited quality. 
Insufficient study protocol and report of data; 
part of screening of 50 flavouring substances. 
Rat; M, F 
10 
Oral 0, 0.1 % in the 
diet 
(0, 50 mg/kg 
bw/day)21 
28 weeks 502 (FDA, 1954) Unpublished study of limited quality. 
Insufficient study protocol and report of data; 
part of screening of 50 flavouring substances. 
Rat; M, F 
10 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
15 weeks 5002 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
10 
Oral 0, 0.1 % 
(0, 50 mg/kg 
bw/day)21 
27 - 28 weeks 502 (Hagan et al., 
1967) 
Published summary of subacute and/or chronic 
toxicity studies on 48 food flavourings carried 
out by the FDA. Validity of the results cannot be 
evaluated. Results not reported in detail but 
summarised in a table only. 
Rat; M, F 
NR 
Oral 0, 0.1 % in the 
diet  
(0, 50 mg/kg 
bw/day)21 
28 weeks 502 (Hagan et al., 
1965) 
Published report of subchronic and/or chronic 
toxicity studies on 7 food flavourings carried out 
by the FDA. Validity of the results cannot be 
evaluated. No detailed results reported. 
Rat; M, F 
NR 
Oral 0, 1 % in the diet 
(0, 500 mg/kg 
bw/day)21 
16 weeks 5002 (Hagan et al., 
1965) 
Published report of subchronic and/or chronic 
toxicity studies on 7 food flavourings carried out 
by the FDA. Validity of the results cannot be 
evaluated. No detailed results reported. 
Rat; M, F 
20 -60 
Oral 0, 0.1, 0.5 % in 
the diet 
(0, 50, 250 mg/kg 
bw/day)21 
1.5 - 2 years 2502 (Bär and 
Griepentrog, 1967) 
Published study with incomplete report of 
experimental details and results. 
3,4-Dihydroxybenzoic acid 
[08.133] 
Rat; M, F 
10 
Oral 0, 1.5 % in the 
diet (0, 750 mg/kg 
bw/day) 
4 weeks 750 (Shibata et al., 
1990) 
Published non-GLP study of limited quality. 
Experimental details and results insufficiently 
reported. 
Rat, M 
10 
Oral 0, 50 mg/kg 
bw/day 
2 weeks 50 (Guglielmi et al., 
2003) 
 
Rat, M 
11 
Oral 0, 1000 ppm (0, 
50 mg/kg bw/day) 
28 weeks 50 (Tanaka et al., 
1993a; Tanaka et 
al., 1993b) 
 
Rat, M 
16 
Oral 0, 2000 ppm (0, 
100 mg/kg 
bw/day) 
32 weeks 100 (Tanaka et al., 
1994) 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
Rat, M 
15 
Oral 0, 2000 ppm (0, 
100 mg/kg 
bw/day) 
41 weeks 100 (Hirose et al., 
1995) 
 
Rat, M 
15 
Oral 0, 1.5 % in the 
diet (0, 530 mg/kg 
bw/day) 
51 weeks < 530 (Hirose et al., 
1992) 
It was noted  that the relative liver and kidney 
weight was significantly increased but this was 
not further evaluated. 
1 Six aromatic esters (ethyl benzoate, 0.15 ppm; isobutyl benzoate, 25 ppm; benzyl acetate, 18.7 ppm; benzyl butyrate, 25 ppm; ethyl methylphenyl glycidate, 25 ppm; and glycidate M-116, 25 ppm) were blended in the diet. 
2 This study was performed at either a single dose level or multiple dose levels that produced no adverse effects. Therefore, this dose level is the highest dose tested that produced no adverse effects.  
3 Five rats were used per group for low dose. Nine rats were used per group for high dose. 
4 Rats were fed a test mixture containing 123 ppm of eugenol, 10 ppm of 4-methoxybenzaldehyde and 22 ppm of piperonal. 
5 Compound was administered two times per week. 
6 Study evaluated histological changes in the rat forestomach. 
7 This study was performed at a single dose level or at multiple dose levels that produced adverse effects. No NOEL could be derived from that study. 
8 Two groups fed ad libitum (2.0 and 0.6 %) and one group (0.6 %) pair-fed. 
9 The 0.6 % pair-fed rats showed adverse effects; however, those fed ad libitum did not. 
10 Two animals from the 150 mg/kg/day group and three animals from the 300 mg/kg/day group were sacrificed after 6.5 months. Additionally, three animals from the 300 mg/kg/day group discontinued feeding at 6.5 months and recovered for 1.5 
months, before being sacrificed. 
11 There were 8 dogs used for the 50 and 100 mg/kg bw doses and 12 dogs used for 167 mg/kg bw. 
12 All animals were fed the substance for six months and then sacrificed, with the exception of two dogs from the high dose group. These animals were fed the substance for four months, placed on control diets for two months, and then sacrificed 
with the other animals at six months. 
13 Pair-fed study.  
14 Rats were fed a test mixture containing 123 ppm of eugenol, 10 ppm of 4-methoxybenzaldehyde, and 22 ppm of piperonal. 
15 This study evaluated the cell proliferation in the rat forestomach at a single concentration, 1.5 %. There was a statistically significant weight reduction in the females; however, it was deemed to be associated with a palatability problem.  
16 Calculated based on a bw of 250 g and a daily food intake of 12 g. 
17 Calculated by using mean values of body weight and food intake in the 0.2 % group. 
18 Estimated based on FDA (1993). Priority-based assessment of food additives (PAFA) database. Center for food safety and applied nutrition. p. 58.   
19 One animal was treated for 56 days and two animals for 126 days. 
20 Calculated based on a final bw of 453, 444, 427g  and a total consumption of test compound of 18.2, 95.0 and 186.8 mg/animal/day, respectively, in the three dose groups. 
21 Calculated based on general assumptions for bw and food intake (e.g. 1 % in diet resulting in 500 mg/kg bw/day). As estimated by JECFA (2002a). 
22 The dogs were given one-half of the dose in the morning and the other half in the afternoon for six days/week. 
23 Also lower dose levels applied, however, not reported in more detail. 
24 Benzyl butyrate administered in the diet in a mixture of six aromatic esters (ethyl benzoate 0.15 mg/kg, isobutyl benzoate 25 mg/kg, benzyl acetate 18.7 mg/kg, benzyl butyrate 25 mg/kg, ethyl methylphenylglycidate 25 mg/kg, glycidate 25 
mg/kg) providing intakes of 26.5 mg benzylbutyrate/kg bw/day and a total of 126 mg/kg bw/day of the mixture. 
25 Calculated based on a final bw of 200 g and a daily intake of 15.2 g/rat, as reported for the 20000 mg/kg feed group, for all groups. 
26 Additional groups with either 50000 mg benzyl acetate/kg feed plus 27000 mg glycine/kg feed or 32000 mg L-alanine/kg feed (supplemental L-alanine and glycine were equimolar). The L-alanine group  served as amino-nitrogen control. 
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Developmental and reproductive toxicity data are available for one candidate substance of the present flavouring group evaluation from chemical group 23 
and for twelve supporting substances evaluated by the JECFA at the 57th meeting (JECFA, 2002a). Supporting substance listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  Study type 
Durations  
Species/Sex 
No / group 
Route  Dose  levels NOAEL  (mg/kg bw/day), 
Including information of 
possible maternal toxicity 
Reference  Comments 
(Benzyl alcohol [02.010]) Developmental toxicity:  
Gestation days 6 - 15 
Mouse; F 
50 
Gavage 0, 550 mg/kg bw/day Maternal: 550  
Foetal: 550 
(JECFA, 1996a) Unpublished study carried out by NIOSH 
of assumed good quality. Only summary 
available. In a preliminary experiment 
clinical signs of maternal toxicity were 
observed at 1320 mg/kg and reduced 
number of viable fetuses at 720 mg/kg. 
Developmental toxicity:  
Gestation days 6 - 13 
Mouse; F 
50 
Gavage 0, 750 mg/kg bw/day Maternal: ND1  
Foetal: ND1 
(Hardin et al., 1987) Published study carried out by NIOSH of 
assumed good quality. Increased 
mortality, clinical signs of matermal 
toxicity, reduced maternal body weight-
gain and reduced pup weight in treated 
group. 
(Benzyl acetate [09.014]) Developmental toxicity:  
Gestation days 6 - 15 
Rat; F 
20 
Gavage 0, 10, 100, 500, 1000 mg/kg 
bw/day 
Maternal: 1000 
Foetal: 500 
(Ishiguro et al., 1993) Published non-GLP study. At highest 
dose, slight, but not significant maternal 
toxicity observed with slightly reduced 
maternal weight-gain. Also significantly 
reduced fetal body weight at highest dose 
and increased incidence of skeletal 
internal variations.  
Reproductive toxicity: Sperm 
morphology and vaginal 
cytology: 
13 weeks 
Mouse; M, F 
20 
Oral 0, 3130, 6250, 12500, 25000, 
50000 mg/kg in the diet 
(equivalent to 0, 425, 1000, 
2000, 3700, 7900 mg/kg 
bw/day for males and 0, 650, 
1280, 2980, 4300, 9400 mg/kg 
bw/day for females) 
Reproductive toxicity: 
Females: 3700 
Males: 7900 
(Morrissey et al., 1988; 
NTP, 1993d) 
Published report of screening test 
(SMVCE assay) carried out at end of 
fully described NTP-study. Statistically 
significant, dose-related decreases in 
final body weights (over 10 %) observed 
in all treated animals. Mean length of 
estrous cycle significantly greater in high 
dose than in controls. No effects on male 
reproductive endpoints. 
Reproductive toxicity. Sperm 
morphology and vaginal 
cytology: 
13 weeks 
Rat; M, F 
20 
Oral 0, 3130, 6250, 12500, 25000, 
50000 mg/kg in the diet 
(equivalent to 0, 230, 460, 
900, 1750, 3900 mg/kg bw/day 
for males 
0, 240, 480, 930, 1870, 4500 
mg/kg bw/day for females) 
Reproductive toxicity: 
Females: 4500  
Males: 3900 
(Morrissey et al., 1988; 
NTP, 1993d) 
Published report of screening test 
(SMVCE assay) carried out at end of 
fully described NTP-study. Statistically 
significant decreases in final body 
weights (over 10 %) observed at 25000 
mg/kg feed. Clinical signs of intoxication 
at 50000 mg/kg feed. No effects on male 
and female reproductive endpoints. 
(Benzaldehyde [05.013]) Reproductive toxicity 
32 weeks (every other day) 
Rat; M, F 
10 
Gavage 2 mg/animal (equivalent to 5 
mg/kg bw/day) 
ND1 (Sporn et al., 1967) Published non-GLP study of limited 
quality. Study in Romanian with English 
summary only. Reduced number of 
pregnant females among treated animals 
(no statistics presented). 
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  Study type 
Durations  
Species/Sex 
No / group 
Route  Dose  levels NOAEL  (mg/kg bw/day), 
Including information of 
possible maternal toxicity 
Reference  Comments 
(Benzoic acid [08.021]) Developmental toxicity  
Gestation day: 9 
Rat; F 
7 
Gavage 510 mg/kg bw/day2  Maternal: NR  
Foetal: 510  
(Kimmel et al., 1971) Published non-GLP study of limited 
validity due to inadequate study design. 
Study evaluated the influence of benzoic 
acid on the teratogenic effects of 
acetylsalicylic acid. No teratogenicity 
was observed with a single dose of 
benzoic acid. Pretreatment with benzoic 
acid increased the teratogenicity of 
acetylsalicylic acid by increasing the 
salicylate concentration in the embryo 
and serum. 
Four generation reproduction 
study: Continuously in diet 
Rat; M, F 
40 
Oral 0, 0.5, 1.0 % in the diet  
(0, 275, 550 mg/kg bw/day)3  
550 (Kieckebusch and Lang, 
1960) 
Published non-GLP study of acceptable 
quality. Limited male reproduction 
parameters analysed. 
(Salicylic acid [08.112]) Developmental toxicity  
Gestation days: 8 - 14 
Rat; F 
20 
Oral 0, 0.06, 0.1, 0.2, 0.4 % in the 
diet (0, 46.4, 77.4, 165.4, 330 
mg/kg bw/day) 
(0, 50.7, 77.4, 165.4, 205.9 
mg/kg bw/day) 
Maternal: 165.4 
Foetal: 77.4 
Postnatal: 77.4 
(Tanaka et al., 1973a) Published non-GLP study of acceptable 
quality.  
No maternal mortality. At highest dose 
reduced maternal body weight, signs of 
clinical toxicity (salivation, piloerection), 
no alive fetuses in 9/15 dams, reduced 
litter size. External and skeletal 
anomalies in fetuses at 0.2 % and more. 
Internal anomalies at 0.4 %. Skeletal 
anomalies in postnatal animals at 0.4 %. 
Developmental toxicity  
Gestation days: 8 - 14 
Rat; F 
20 
Gavage 0, 75, 150, 300 mg/kg bw/day Maternal: 75 
Foetal: 75  
Postnatal: 75 
(Tanaka et al., 1973b) Published non-GLP study of acceptable 
quality.  
At highest dose 3 animals died, reduced 
maternal body weight, signs of clinical 
toxicity (salivation, piloerection), At 150 
mg/kg and more significantly reduced 
uterus weight. No live fetuses at highest 
dose. At 150 mg/kg and more reduced 
litter size and fetal weight, internal, 
skeletal and external anomalies.  
Ethyl 4-hydroxybenzoate 
[09.367] 
Developmental toxicity  
Gestation days: 8 - 15 
Rat; F 
5 to 12 
Oral 0, 0.1, 1, 10 % in the diet (0, 
50, 460, 2600 mg/kg bw/day)4  
Maternal: 460 
Foetal: 2600 
(Moriyama et al., 1975) Published non-GLP study of good 
quality. Sufficient parameters analysed 
and detailed report of experimental 
design and results. Reduced terminal 
maternal body weight at high dose. 
Postnatal development  
Gestation days: 8 - 15 
Rat; F 
5 to 12 (46 to 
73 fetuses 
nursed for 1 
month) 
Oral 0, 0.1, 1, 10 % in the diet (0, 
50, 460, 2600 mg/kg bw/day)4  
Maternal: NR 
Neonatal: 2600 
(Moriyama et al., 1975) Published non-GLP study of good 
quality. Sufficient parameters analysed 
and detailed report of experimental 
design and results. 
Reproductive toxicity 
8 weeks 
Rat; M 
8 
Oral 0, 0.1, 1.0 % in the diet  
(0, 103, 1043 mg/kg bw/day) 
1043 (Oishi, 2004) Published study of good quality. No 
effects on weights of reproductive 
organs, on sperm counts in the testes and 
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  Study type 
Durations  
Species/Sex 
No / group 
Route  Dose  levels NOAEL  (mg/kg bw/day), 
Including information of 
possible maternal toxicity 
Reference  Comments 
epididymides and sperm morphology. No 
effect on serum testosterone, LH, FSH 
Uterotrophic assay 
3 days 
Mouse; F 
(immature) 
7-10 
SC 
 
Oral 
0, 100 mg/kg bw/day 
 
0, 1000 mg/kg bw/day 
100 
 
1000 
(Hossaiani et al., 2000) Published non-GLP study of good 
quality. No estrogenic response observed 
at the dose levels tested. 
Uterotrophic assay 
3 days 
Rat; F 
(immature) 
11-16 
SC 0, 6, 18, 60, 180 mg/kg bw/day 60 (Lemini et al., 2003) Published non-GLP study of good 
quality. Significantly increased uterine 
weight (wet and dry) at the highest dose 
(ED50 for uterotrophic effect: uterine wet 
weight 68 mg/kg, uterine dry weight 94 
mg/kg). 
Uterotrophic assay 
3 days 
Mouse; F 
(immature and 
ovarectomized 
adult) 
10-25 
 
SC 0, 0.6, 6.0, 18, 60, 180 mg/kg 
bw/day5  
0.6 (Lemini et al., 2003) Published non-GLP study of good 
quality. Significantly increased uterine 
weight in immature mice at 6 mg/kg and 
more and in ovarectomized mice at 18 
mg/kg an more (ED50 74 mg/kg and 25 
mg/kg, respectively). 
Uterotrophic assay 
3 days 
Mouse; F 
(adult 
ovarectomized
) 
6 
 
SC 0, 60, 180 mg/kg bw/day ND1 (Lemini et al., 2004) Published study of good quality with full 
report of experimental details and results.  
Uterotrophic effect with estrogenic 
histological changes in uteri in both dose 
groups. 
(Butyl p-hydroxybenzoate 
[09.754]) 
Reproductive toxicity 
8 weeks  
Rat; M 
8 
Oral 0, 0.01, 0.10, 1.0% in the diet  
(0, 10, 100, 1000 mg/kg 
bw/day) 
ND1 (Oishi, 2001) Published non-GLP study of good 
quality. Reduced cauda epididymal 
sperm reserve and daily sperm 
production in testis significantly reduced 
in all treated groups. Dose-dependently 
reduced serum testosterone concentration 
and absolute and relative epididymis 
weight (significant  at 0.1 % or more).    
Reproductive toxicity 
10 weeks  
Mouse; M 
8 
Oral 0, 0.01, 0.10, 1.0% in the diet  
(0, 14, 146, 1500 mg/kg 
bw/day) 
ND1 (Oishi, 2002) Published non-GLP study of good 
quality. Absolute and relative weight of 
epididymides significantly increased at 
1.0 %. Dose-dependent decrease of both 
round and elnongated spermatid counts. 
Significantly decreased elongated 
spermatid counts in all treated groups. 
Dose-dependant decrease of serum 
testosterone concentrations (significant 
at 1.0 %).  
Uterotrophic assay 
3 days  
Rat; F
(ovarectomize
d) 
5 
Oral 
 
 
SC 
4, 40 , 400, 800, 1200 mg/kg 
bw6  
 
40, 200, 400, 600, 800, 1000, 
1200 mg/kg bw/day6  
1200 
 
 
40 
(Routledge et al., 1998) Published study of good quality. No 
estrogenic activity found after oral 
administration (small, statistically 
insignificant increase in uterus wet 
weight) in immature rats. Positive 
response after s.c. administration. In the 
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  Study type 
Durations  
Species/Sex 
No / group 
Route  Dose  levels NOAEL  (mg/kg bw/day), 
Including information of 
possible maternal toxicity 
Reference  Comments 
same study also an in vitro estrogenic 
activity test in yeast  was carried out in 
which butyl paraben was found to be 
weakly estrogenic. 
Uterotrophic assay 
3 days 
Mouse; F 
(immature) 
10 
SC 0, 100 mg/kg bw/day 100 (Hossaiani et al., 2000) Published non-GLP study of good 
quality. No estrogenic response observed 
at the dose level tested. 
Uterotrophic assay 
3 days 
Rat; F 
(immature) 
10 
SC 0, 100, 400, 600 mg/kg bw/day 400 (Hossaiani et al., 2000) Published non-GLP study of good 
quality. A weak estrogenic response with 
a significantly increase relative uterus 
weight was observed at 600 mg/kg. At 
100 and 400 mg/kg the uterus wet weight 
was significantly increased, but not the 
relative uterus weight. 
Uterotrophic assay 
3 days 
Rat; F 
(immature) 
11-16 
SC 0, 7, 21, 70, 210 mg/kg bw/day 21 (Lemini et al., 2003) Published non-GLP study of good 
quality. Significantly increased uterine 
wet weight at 70 mg/kg and more, and 
uterine dry weight at 210 mg/kg (ED50 
for uterotrophic effect: uterine wet 
weight 87 mg/kg, 338 mg/kg uterine dry 
weight). 
Uterotrophic assay 
3 days 
Mouse; F 
(immature and 
ovarectomized 
adult) 
6-16 
 
SC 0, 0.7, 7.0, 21, 70, 210 mg/kg 
bw/day5  
0.7 (Lemini et al., 2003) Published non-GLP study of good 
quality. Significantly increased uterine 
weight in immature mice at 7 mg/kg and 
more and in ovarectomized mice at 21 
mg/kg an more (ED50 65 mg/kg and 22 
mg/kg, respectively). 
Uterotrophic assay 
3 days 
Mouse; F 
(adult 
ovarectomized
) 
6 
 
SC 0, 70, 210 mg/kg bw/day ND1 (Lemini et al., 2004) Published study of good quality with full 
report of experimental details and results.  
Uterotrophic effect with estrogenic 
histological changes in uteri in both dose 
groups. 
Developmental toxicity 
Gestation days: 6 - 19 
Rat; F 
25 
Gavage 0, 10, 100, 1000 mg/kg bw/day Maternal: 100 
Foetal: 1000 
(Daston, 2004) Published study of good quality with full 
report of experimental details and results. 
Maternal food consumption and weight 
gain significantly decreased at highest 
dose. 
(Methyl salicylate [09.749]) Reproductive toxicity: 
continuous breeding (RACB) 
18 weeks7  
Mouse; M, F 
40 
Gavage 0, 100, 250, 500 mg/kg bw/day 250 (NTP, 1984a) Fully described NTP-study. Significant 
slight decrease in mean number of litters, 
number of pups per litter, mean number 
of pups born alive per litter and mean 
live pup weight at highest dose. The 
experiment was unable to discriminate 
which sex was affected in reproduction.  
(Veratraldehyde [05.017]) Reproductive and Rat; F Gavage 0, 80, 400, 800 mg/kg bw/day Maternal: ND1 (Vollmuth et al., 1990) Unpublished study with limited report of 
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  Study type 
Durations  
Species/Sex 
No / group 
Route  Dose  levels NOAEL  (mg/kg bw/day), 
Including information of 
possible maternal toxicity 
Reference  Comments 
developmental toxicity: 1 
week before mating until 4 
days post parturition 
10 Foetal: 800 results. Summary of study published as 
abstract. Validity of the study cannot be 
evaluated. 
(Vanillin [05.018]) Reproductive and 
developmental toxicity: 1 
week  
before mating until 4 days post 
parturition 
Rat; F 
10 
Gavage 0, 125, 250, 500 mg/kg bw/day Maternal: 250 
Foetal: 500 
(Vollmuth et al., 1990) Unpublished study with limited report of 
results. Summary of study published as 
abstract. Validity of the study cannot be 
evaluated. 
(2,4-Dihydroxybenzoic acid 
[08.076]) 
Teratogenicity:  
Gestation day 9 
Rat; F 
10 
SC 0, 380 mg/kg bw/day 380 (Koshajki and Schulert, 
1973) 
Published study of limited quality. 
Limited report of experimental details 
and results. Insufficient endpoints 
analysed. 
Teratogenicity 
Gestation day 11 
Rat; F 
Not Reported 
SC 0, 428 mg/kg bw/day (plus 214 
mg/kg bw/day after 2 hours) 
ND1 (Saito et al., 1982) Published study of limited quality. 
Unusual study design and limited report 
of experimental details and results. No 
effect on plasma Ca level in dams after a 
single dose. Reduced plasma Ca levels in 
dams and malformations and 
foetotoxicity after the additional dose. 
No effects on maternal reproductive 
parameters. 
(Ethyl vanillin [05.019]) Reproductive and 
developmental toxicity: 1 
week before mating until 4 
days post parturition 
Rat; F 
10 
Gavage 0, 200, 1000, 2000 mg/kg 
bw/day 
Maternal: ND1  
Foetal: 2000 
(Vollmuth et al., 1990) Unpublished study with limited report of 
results. Summary of study published as 
abstract. Validity of the study cannot be 
evaluated. 
(Piperonal [05.016]) Reproductive and 
developmental toxicity: 1 
week before mating until 4 
days post parturition 
Rat; F 
10 
Gavage 0, 250, 500, 1000 mg/kg 
bw/day 
Maternal: 500  
Foetal: 500 
(Vollmuth et al., 1990) Unpublished study with limited report of 
results. Summary of study published as 
abstract. Validity of the study cannot be 
evaluated. 
1 This study was performed at a single dose level or at multiple dose levels that produced adverse effects. No NOEL could be derived from that study. 
2 Study evaluated the effects of Aspirin (acetylsalicylic acid) when administered to rats during gestation; however, two dose groups used benzoic acid (510 mg/kg) as a pretreatment and one dose group was administered only benzoic acid. Benzoic 
acid alone had no effect. 
3 Calculated based on the reported daily intake of 150 mg per animal, equal to 0.45 mMol per 100 g bw, in animals of the high dose group and a molecular weight of 122.12. 
4  Calculated from data on bw and food consumption presented in the article. 
5 The lowest dose was used in immature mice only. 
6  The number of dose groups was comprised from two separate experiments. In the first experiment dose levels of 40 and 400 mg/kg/day were investigated, while in the second experiment dose levels of 800 and 1200 mg/kg/day were explored. 
7 Reproductive assessment by continuous breeding (RACB) consisted of a 7-day premating phase, a 98-day cohabitation period and a 21-day segregation period. 
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In vitro mutagenicity/genotoxicity data are available for nine candidate substances of the present flavouring group evaluation from chemical groups 23 and 30 
and for 28 supporting substances evaluated by the JECFA at the 46th and 57th meeting (JECFA, 1996b; JECFA, 2002a) and for one related substance. 
Supporting substances are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test System Test Object  Concentration Result  Reference  Comments 
(Benzyl alcohol [02.010]) Ames test (preincubation 
method) 
S. typhimurium TA92; TA94; TA98; 
TA100; TA1535; TA1537 
Up to 10,000 µg/plate (6 
concentrations) 
Negative1 (Ishidate et al., 1984) Published study in accordance with OECD guideline 471. 
Although some details of results are not reported the study 
is considered valid. 
Ames test (plate 
incorporation method) 
S. typhimurium TA100 1000 µg/plate Negative2 (Ball et al., 1984)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 Not reported Negative2 (Rogan et al., 1986)  
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
6666 µg/plate Negative1 (Mortelmans et al., 1986)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
3 µmole/plate Negative1 (Florin et al., 1980)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
50,000 µg/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested.  
The test guidelines do not require more than 5 mg/plate. 
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated.  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
5 µl/plate Negative2 (Milvy and Garro, 1976)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
0, 100, 333, 1000, 3333, 
6666 µg/plate 
Negative1 (NTP, 1989a) Valid study in accordance with OECD guideline 471 
(except that only four strains were used). Cytotoxicity was 
reported at the highest concentration tested. 
Ames test (plate 
incorporation method) 
S. typhimurium TA97; TA102 1000 µg/plate Negative1 (Fujita et al., 1992)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA1535 5 µM/plate Negative1 (Wiessler et al., 1983)  
Mutation assay Escherichia coli WP2 uvrA 1000 to 8000 µg/plate Negative (Yoo, 1986) Study published in Japanese with English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. No information on the use of metabolic 
activation. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 21 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 10 µg/disc Positive (Kuroda et al., 1984b) Study published in Japanese with English abstract. Data 
extracted from figure. Validity of the study cannot be 
evaluated. Inhibition of growth was reported. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 20 µl/disc Positive (Yoo, 1986) Study published in Japanese with English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. A weak positive result (i.e. 4 mm ≤  D < 8 mm). 
was reported (D=5 mm). No information on the use of 
metabolic activation. 
Chromosomal aberration test Chinese hamster fibroblast cells 1000 µg /ml4 (three Negative2 (Ishidate et al., 1984) Published study carried out only in the absence of 
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concentrations, max. 
concentration inducing 
50 % cell-growth 
inhibition) 
metabolic activation. Thus, study is not considered valid. 
Cells were exposed for 24 and 48 hours. Negative response 
for chromosomal aberrations and polyploidization. 
Chromosomal aberration test Chinese hamster ovary cells 50 to 5000 µg/ml Equivocal1 (Anderson et al., 1990) Published summary report including detailed results from 
studies on 42 compounds tested in various laboratories 
within the NTP in accordance with OECD guideline 473. 
Lowest effective dose was 4000 µg/ml with and without 
S9. No dose-response observed. Positive results were not 
reproducible in all trials. Absence of cytotoxicity reported 
up to the highest dose. 
Chromosomal aberration test Chinese hamster ovary cells 50 to 5000 µg/ml Negative2 
Positive3 
(NTP, 1989a) Valid study in accordance with OECD guideline 473. A 
positive result was reported only in the presence of S9 at 
relatively high concentrations of 4000 µg/ml in 3 of 4 tests 
carried out with harvest times between 12 and 18 hours. No 
data on cytotoxicity reported. 
Sister chromatid exchange 
assay 
Chinese hamster ovary cells 16 to 5000 µg/ml Positive (NTP, 1989a) Valid study in accordance with OECD guideline 479. Dose-
related increase in frequency of SCE at concentrations from 
500 - 1250 µg/ml (without metabolic activation) and 500 - 
4000 µg/ml (with metabolic activation). No data on 
cytotoxicity reported. Number of chromosomes per cell 
reduced at 4000 µg/ml with S9. 
Sister chromatid exchange 
assay 
Chinese hamster ovary cells 16 to 1250 µg/ml2
16 to 4000 µg/ml3 
Positive1 (Anderson et al., 1990) Published summary report including detailed results from 
studies on 42 compounds tested in various laboratories 
within the NTP in accordance with OECD guideline 479. 
Significant increase (20 %) in SCE only at the highest 
doses. No dose-response observed. No second trial using 
high concentrations to reproduce the positive effects 
performed. Absence of cytotoxicity reported up to the 
highest dose.  
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells Up to 5000 µg/ml Questionable (McGregor et al., 1988a; 
Myhr et al., 1990) 
Published summary report including detailed method and 
results from study on 72 compounds tested in various 
laboratories within the NTP in accordance with OECD 
guideline 476 (however, no colony sizing performed). 
Positive responses observed in some experiments at 
concentrations of 3500 and higher. No dose-response was 
observed. The highest concentration was letal in some 
experiments. Positive and negative responses could not be 
reproduced in all experiments.  
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 150 to 5000 µg/ml Negative3 
Positive2 
(NTP, 1989a) Valid study in accordance with OECD guideline 476. In 
one of three trials without S9 a positive result (relative 
mutant fraction ≥ 1.6) was reported at 4500 µg/ml with 
relative total growth of 20 %. The concentration of 5000 
µg/ml was letal in this trial, whereas in another one of three 
trials without S9 3500 µg/ml was letal. 
Mutation assay E. coli WP2 uvrA Not reported Negative (Kuroda et al., 1984a) Only abstract available. Methods, test concentrations and 
detailed results not reported. 
Cytotoxicity assay Human alveolar tumour cells 0.5 mM Negative (Waters et al., 1982)  
DNA damage assay Human alveolar tumour cells 0.5 mM Negative (Waters et al., 1982)  
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DNA damage assay Rat hepatocytes 10 mM Negative (Storer et al., 1996) Cytotoxicity was reported at the highest concentration 
tested. 
DNA damage assay E. coli P3478 50 µl/disc Negative1 (Fluck et al., 1976)  
(Benzyl formate [09.077]) Rec assay B. subtilis M45 (rec-), H17 (rec+) 20 µl/disc Positive (Yoo, 1986) Study published in Japanese with English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. A weak positive result (i.e. 4 mm ≤  D < 8 
mm).was reported (D = 4 mm). No information on the use 
of metabolic activation. 
Mutation assay E. coli WP2 uvrA 500 to 4000 µg/plate Negative (Yoo, 1986) Study published in Japanese with English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. No information on the use of metabolic 
activation. 
(Benzyl acetate [09.014]) Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
10,000 µg/plate Negative1 (Mortelmans et al., 1986)  
Ames test (preincubation and 
plate incorporation method) 
S. typhimurium TA98; TA100 5000 µg/plate Negative1 (Schunk et al., 1986) Cytotoxicity was observed at the three highest doses tested. 
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
3 µM/plate Negative1 (Florin et al., 1980)  
Rec assay B. subtilis M45 (rec-), H17 (rec+) 21 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 20 µl/disc Positive (Yoo, 1986) Study published in Japanese with English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. A weak positive result (i.e. 4 ≤ D < 8) was 
reported (D could not clearly be determined). No 
information on the use of metabolic activation. 
Mutation assay E. coli WP2 uvrA 250 to 2000 µg/plate Negative (Yoo, 1986) Study published in Japanese with English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. No information on the use of metabolic 
activation. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells; 
Human lymphoblast TK6 cells 
Mouse cells 0, 250, 500, 
1000 µg/ml; Human 
cells 0, 500, 1000, 1250, 
1500 µg/ml 
Negative2
Positive3 
(Caspary et al., 1988) Published non-GLP study in accordance with OECD 
guideline 476 (except that no colony sizing was 
performed). Thus, the study is considered not fully valid. 
The lowest significantly effective doses in the presence of 
S9 were 500 µg/ml in mouse cells and 1500 µg/ml in 
human cells. Cytotoxicity was reported above 500 µg/ml 
with and without S9. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 0-1600 µl/ml (6 
concentrations) 
Positive2 (McGregor et al., 1988a) Published summary report including detailed method and 
results from study on 72 compounds tested in various 
laboratories within the NTP. The study was not in 
accordance with OECD guideline 476 (no colony sizing 
performed, only in the absence of metabolic activation) and 
thus not considered valid. The lowest significantly effective 
doses was 900 µg/ml at which the relative total growth was 
50 %. The highest dose was lethal. A positive response was 
observed in two of three experiments. No dose-response 
was observed. 
Mammalian cell gene Mouse lymphoma L5178Y cells Not reported Negative2 (Rudd et al., 1983) Study carried out within a larger NTP project. Only abstract 
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mutation test Positive3, available. Validity of the study cannot be evaluated. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y TK+/- cells Not reported Negative2
Inconclusive3 
(Honma et al., 1999a) Published collaborative study on 40 chemicals. Protocol 
was in accordance with OECD guideline 476, except that 
no colony sizing was performed. As the results are 
insufficiently reported, their validity cannot be evaluated. 
In the presence of S9 metabolic activation one laboratory 
achieved a statistically significant dose-dependant result, 
but did not induce mutations greater than three times the 
spontaneous response. The second laboratory did not obtain 
a positive response. 
Chromosomal aberration test Chinese hamster ovary cells 160-1600 µg/ml2; 500-
5000 µg/ml3 
Negative1 (Galloway et al., 1987a) Published non-GLP study. Doses were selected based on 
preliminary assay. Although some details of results are not 
reported the study is considered valid.  
Chromosomal aberration test Chinese hamster lung fibroblast cells 2400 µg/ml Negative1 (Matsuoka et al., 1996) Cytotoxicity was reported at the highest concentration 
tested. 
Sister chromatid exchange 
assay 
Chinese hamster ovary cells 50-500 µg/ml2; 500-
5000 µg/ml3 
Negative1, (Galloway et al., 1987a) Published non-GLP study. Doses were selected based on 
preliminary assay. Although some details of results are not 
reported the study is considered valid. 
Unscheduled DNA synthesis 
test 
Rat hepatocytes Not reported Negative (Mirsalis et al., 1983) Only abstract available. Methods, test concentrations and 
detailed results not reported. 
Micronucleus test Human lymphocytes and hepatoma cell 
line Hep G2 
500 µM Negative1 (Kevekordes et al., 2001)  
(Benzyl propionate [09.132]) Rec assay B. subtilis M45 (rec-), H17 (rec+) 21 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
(Benzyl benzoate [09.727]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
3 µM/plate Negative1 (Florin et al., 1980)  
Ames test (preincubation and 
plate incorporation method) 
S. typhimurium TA98; TA100 Up to 5000 µg/plate Negative1 (Schunk et al., 1986) Cytotoxicity was observed at the three highest doses tested. 
(Benzaldehyde [05.013]) Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
37,500 nl/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested.  
The test guidelines do not require more than 5 mg/plate. 
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated.  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 50 to 300 µl/plate Negative1 (Rockwell and Raw, 1979) Assay of urine samples from rats given benzaldehyde by 
oral gavage. 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 100 µl/plate Negative3 (Rockwell and Raw, 1979) Samples assayed prior to administration to rats. 
Ames test S. typhimurium TA98; TA100; TA2637 2000 mg/plate Negative1 (Nohmi et al., 1985) Article published in Japanese. Data reported from English 
summary. 
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
3 µM/plate Negative1 (Florin et al., 1980)  
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
0, 10, 33, 100, 333, 
1000 µg/plate 
Negative1 (Haworth et al., 1983) Published summary report including detailed results from 
studies on 250 compounds tested in various laboratories 
within the NTP to a large extent in accordance with OECD 
guideline 471. 
Ames test S. typhimurium TA100; TA102; TA104 3333 µg/plate Negative1 (NTP, 1990c)  
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Ames test S. typhimurium TA100 1000 µg/plate Negative (Rapson et al., 1980) The use of metabolic activation was not reported. 
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100 Not reported Negative1 (Sasaki and Endo, 1978)  
Ames test (preincubation 
method) 
S. typhimurium TA100; TA102; TA104 Not reported Negative1 (Dillon et al., 1992)  
Ames test (preincubation 
method) 
S. typhimurium TA100 2000 nM/plate Negative1 (Vamvakas et al., 1989)  
Ames test (preincubation 
method) 
S. typhimurium TA97; TA102 1000 µg/plate Negative1 (Fujita et al., 1992)  
Ames test S. typhimurium TA98; TA100 0.05 to 500 µg/plate Negative1 (Kasamaki et al., 1982) Published non-GLP study with insufficient report of some 
details of method and results. Thus, the validity of the study 
cannot be evaluated. 
Ames test (preincubation 
method) 
S. typhimurium TA98; TA1535 5 µM/plate Negative1 (Wiessler et al., 1983)  
Ames test (preincubation 
method) 
S. typhimurium TA97a; TA100; 
TA102; TA104 
Not reported Negative1 (Dillon et al., 1998)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA1537; 
TA7001; TA7002; TA7003; TA7004; 
TA7006; Mix of TA7001–7006  
TA7005 
1000 µg/ml Negative1 
 
 
Negative2; 
Positive3 
(Gee et al., 1998)  
Rec assay B. subtilis M45 (rec-), H17 (rec+) 21 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) Not reported Negative2
Positive3 
(Matsui et al., 1989) Published non-GLP study with insufficient report of some 
details of method and results. Thus, the validity of the study 
cannot be evaluated.  
Unscheduled DNA synthesis 
test 
Rat hepatocytes 251 nl/ml Negative (Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 12.5 to 800 nl/ml Negative2
Positive3 
(Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. Different concentration ranges 
(12.5-800, 25-600, 400-600 nl/ml) were used in three 
independent experiments within which positive responses 
were observed. A 2.8 to 5.2-fold increase in mutant 
frequency was observed in the presence of S9.  
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 0 to 800 µg/ml (6 
concentrations) 
Positive2 (McGregor et al., 1991) Published summary report including detailed method and 
results from study on 27 compounds tested in various 
laboratories within the NTP in accordance with OECD 
guideline 476 (however, no colony sizing performed). 
Statistically significant increase in mutant fraction at the 
highest non-lethal concentration (400 µg/ml) in two 
experiments. Concentration of 640 and 800 µg/ml were 
lethal. Thus, significant increases in mutant fraction were 
close to toxic doses. No dose-response was observed. Since 
a positive response was observed without S9, no 
experiment was carried out with S9. 
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Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y +/- cells 600 µg/ml Negative2 (Bigger and Clarke, 1991)  
Chromosomal aberration test Chinese hamster cells 0, 800, 1000, 1200 
µg/ml 
Positive2 
Weak positive3 
(Sofuni et al., 1985) Article published in Japanese. Data extracted from English 
summary and tables. Validity of the study cannot be 
evaluated. Cytotoxicity was observed at the two maximum 
concentrations tested. In the presence and in the absence of 
S9 a positive response was only observed at cytotoxic 
concentrations. Polyploidization (11 %) was reported at 
non-cytotoxic concentrations. 
Chromosomal aberration test Chinese hamster ovary cells 50-500 µg/ml2; 160-
1600 µg/ml3 
Negative1 (Galloway et al., 1987a) Published non-GLP study. Doses were selected based on 
preliminary assay. Although some details of results are not 
reported the study is considered valid. 
Chromosomal aberration test Chinese hamster cell line B241 50 nM (0.0053 µg/ml) Positive1 (Kasamaki et al., 1982) Published non-GLP study of sufficient quality to be taken 
into account for the evaluation, although some details of 
method and results are not reported. Information is only 
given for the final concentration at which maximal 
frequency of aberration was observed without visible 
cytotoxicity in the treated cells. Dose-dependent increase of 
total aberrations (chromatid gaps, chromatid breaks, 
chromosome breaks observed, no ring or dicentric 
aberrations or chromatic exchanges). 
Sister chromatid exchange 
assay 
Chinese hamster ovary cells 5-160 µg/ml2; 160-1600 
µg/ml3 
Positive2
Positive3 
(Galloway et al., 1987a) Published non-GLP study. Doses were selected based on a 
preliminary assay. Although some deatails of results are not 
reported the study is considered valid. Weakly positive 
results with metabolic activation were observed at the 
highest concentration which was cytotoxic and resulted in 
50 % growth reduction.  
Sister chromatid exchange 
assay 
Chinese hamster ovary cells Up to 1000 µM (up to 
106 µg/ml) 
Negative3 (Sasaki et al., 1989) Published non-GLP study of limited quality. Study 
designed to investigate the influence on spontaneous as 
well as on mitomycin-induced SCEs. The substance did not 
influence cell cycle (data not shown) and spontaneous 
SCEs at the concentrations used. Cytotoxicity was reported 
at the highest concentration tested. 
Sister chromatid exchange 
assay 
Human lymphocytes 0-2 mM (0-212 µg/ml) Positive2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
(Benzoic acid [08.021]) Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1538 
2500 µg/plate Negative1 (Anderson and Styles, 
1978) 
 
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1536 
3.6 µg/plate Negative1 (Cotruvo et al., 1977)  
Ames test (preincubation 
method) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TA1537 
10,000 µg/plate Negative1 (Zeiger et al., 1988)  
Ames test S. typhimurium TA100 Up to 1000 µg/plate Negative (Rapson et al., 1980) Cytotoxicity was reported at the highest concentration 
tested. 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
1000 µg/plate Negative3 (McCann et al., 1975)  
Ames test (preincubation S. typhimurium TA92; TA94; TA98; Up to 10,000 µg/plate (6 Negative1 (Ishidate et al., 1984) Published study in accordance to OECD guideline 471. 
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method) TA100; TA1535; TA1537 concentrations) Although some details of results are not reported the study 
is considered valid. 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
100 µg/plate Negative2 (Milvy and Garro, 1976)  
Ames test (plate 
incorporation method) 
S. typhimurium TA1535; TA1537; 
TA1538 
0.5 % (5 mg/ml) Negative1 (FDA, 1975b)  
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100 100 to 10000 µg/plate Negative1 (Kuboyama and Fujii, 
1992) 
Published non-GLP study deficient in the report of some 
details on method and results (no single doses, no data on 
cytotoxicity reported), however, of sufficient quality to be 
taken into account in the evaluation. 
Umu mutation assay S. typhimurium TA1535/ pSK1002 1607 µg/ml Negative1 (Nakamura et al., 1987)  
Rec assay (liquid method) B. subtilis M45 (rec-), H17 (rec+) Not reported Positive (Nonaka, 1989) Only abstract available. Details on method and results not 
reported. Use of metabolic activation not reported. The 
validity of the study cannot be evaluated. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 0 to 5000 µg/disc Positive (Kuboyama and Fujii, 
1992) 
Well conducted published non-GLP study, with some 
minor deficiencies (no cytotoxicity data, no detailed data 
for different concentrations reported), however, of 
sufficient quality to be taken into account in the evaluation. 
A weak positive result (D > 2 mm) was observed at 
concentrations of 4 mg/disc or more. At 5 mg/disc D = 2.9 
mm. 
Mutation assay S. cerevisiae D3 0.18 % Negative1 (Cotruvo et al., 1977)  
Mutation assay S. cerevisiae D4 0.15 % Negative1 (FDA, 1975b)  
Indirect DNA repair test E. coli PQ37 400 µg/ml Negative (Glosnicka and 
Dziadziuszko, 1986) 
Genotoxicity measured as ability to induce ß-galactosidase. 
      
SOS Chromotest E. coli PQ37 50 µg Negative1 (Kevekordes et al., 1999)  
Chromosomal aberration test Chinese hamster fibroblast cells 1500 µg/ml (three 
concentrations, max. 
concentration inducing 
50% cell-growth 
inhibition) 4 
Equivocal2 (Ishidate et al., 1984) Published study carried out only in the absence of 
metabolic activation. Thus, study is not considered valid. 
Cells were exposed for 24 and 48 hours. Total incidence of 
cells with aberrations was 8 %. Negative response for 
polyploidization.  
Sister chromatid exchange 
assay 
Human lymphocytes 0-2 mM (0-244 µg/ml) Negative2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
In vitro Micronucleus assay Mouse lymphoma L5178Y cells 1000 µg/ml Negative1 (Nesslany and Marzin, 
1999) 
 
(Methyl benzoate [09.725]) Ames test (preincubation 
method) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TA1537 
0 to 666 µg/plate (-S9); 
0 to 6666 µg/plate (+S9) 
(6 concentrations) 
Negative1 (Zeiger et al., 1992) Published summary report including detailed results from 
NTP studies on 311 compounds in accordance with OECD 
guideline 471. 
Mutation assay E. coli Sd-4-73 Not reported Negative2 (Szybalski, 1958)  
Methyl 4-methylbenzoate [09.631] Ames test (preincubation 
method) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TA1537;  
0 to 333 µg/plate (-S9); 
0 to 3333 µg/plate (+S9) 
(6 concentrations) 
Negative1 (Zeiger et al., 1992) Published summary report including detailed results from 
NTP studies on 311 compounds in accordance with OECD 
guideline 471. 
(Isopentyl benzoate [09.755]) Mutation assay E. coli Sd-4-73 Not reported Negative2 (Szybalski, 1958)  
(4-Isopropylbenzyl alcohol [02.039]) Ames test (plate S. typhimurium TA98; TA100 100 µl/plate Negative3 (Rockwell and Raw, 1979)  
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incorporation method) 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 300 µl/plate Negative1 (Rockwell and Raw, 1979) Assay of urine samples from rats given isopropylbenzyl 
alcohol by oral gavage. 
 
(Tolualdehydes (mixed o, m, p) 
[05.027]) 
Ames test (preincubation 
method) 
S. typhimurium TA104 0.8 µM/plate Negative1 (Marnett et al., 1985a)  
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
3 µM/plate Negative1 (Florin et al., 1980)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
18,750 µg/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested.  
The test guidelines do not require more than 5 mg/plate. 
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated.  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; TA102 0.8 mM/plate Negative1 (Aeschbacher et al., 1989)  
Ames test (preincubation 
method) 
S. typhimurium TA97; TA100; 
TA1535; TA1537 
666 µg/plate Negative1 (Zeiger et al., 1988)  
Unscheduled DNA synthesis 
test 
Rat hepatocytes 1000 µg/ml4 Negative (Heck et al., 1989) Published non-GLP study. No information concerning the 
number of concentrations tested.  
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 300 µg/ml (+S9), 600 
µg/ml (-S9)4 
Negative1 (Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. 
(4-Isopropylbenzaldehyde [05.022]) Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 100 µl/plate Negative3 (Rockwell and Raw, 1979)  
Ames test (plate 
method)incorporation 
S. typhimurium TA98; TA100 300 µl/plate Negative1 (Rockwell and Raw, 1979) Assay of urine samples from rats given 4-isopropyl 
benzaldehyde (cuminaldehyde) by gavage. 
Umu test S. typhimurium TA1535/ pSK1002 1 µmole/ml Negative (Miyazawa et al., 2000) Results indicated that 4-isopropyl benzaldehyde 
(cuminaldehyde) was positive for antimutagenicty, but not 
genotoxic. 
Sister chromatid exchange 
assay 
Chinese hamster ovary cells Up to 333 µM (up to 50 
µg/ml) 
Negative2 (Sasaki et al., 1989) Published non-GLP study of limited quality. Study 
designed to investigate the influence on spontaneous as 
well as on mitomycin-induced SCEs. The substance did not 
influence cell cycle (data not shown) and spontaneous 
SCEs at the concentrations used. Cytotoxicity was reported 
at the highest concentration tested. 
(4-Hydroxybenzoic acid [08.040]) Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 5000 µg/plate Negative2 (Mikulasova and 
Bohovicova, 2000) 
 
DNA Repair test E. coli WP2, WP2uvrA, CM611; 
CM561 
2000 µg/ml Negative (Mikulasova and 
Bohovicova, 2000) 
 
(Salicylic acid [08.112]) Ames test (preincubation 
method) 
S. typhimurium TA98; TA100 100 to 10000 µg/plate Negative1 (Kuboyama and Fujii, 
1992) 
Published non-GLP study deficient in the report of some 
details on method and results (no single doses, no data on 
cytotoxicity reported), however, of sufficient quality to be 
taken into account in the evaluation. 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
Not reported Negative2 (McCann et al., 1975)  
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Rec assay B. subtilis M45 (rec-), H17 (rec+) 0 to 5000 µg/disc Positive (Kuboyama and Fujii, 
1992) 
Well conducted published non-GLP study, with some 
minor deficiencies (no cytotoxicity data, no detailed data 
for different concentrations reported), however, of 
sufficient quality to be taken into account in the evaluation. 
A weak positive result (D >2 mm) was observed at 
concentrations of 2 mg/disc or more. At 5 mg/disc D = 4.7 
mm. 
Mitotic recombination assay S. cerevisiae D7 10,000 µg/ml Negative2 (Rosin, 1984) Published non-GLP study with insufficient report of 
experimental details and results. Study was carried out only 
in the absence of metabolic activation and is thus not 
considered valid. Negative response reported both at 
neutral and alkaline conditions. 
Mutation assay S. cerevisiae rad18 Up to 0.1 mM (up to 
13.8 µg/ml; 8 
concentrations) 
Positive (Zetterberg, 1979) Published non-GLP study with limited report of 
experimental details and result. Use of metabolic activation 
not reported. The validity of the study cannot be evaluated. 
The dose level tested was clearly cytotoxic. An increase in 
mutant frequency was not evident until 95 - 99 % of cells 
were killed. 
Ethyl 4-hydroxybenzoate [09.367] Ames test S. typhimurium TA98; TA100 Not reported Negative1 (Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Rec assay B. subtilis Not reported Negative1 (Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Chromosomal aberration 
assay 
Hamster lung fibroblast cells Not reported Positive2 
Negative3 
(Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Chromosomal aberration 
assay 
Human embryo fibroblasts Not reported Negative2 (Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Chromosomal aberration 
assay 
Chinese hamster fibroblast cells Up to 250 µg/ml Positive (Ishidate et al., 1978) Published non-GLP study in Japanese with English 
summary and tabulated results. Some important details of 
method and results are not available. There is no 
information on the use of metabolic activation. The 
substance was tested up to the maximum dose tolerated. 
Thus, the validity of the study cannot be evaluated. 
Sister chromatid exchange 
assay 
Human embryo fibroblasts Not reported Negative2 (Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Sister chromatid exchange 
assay 
Human fibroblastic cells HE2144 0, 83, 166 µg/ml Negative2 (Sasaki et al., 1980) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
Mutation assay Silk worms Not reported Negative (Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  Unusual protocol, no details of method 
and results reported. Thus, the validity of the study cannot 
be evaluated. 
(Butyl 4-hydroxybenzoate [09.754]) Ames test S. typhimurium TA98; TA100 1000 µg/plate Negative1 (Haresaku et al., 1985)  
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 Ames test (preincubation 
method) 
S. typhimurium TA92; TA94; TA98; 
TA100; TA1535; TA1537; TA2637 
Up to 1000 µg/plate (6 
concentrations) 
Negative1 (Ishidate et al., 1984) Published study in accordance to OECD guideline 471. 
Although some details of results are not reported the study 
is considered valid. 
Chromosomal aberration test Chinese hamster fibroblast cells 60 µg/ml (three 
concentrations, max. 
concentration inducing 
50% cell-growth 
inhibition) 4 
Negative2 (Ishidate et al., 1984) Published study carried out only in the absence of 
metabolic activation. Thus, study is not considered valid. 
Cells were exposed for 24 and 48 hours. Negative response 
for chromosomal aberrations and polyploidization. 
Ames test (plate 
incorporation assay) 
S. typhimurium TA100 500 µg/plate Negative2 (Ball et al., 1984)  
(Veratraldehyde [05.017]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA15378 
8000 µg/plate Negative1 (Nestmann et al., 1980)  
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
8000 µg/plate Negative1 (Douglas et al., 1979)  
Ames test (preincubation 
method) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TTA1537 
6666 µg/plate Negative1 (Mortelmans et al., 1986)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
1000 µg/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested. Due to the lack of some important 
details of study design and results the validity of the study 
cannot be evaluated.  
Ames test  (preincubation 
method) 
S. typhimurium TA100; TA102; 
TA104; TA982; TA1538 
Not reported Negative1 (Dillon et al., 1992)  
Ames test (preincubation 
protocol) 
S. typhimurium TA100; TA102; TA104 33 - 3333 µg/plate Negative1 (Dillon et al., 1998)  
Mutation assay S. cerevisiae D7; XV185-14C Not reported Negative2 (Nestmann and Lee, 1983)  
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 250 to 1800 µg/ml  Positive1 (Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. Different concentration ranges 
(250, 1400-1600, 1400-1800 µg/ml) were used in three 
independent experiments within which positive responses 
were observed. A 2.3 to 6.2 fold increase in the  mutation 
frequency was observed both with and without S9. 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 5000 µg/plate Negative2 (Mikulasova and 
Bohovicova, 2000) 
 
DNA Repair test E. coli WP2; WP2uvrA; CM611; 
CM561 
2000 µg/ml Negative (Mikulasova and 
Bohovicova, 2000) 
 
Unscheduled DNA synthesis 
test 
Rat hepatocytes 100 µg/ml4 Negative (Heck et al., 1989) Published non-GLP study. No information concerning the 
number of concentrations tested.  
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated. 
(4-Methoxybenzaldehyde [05.015]) Ames test (preincubation 
method) 
S. typhimurium TA92; TA94; TA98; 
TA100; TA1535; TA1537; TA2637 
Up to 5000 µg/plate (6 
concentrations) 
Negative1 (Ishidate et al., 1984) Published study in accordance to OECD guideline 471. 
Although some details of results are not reported the study 
is considered valid. 
Ames test S. typhimurium TA98; TA100 0.05 to 500 µg/plate Negative1 (Kasamaki et al., 1982) Published non-GLP study with insufficient report of some 
details of method and results. Thus, the validity of the study 
cannot be evaluated. 
Ames test (preincubation S. typhimurium TA1537 Up to 5000 µg/plate (6 Negative1 (Engelhardt, 1986)  
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method) concentrations) 
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
408 µg/plate Negative1 (Florin et al., 1980)  
Ames test (preincubation 
method) 
S. typhimurium TA97; TA102 1000 µg/plate Negative1 (Fujita and Sasaki, 1987)  
Rec assay B. subtilis M45 (rec-), H17 (rec+) 22 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. No information on the use of metabolic 
activation. 
Ames test S. typhimurium TA102 5000 µg/plate Negative1 (Müller et al., 1993)  
Ames test S. typhimurium TA 100 1000 µg/plate Negative (Rapson et al., 1980)  
Mutation assay Phage PM2 1362 µg/ml Negative (Becker et al., 1996)  
Chromosomal aberration test Chinese hamster fibroblast cells 500 µg/ml (three 
concentrations, max. 
concentration inducing 
50% cell-growth 
inhibition) 4 
Negative2 (Ishidate et al., 1984) Published study carried out only in the absence of 
metabolic activation. Thus, study is not considered valid. 
Cells were exposed for 24 and 48 hours. Negative response 
for chromosomal aberrations and polyploidization. 
Chromosomal aberration test Chinese hamster cell line B241 50 nM (0.0068 µg/ml) Positive1 (Kasamaki et al., 1982) Published non-GLP study of sufficient quality to be taken 
into account for the evaluation, although some details of 
method and results are not reported. Results are reported 
for the concentration at which maximal frequency of 
aberration was observed without visible cytotoxicity in the 
treated cells. Dose-dependent increase of total aberrations 
(chromatid gaps, chromatid breaks, chromosome breaks 
observed, ring and dicentric aberrations, chromatic 
exchanges). 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y TK+/- cells 0 -3.0 mM (0 - 408 
µg/ml) 
3.6 - 5.1 mM (484 - 691 
µg/ml) 
Negative2
Positive2 
(Wangenheim and 
Bolcsfoldi, 1988) 
Published non-GLP study not in accordance with OECD 
guideline 476 (no metabolic activation, no colony sizing). 
Important details of method and results are insufficiently 
reported. This study is not considered valid. 
Ames test S. typhimurium TA102 5000 µg/plate Negative1 (Jung et al., 1992) Results confirmed at three separate contract laboratories 
Sister chromatid exchange 
assay 
Human lymphocytes 0-2 mM (0-273 µg/ml) Positive2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
Sister chromatid exchange 
assay 
Chinese hamster ovary K1 cells 14 µg/ml Negative (Sasaki et al., 1987)  
DNA alkaline unwinding 
assay 
Mouse lymphoma L5178Y TK+/- cells 0, 4, 5, 6 mole/l (0, 544, 
680, 816 µg/ml ) 
7, 8 mole/l (953, 1089 
µg/ml )  
Negative2 
 
Positive2 
(Garberg et al., 1988) Published study on 78 compounds not in accordance with 
standard guidelines. Test suitable for rapid screening only. 
Strand breaks or mutations observed only at cytotoxic 
concentrations. 
2-Methoxybenzaldehyde [05.129] Mutation assay E. coli WP2uvrA, trpE 5000 µg/plate Negative2 (Watanabe et al., 1989) Published non-GLP study with limited report of 
experimental details and results. Study evaluating the 
enhancing effect on N'-nitro-N-nitrosoguanidine (MNNG)-
induced mutagenesis in pretreated cells and not on the 
mutagenicity of the substance itself. Absence of an 
enhancing effect reported.  
Sister chromatid exchange Human lymphocytes 0 - 0.25 mM  Positive2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
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assay (0 - 34 µg/ml) guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
3-Methoxybenzaldehyde [05.158] Sister chromatid exchange 
assay 
Human lymphocytes 0 - 2.0 mM  
(0 - 273 µg/ml) 
Positive2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y TK+/- cells 0 -  2.5 mM (0 - 340 
µg/ml) 
 
3 mM (408 µg/ml) 
Negative2
 
Positive2 
(Wangenheim and 
Bolcsfoldi, 1988) 
Published non-GLP study not in accordance with OECD 
guideline 476 (no metabolic activation, no colony sizing). 
Important details of method and results are insufficiently 
reported. This study is not considered valid. 
(4-Ethoxybenzaldehyde [05.056]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
3600 µg/plate Negative2 (Wild et al., 1983)  
(Methyl 4-methoxybenzoate 
[09.713]) 
Paper disk mutation assay E. coli Sd-4-73 Not reported Negative2 (Szybalski, 1958)  
Gallic acid [08.080] Ames test (preincubation 
method) 
S. typhimurium TA98; TA100 3000 µg/plate Negative1 (Chen and Chung, 2000)  
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
0, 100, 333, 1000, 3333, 
6666 µg/plate (solvent 
DMSO) 
0, 100, 333, 1000, 3333, 
10,000 µg/plate (solvent 
acetone) 
Negative1
 
Equivocal1 
(Haworth et al., 1983) Published summary report including detailed results from 
studies on 250 compounds tested in various laboratories 
within the NTP to a large extent in accordance with OECD 
guideline 471. Results on gallic acid from two different 
laboratories using different solvent. A negative response 
was observed in both laboratories with TA98, TA1535, 
TA1537. A negative result was also reported with TA100 
in the laboratory using DMSO as solvent. With acetone, a 
low-level response with a dose-related trend was found 
with TA100 both in the absence and in the presence of 
metabolic activation. The effect was reproducible in a 
second, not reproducible in a third experiment. 
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; TA1535 5000 µg/plate Negative1 (Rashid et al., 1985) Inhibition was noted at the 5000-µg/plate dose-level; 
however, this may have been due to toxicity. No 
mutagenicity was observed at the 1000-µg/plat dose-level. 
Ames test S. typhimurium TA98; TA100; TA1537 15 µM/plate Negative1 (Wang and Klemencic, 
1979) 
 
Ames test  S. typhimurium TA100 100 µg/plate Positive2 
Positive3 
(Yamaguchi, 1981) Published non-GLP. Insufficient report of important details 
of method and results, thus the validity of the result cannot 
be evaluated. 
Ames test S. typhimurium TA98; TA100 Not reported Negative1 (Sugimura et al., 1976)  
Chromosomal aberration test Chinese hamster ovary cells 50 µg/ml Positive1 (Stich et al., 1981c) Published non-GLP study. Some important details of 
method and results are not reported. Thus, the validity of 
the study cannot be evaluated. Results are reported for one 
concentration only which was half the dose inducing 
mitotic inhibition.The clastogenic activity was reported to 
be reduced by the addition of S9. 
Chromosomal aberration test Chinese hamster ovary K1 cells Up to 2 mM (up to 340 
µg/ml) 
Negative1 (Tayama and Nakagawa, 
2001) 
Published non-GLP study. Part of the study with 
insufficient report of important details of method and 
results. The validity of the results cannot be evaluated. 
Sister chromatid exchange Chinese hamster ovary K1 cells 0, 0.25, 0.5, 1.0, 1.5, 2.0 Positive2 (Tayama and Nakagawa, Published non-GLP study. Well conducted part of the 
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assay mM  
(0, 42.5, 85, 170, 255, 
340 µg/ml) 
2001) study, however with insufficient report of some important 
details of method and results (results with metabolic 
activation not reported). 
Mitotic gene conversion 
assay 
S. cerevisiae D7 0, 100, 1000 µg/ml Negative2 
Positive2 
(Rosin, 1984) Published non-GLP study with insufficient report of 
experimental details and results. Study was carried out only 
in the absence of metabolic activation and is thus not 
considered valid. Gallic acid did not induce a significant 
extent of gene conversions under acidic conditions. At 
neutral pH no convertogenic activity was reported at 100 
µg/ml, however, gallic acid was considerably 
convertogenic at 1000 µg/ml. The presence of catalase 
completely inhibited the convertogenic activity.gene 
conversions.  Under alkaline conditions (pH 10), the 
concentration of 100 µg/ml was reported to induce a 
significant (p <0.01) increase of Trp+ convertants. 
(Vanillin [05.018]) Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
10,000 µg/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested.  
The test guidelines do not require more than 5 mg/plate. 
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated.  
Ames test S. typhimurium TA98; TA100; TA 
1535; TA1537; TA1538 
5000 µg/plate Negative1 (Pool and Lin, 1982)  
Rec assay B. subtilis M45 (rec-), H17 (rec+) 21 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Ames test (preincubation 
assay) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TA1537 
10,000 µg/plate Negative1 (Mortelmans et al., 1986)  
Ames test S. typhimurium TA98; TA100 0.05 to 1000 µg/plate Negative1 (Kasamaki et al., 1982) Published non-GLP study with insufficient report of some 
details of method and results. Thus, the validity of the study 
cannot be evaluated. 
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
Not reported Negative1 (Nagabhushan and Bhide, 
1985) 
 
Ames test S. typhimurium TA92; TA94; TA98; 
TA100; TA1535; TA1537; TA2637 
Up to 10,000 µg/plate (6 
concentrations) 
Negative1 (Ishidate et al., 1984) Published study in accordance with OECD guideline 471. 
Although some details of results are not reported the study 
is considered valid. 
Ames test S. typhimurium TA100 1000 µg/plate Negative (Rapson et al., 1980)  
Paper disk mutation assay E. coli Sd-4-73 Not reported Negative2 (Szybalski, 1958)  
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100 2500 µg/plate Negative2 (Mikulasova and 
Bohovicova, 2000) 
 
DNA Repair test E. coli WP2; WP2uvrA; CM611; 
CM561 
2000 µg/ml Negative (Mikulasova and 
Bohovicova, 2000) 
 
Mutation assay E. coli CSH26/pYM3; CSH26/pSK 
1002 
15,215 µg/ml Negative (Takahashi et al., 1990)  
Mitotic recombination assay S. cerevisiae D7 10,000 µg/ml Negative2 (Rosin, 1984) Published non-GLP study with insufficient report of 
experimental details and results. Study was carried out only 
in the absence of metabolic activation and is thus not 
considered valid. Negative response reported both at 
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neutral and alkaline conditions. 
Chromosomal aberration test Chinese hamster cell line B241 5, 20, 40 nM (0.0008, 
0.003, 0.006 µg/ml) 
Negative (Kasamaki and Urasawa, 
1985) 
 
Chromosomal aberration test Chinese hamster fibroblast cells 1000 µg/ml (three 
concentrations, max. 
concentration inducing 
50% cell-growth 
inhibition) 4 
Negative2 (Ishidate et al., 1984) Published study carried out only in the absence of 
metabolic activation. Thus, study is not considered valid. 
Cells were exposed for 24 and 48 hours. Negative response 
for chromosomal aberrations and polyploidization. 
Chromosomal aberration test Chinese hamster V79 lung cells 15,215 - 152,150 µg Negative2 (Tamai et al., 1992)  
Chromosomal aberration test Human lymphocytes 0, 1, 2, 4 mM (0, 152, 
304, 608 µg/ml) 
Negative (Jansson and Zech, 1987) Published non-GLP study not in accordance with OECD 
guideline 473 (no metabolic activation). Insufficient report 
of important details of method and results. No information 
on cytotoxicity. This study is not considered valid. 
Chromosomal aberration test Chinese hamster cell line B241 20 nM (0.003 µg/ml) Negative1 (Kasamaki et al., 1982) Published non-GLP study of sufficient quality to be taken 
into account for the evaluation, although some details of 
method and results are not reported. Results are only 
reported for the final concentration at which maximal 
frequency of aberration was observed without visible 
cytotoxicity in the treated cells. No significant increase of  
single types of aberrations and of total aberrations. 
Sister chromatid exchange 
assay 
Human lymphocyte cells 0 - 1.0 mM (0 - 152 
µg/ml) 
Positive2 (Jansson et al., 1986) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). This study is not 
considered valid. Dose-dependent effect reported. 
Insufficient report of important details of method and 
results.  
Sister chromatid exchange 
assay 
Chinese hamster ovary K1 cells 15 µg/ml Negative (Sasaki et al., 1987)  
Sister chromatid exchange 
assay 
Human lymphocytes 0, 1, 2 mM (0, 152, 304 
µg/ml) 
Positive2 (Jansson and Zech, 1987) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. Dose-dependent 
effect reported This study is not considered valid. 
Mutation assay Mouse lymphoma L5178Y cells 1000 µg/ml (-S9), 1500 
µg/ml (+S9) 4 
Negative1 (Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. 
Unscheduled DNA synthesis 
test 
Rat hepatocytes 500 µg/ml4 Negative (Heck et al., 1989) Published non-GLP study. No information concerning the 
number of concentrations tested.  
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated. 
Micronucleus assay Human hepatoma (Hep-G2) cells 5, 50 µg/ml 
500 µg/ml 
Negative 2
Positive2 
(Sanyal et al., 1997) Published non-GLP study carried out only in the absence of 
metabolic activation. Thus, the study is not considered 
valid. A statistically significant increase of spontaneus 
micronucleus frequency was reported at the highest 
concentration. Low concentrations of vanillin (0.25 – 5 
µg/ml) but not higher (50, 500 µg/ml) showed an inhibitory 
effect on micronuclei induced by heterocyclic amines. 
 
(Vanillic acid [08.043]) Chromosomal aberration test Chinese hamster ovary cells 25,000 µg/ml Positive1 (Stich et al., 1981c) Published non-GLP study. Some important details of 
method and results are not reported. Thus, the validity of 
the study cannot be evaluated. Data are only reported for 
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one concentration which was half the dose inducing mitotic 
inhibition.The clastogenic activity was reported to be 
increased by the addition of S9. 
Mitotic recombination assay S. cerevisiae D7 10,000 µg/ml Negative2 (Rosin, 1984) Published non-GLP study with insufficient report of 
experimental details and results. Study was carried out only 
in the absence of metabolic activation and is thus not 
considered valid. Negative response reported both at 
neutral and alkaline conditions. 
4-Hydroxy-3,5-
dimethoxybenzaldehyde [05.153] 
Ames test S. typhimurium TA100 10,000 µg/plate Negative (Rapson et al., 1980) The use of metabolic activation was not reported. 
4-Hydroxy-3,5-dimethoxybenzoic 
acid [08.087] 
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
366 µg/plate Negative1 (Florin et al., 1980)  
Chromosomal aberration test Chinese hamster ovary cells 3000 µg/ml Positive1 (Stich et al., 1981c) Published non-GLP study. Some important details of 
method and results are not reported. Thus, the validity of 
the study cannot be evaluated. Data are only reported for 
one concentration which was half the dose inducing mitotic 
inhibition. The clastogenic activity was reported to be 
reduced by the addition of S9. 
Mitotic recombination assay S. cerevisiae D7 10,000 µg/ml Negative2 (Rosin, 1984) Published non-GLP study with insufficient report of 
experimental details and results. Study was carried out only 
in the absence of metabolic activation and is thus not 
considered valid. 
(Salicylaldehyde [05.055]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
366 µg/plate Negative1 (Florin et al., 1980)  
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100 Not reported Negative1 (Sasaki and Endo, 1978)  
Ames test S. typhimurium TA98; TA100 16 µg/ml Negative1 (Kono et al., 1995)  
Mutation assay S. typhimurium TA1535/ pSK1002 111 µg/ml Negative1 (Nakamura et al., 1987)  
Chromosomal aberration test CHL/IU cells Not reported (max. 5 
mg/ml) 
Positive1 (Kusakabe et al., 2002) Published study in accordance with OECD guideline 473. 
However, some details on method and results are 
insufficiently reported. Thus the validity of the study 
cannot be evaluated. Positive result with minimum 
effective dose manifesting over 50 % cytotoxicity at short-
term treatment (6 hours, less than 50 %  cells with 
chromosomal aberrations without S9, less than 20 %  cells 
with chromosomal aberrations with S9). Reduced effect at 
continuous treatment without S9 (24 hours less than 10 %  
cells with chromosomal aberrations). No chromosomal 
aberrations after 48 hours treatment without S9. After 48 
hours treatment without S9 18 % polyploid cells. 
Sister chromatid exchange 
assay 
Human lymphocyte cells 0-0.5 mM (0-61 µg/ml) Negative2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
(Methyl salicylate [09.749]) Ames test S. typhimurium TA92; TA94; TA98; 
TA100; TA1535; TA1537; TA2637 
Up to 10,000 µg/plate (6 
concentrations) 
Negative1 (Ishidate et al., 1984) Published study in accordance with OECD guideline 471. 
Although some details of results are not reported the study 
is considered valid. 
Ames test (preincubation S. typhimurium TA97; TA98; TA100; 333.3 µg/plate Negative1 (Mortelmans et al., 1986)  
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method) TA1535; TA1537 
Ames test S. typhimurium TA98; TA100 Not reported Negative1 (Kawachi et al., 1980b; 
Kawachi et al., 1980a) 
Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Chromosomal aberration test  Hamster lung fibroblast cells Not reported Positive2
Negative3 
(Kawachi et al., 1980b; 
Kawachi et al., 1980a) 
Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Chromosomal aberration test Chinese hamster fibroblasts 250 µg/ml4 (three 
concentrations, max. 
concentration inducing 
50% cell-growth 
inhibition) 
Negative2 (Ishidate et al., 1984) Published study carried out only in the absence of 
metabolic activation. Thus, study is not considered valid. 
Cells were exposed for 24 and 48 hours. Negative response 
for chromosomal aberrations and polyploidization. 
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100 100 to 10000 μg/plate Positive1 (Kuboyama and Fujii, 
1992) 
Published non-GLP study deficient in the report of some 
details on method and results (no single doses, no data on 
cytotoxicity reported), however, of sufficient quality to be 
taken into account in the evaluation. At 100 μg/plate a 
positive response was observed in strain TA98 in the 
presence of S9 mix obtained from hamsters a negative 
response was observed in TA98 in the presence of S9 mix 
obtained from rat, mouse and guinea pig. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 23 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Rec assay B. subtilis Not reported Negative1 (Kawachi et al., 1980b; 
Kawachi et al., 1980a) 
Published summary report of unpublished extensive 
screening study.  No details of method and results reported. 
Thus, the validity of the study cannot be evaluated. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 0 to 5000 µg/disc Negative (Kuboyama and Fujii, 
1992) 
Well conducted published non-GLP study with some minor 
deficiencies (no cytotoxicity data, no detailed data for 
different concentrations reported), however, of sufficient 
quality to be taken into account in the evaluation. 
Mutation assay Silkworm Not reported Negative (Kawachi et al., 1980b; 
Kawachi et al., 1980a) 
Published summary report of unpublished extensive 
screening study.  Unusual protocol, no details of method 
and results reported. Thus, the validity of the study cannot 
be evaluated. 
Chromosomal aberration test Human embryo fibroblast cells Not reported Negative2 (Kawachi et al., 1980b; 
Kawachi et al., 1980a) 
Published summary report of unpublished extensive 
screening study.  Unusual protocol, no details of method 
and results reported. Thus, the validity of the study cannot 
be evaluated. 
Sister chromatid exchange 
assay 
Human embryo fibroblast cells Not reported Negative2 (Kawachi et al., 1980b; 
Kawachi et al., 1980a) 
Published summary report of unpublished extensive 
screening study.  Unusual protocol, no details of method 
and results reported. Thus, the validity of the study cannot 
be evaluated. 
(Butyl vanillyl ether [04.093]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537 
5000 µg/plate Negative1 (Watanabe and Morimoto, 
1989c) 
 
Mutation assay E. coli WP2 uvrA 5000 µg/plate Negative1 (Watanabe and Morimoto, 
1989c) 
 
(Ethyl vanillin [05.019]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
3600 µg/plate Negative1 (Wild et al., 1983)  
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Chemical Name [FL-no] Test System Test Object  Concentration Result  Reference  Comments 
Ames test (preincubation 
method) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TA1537 
8000 µg/plate Negative1 (Mortelmans et al., 1986)  
Ames test S. typhimurium TA92; TA94; TA98; 
TA100; TA1535; TA1537; TA2637 
Up to 10,000 µg/plate 
(six concentrations) 
Negative1 (Ishidate et al., 1984) Published study in accordance with OECD guideline 471. 
Although some details of results are not reported the study 
is considered valid. 
Ames test (preincubation 
method) 
S. typhimurium TA97; TA102 1000 µg/plate Negative1 (Fujita and Sasaki, 1987)  
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
10,000 µg/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested.  
The test guidelines do not require more than 5 mg/plate. 
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated.  
Rec assay B. subtilis M45 (rec-), H17 (rec+) 21 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Chromosomal aberration test Chinese hamster fibroblast cells 250 µg/ml (three 
concentrations, maximal 
concentration inducing 
50 % cell-growth 
inhibition)4 
Positive2 (Ishidate et al., 1984) Published study carried out only in the absence of 
metabolic activation. Thus, study is not considered valid. 
Polyploidization in 48 % of cells reported at 48 hours. 
Negative response for chromosomal aberrations.  
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 125-800 µg/ml Negative2
Weak positive3 
(Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. Different concentration ranges 
(125-500 µg/ml, 600 µg/ml, 800 µg/ml) were used in three 
independent experiments within which positive responses 
were observed. In the presence of S9 a 2.1 to 3-fold 
increase in the mutant frequency was reported. 
Unscheduled DNA synthesis 
test 
Rat hepatocytes 199 µg/ml4 Negative (Heck et al., 1989) Published non-GLP study. No information concerning the 
number of concentrations tested.  
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated. 
Sister chromatid exchange 
assay 
Human lymphocytes 0-2.0 mM (0-332 µg/ml) Negative2 (Jansson et al., 1988) Published non-GLP study not in accordance with OECD 
guideline 479 (no metabolic activation). Insufficient report 
of important details of method and results. This study is not 
considered valid. 
Sister chromatid exchange 
assay 
Chinese hamster ovary K1 cells 17 µg/ml Negative (Sasaki et al., 1987)  
(Ethyl vanillin isobutyrate  [09.933]) Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
5000 µg/plate Negative1 (King and Harnasch, 1997)  
(Piperonyl acetate [09.220]) Ames test (preincubation 
method) 
S. typhimurium TA97; TA98; TA100; 
TA1535; TA1537 
3333 µg/plate Negative1 (Mortelmans et al., 1986)  
Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
3600 µg/plate Negative1 (Wild et al., 1983)  
(Piperonal [05.016]) Ames test      
Modified Ames test S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538  
E. coli WP2uvrAtrp- 
0, 300, 600, 1200, 2400 
µg/plate 
Negative1 (Sekizawa and Shibamoto, 
1982) 
Valid study in accordance with OECD guideline 471. The 
plate incorporation method was used -S9; the preincubation 
method +S9. 
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Chemical Name [FL-no] Test System Test Object  Concentration Result  Reference  Comments 
Ames test (plate 
incorporation method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537; TA1538 
10,000 µg/plate4 Negative1 (Heck et al., 1989) Published non-GLP study. No information concerning a 
possible cytotoxic effect nor on the number of 
concentrations tested.  
The test guidelines do not require more than 5 mg/plate. 
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated. 
Ames test S. typhimurium TA98; TA100 0.05 to 5000 µg/plate Negative1 (Kasamaki et al., 1982) Published non-GLP study with insufficient report of some 
details of method and results. Thus, the validity of the study 
cannot be evaluated. 
Ames test S. typhimurium TA98; TA100; 
TA1537; TA1538 
5000 µg/plate Negative1 (White et al., 1977)  
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; 
TA1535; TA1537 
0, 10, 33, 100, 333, 
1000 µg/plate 
Negative1 (Haworth et al., 1983) Published summary report including detailed results from 
studies on 250 compounds tested in various laboratories 
within the NTP to a large extent in accordance with OECD 
guideline 471. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 20 µg/disc Negative (Oda et al., 1979) Study published in Japanese without English abstract. Data 
extracted from tables. Validity of the study cannot be 
evaluated. 
Rec assay B. subtilis M45 (rec-), H17 (rec+) 5000 µg/disc Positive2 (Sekizawa and Shibamoto, 
1982) 
Well designed and reported study, however with some 
limitations with respect to results. DNA-repair tests in the 
presence of S9 were not successful (no data reported). 
Chromosomal aberration test Chinese hamster cell line B241 50 nM (0.0075 µg/ml) Positive1 (Kasamaki et al., 1982) Published non-GLP study of sufficient quality to be taken 
into account for the evaluation, although some details of 
method and results are not reported. Data are only reported 
for the concentration at which maximal frequency of 
aberration was observed without visible cytotoxicity in the 
treated cells. Dose-dependent increase of total aberrations 
(chromatid gaps, chromatid breaks, chromosome breaks 
observed, no ring or dicentric aberrations or chromatic 
exchanges).  
Chromosomal aberration test Chinese hamster cell line B241 0.15 µg/ml Negative (Kasamaki and Urasawa, 
1985) 
 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 1000 µg/ml4 Negative1 (Heck et al., 1989) Published non-GLP study. Some important details of study 
design and results are not reported. Thus, the validity of the 
study cannot be evaluated. 
Unscheduled DNA synthesis 
test 
Rat hepatocytes 10 to 502 µg/ml Positive (Heck et al., 1989) Published non-GLP study. No information concerning the 
number of concentrations tested.  
Due to the lack of some important details of study design 
and results the validity of the study cannot be evaluated. 
(Vanillin 3-(l-menthoxy)propane-1,2-
diol acetal [02.248]) 5 
Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537 
Up to 5000 µg/plate Negative1 (Kajiura, 1996b)  
Mutation assay E. coli WP2 uvrA Up to 5000 µg/plate Negative1 (Kajiura, 1996b)  
6,6'-Dihydroxy-5,5'-dimethoxy-
biphenyl-3,3'-dicarbaldehyde 
[05.221] 
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; Ta102; 
TA1535; TA1537 
0, 50, 150, 500, 1500, 
5000 µg/plate 
Negative1 (King and Harnasch, 
2002c) 
 
Ames test (preincubation 
method) 
S. typhimurium TA98; TA100; Ta102; 
TA1535; TA1537 
0, 15, 50, 150, 500, 
1500, 5000 µg/plate 
Negative1 (King and Harnasch, 
2002c) 
 
3,4-Dihydroxybenzoic acid [08.133] Sister chromatid exchange 
assay 
Chinese hamster ovary cells  Negative1 (Stich et al., 1981c) Published non-GLP study. Some important details of 
method and results are not reported. Thus, the validity of 
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the study cannot be evaluated. Data are only reported for 
one concentration which was half the dose inducing mitotic 
inhibition.The clastogenic activity was reported to be 
increased by the addition of S9. 
Mammalian cell gene 
mutation test 
Mouse lymphoma L5178Y cells 0, 33, 100, 333, 1000, 
3333 µg/ml 
Negative2 (McGregor et al., 1988c)   
NR = not reported 
1 With and without S9 metabolic activation. 
2 Without S9 metabolic activation. 
3 With S9 metabolic activation. 
4 Concentration listed is either the highest tested if the result was negative or the concentration at which the maximum effect was observed for positive results. 
5 Related substance. 
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In vivo mutagenicity/genotoxicity data are available for two candidate substances of the present flavouring group evaluation from chemical group 23 and for 
ten supporting substances evaluated by JECFA at the 46th and 57th meeting (JECFA, 1996b; JECFA, 2002a). Supporting substances are listed in brackets. 
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no] Test System Test Object  Route Dose Result  Reference  Comments 
(Benzyl alcohol [02.010]) In vivo Sex- linked 
recessive lethal 
mutations(SLRL) 
D. melanogaster Diet 5000 ppm Negative (Foureman et al., 1994)  
In vivo SLRL D. melanogaster Injection 8000 ppm Negative (Foureman et al., 1994)  
In vivo Micronucleus test Mouse bone marrow cells IP injection 200 mg/kg bw Negative (Hayashi et al., 1988)  
In vivo Replicative DNA 
synthesis test 
Mouse and rat hepatocytes Not reported Not reported Negative (Yoshikawa, 1996) Screening test for the detection of non-genotoxic 
hepatocarcinogens. The substance was administered 
once at the maximum tolerated dose or at half the 
maximum tolerated dose to male mice and rats. 
Hepatocytes were prepared after 24, 39 and 48 hours. 
In vivo Replicative DNA 
synthesis test 
Mouse hepatocytes Oral gavage 800 mg/kg Negative (Miyagawa et al., 1995)  
In vivo Replicative DNA 
synthesis test 
Rat hepatocytes Oral or SC injection 600 mg/kg Negative (Uno et al., 1994)  
(Benzyl acetate [09.014]) In vivo SLRL D. melanogaster Diet 300 ppm Negative (NTP, 1993d; Foureman et 
al., 1994) 
 
In vivo SLRL D. melanogaster Injection 20,000 ppm Negative (NTP, 1993d; Foureman et 
al., 1994) 
 
In vivo Sister chromatid 
exchange assay 
Mouse bone marrow cells IP injection 1700 mg/kg bw Negative (NTP, 1993d)  
In vivo Chromosomal 
aberration test 
Mouse bone marrow cells IP injection 0 to 1700 mg/kg 
bw 
Negative (NTP, 1993d) Test substance same batch as NTP chronic bioassays. 
The highest dose caused toxicity and cell cycle delay. 
Test not fully in compliance with the OECD 
guideline (insufficient cells per animal studied). GLP 
status not stated. The study is considered of limited 
validity. 
In vivo Micronucleus test Mouse bone marrow cells 3 IP injection with 24 
h intervals 
0, 312, 625 and 
1250 mg/kg bw 
Negative (NTP, 1993d; Shelby et al., 
1993) 
Test substance same batch as NTP chronic bioassays. 
Study in compliance with OECD guideline. GLP not 
stated. Micronuclei were determiend at 24 hours after 
the last dose. A dose-related decrease in PCE/NCE 
ratio was observed. The study is considered valid. 
In vivo Micronucleus test Mouse erythrocytes Dietary exposure for 
13 weeks. 
 0 to 50,000 ppm 
(equal to 0 to 
7900 mg/kg 
bw/day for males 
and 0 to 9400 
mg/kg bw/day for 
females) 
Negative (NTP, 1993d) Test substance same batch as NTP chronic bioassays. 
In life phase under GLP; for determination of 
genotoxic effects. GLP not specified. Test in 
compliance with OECD guideline. The test is 
considered valid, but of limited relevance because no 
change in PCE/NCE ratio was observed.. 
In vivo Unscheduled 
DNA synthesis test 
Rat hepatocytes Oral gavage 0, 50, 200 and 
1000 mg/kg bw 
Negative (Mirsalis et al., 1989) Test substance same batch as NTP chronic bioassays.  
Test in compliance with OECD guidelines. GLP not 
stated. The test is considered valid. 
In vivo Unscheduled 
DNA synthesis test 
Rat pancreatic cells Oral gavage 1000 mg/kg bw Negative (Steinmetz and Mirsalis, 
1984) 
Only abstract available. Non guideline test. Validity 
cannot be assesed. 
In vivo DNA damage Rat pancreatic cells  IP injection 0, 150, 500 and Negative (Longnecker et al., 1990) Alkaline elution assay. GLP status not specified. 
Flavouring Group Evaluation 20, Revision 3 
 
 
109 EFSA Journal 2011; 9(7):2176 
Table IV.5: GENOTOXICITY (in vivo) 
Chemical Name [FL-no] Test System Test Object  Route Dose Result  Reference  Comments 
1500  mg/kg bw Limited number of animals/group; DNA damage 
monitored at 1 hour post dosing. The study is of 
limited validity. 
In vivo Comet assay Mouse/ Rat Oral 1600 mg/kg 
(mouse); 1200 
mg/kg (rat) 
Positive (Sekihashi et al., 2002) Non-GLP and non-guideline test; but in compliance 
with recommended protocols. Some important details 
of method and results insufficiently reported. No 
toxicity data reported. The administered dose was 0.5 
x LD50. Sampling time was 3, 8 and 24 hours after 
dosing. Positive result reported in mice for stomach, 
colon, kidney, urinary bladder and brain, in rats for 
stomach, colon, liver, kidney, urinary bladder, lung. 
After 24 hours no significant effect in mice, 
significant effects in rat only in lung and kidney. The 
study is of limited validity. 
(Benzaldehyde [05.013]) In vivo SLRL D. melanogaster Diet 1150 ppm Negative (Woodruff et al., 1985)  
In vivo SLRL D. melanogaster Injection 2500 ppm Negative (Woodruff et al., 1985)  
(Salicylic acid [08.112]) In vivo Chromosomal 
aberration assay 
Mouse bone marrow cells IP injection 
gavage 
0, 50, 100, 200 
mg/kg  
0, 350 mg/kg 
Negative 
Negative 
(Giri et al., 1996) Published study widely in accordance with OECD 
guideline 475 and well reported (except that only 
males were tested, only one sampling time was 
chosen and signs of toxicity were not reported). Oral 
and i.p. dose were selected to be 1/3 and 1/5 of the 
reported oral LD50. 
In vivo Sister chromatid 
exchange assay 
Mouse bone marrow cells IP injection 
gavage 
0, 25, 50, 100 
mg/kg 
0, 350 mg/kg 
Negative 
Negative 
(Giri et al., 1996) Well described published study of good quality. Oral 
and i.p. dose were selected to be 1/3 and 1/10 of the 
reported oral LD50. 
Ethyl 4-hydroxybenzoate [09.367] In vivo Chromosomal 
aberration assay 
Rat bone marrow cells Not reported Not reported Negative (Kawachi et al., 1980a) Published summary report of unpublished extensive 
screening study.  No details of method and results 
reported. Thus, the validity of the study cannot be 
evaluated. 
(4-Ethoxybenzaldehyde [05.056]) In vivo Basc test 
Micronucleus test 
D. melanogaster NR 751 µg/ml Negative (Wild et al., 1983) Published non-GLP study.  Details of study protocol 
reported elsewhere. However, results sufficiently 
reported. Study is considered valid. 
In vivo 
Micronucleus test 
NMRI mice NR 1005 mg/ kg bw Negative (Wild et al., 1983) Published non-GLP study. Details of study protocol 
and results insufficiently reported. Effect on 
PCE/NCE ratio not reported. No positive control. 
Validity of the study cannot be evaluated. 
Gallic acid [08.080] In vivo Medium-term rat 
liver bioassay  
Male rats initiated with IP 
injection of diethylnitrosamine 
Not reported. Not reported Negative (Shirai, 1997) Published non-GLP study. Unusual study protocol 
not following OECD guidelines. Some important 
details of method missing and only summarised 
results of a large screening study reported. Thus, the 
validity of the study cannot be evaluated. 
(Vanillin [05.018]) In vivo Micronucleus test Male BDF1 mice Oral gavage 500 mg/kg bw Negative (Inouye et al., 1988) Published non-GLP study not in accordance with 
OECD guideline 474 (smaller group size, only males 
tested, no toxicity data reported, single dose level 
used, no negative control, effect on PCE/NCE ratio 
not reported.)  Induction of micronuclei in 
mitomycin-treated mice was suppressed by post-
treatment with vanillin due to an anticlastogenic 
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effect. Vanillin itself did not induce micronucleated 
PCEs (vanillin control group without mitomycin-
treatment, six sampling times from 5 to 65 hours). 
(Salicylaldehyde [05.055]) In vivo Spot test D. melanogaster BINSC 
D. melanogaster Oregon-R 
NR 1.05 to 1.40 ppm 
0.09 to 0.35 ppm 
Negative 
Negative 
(Kono et al., 1995) Study published in Japanese with English abstract. 
Data extracted from tables. Validity of the study 
cannot be evaluated 
(Ethyl vanillin [05.019]) In vivo Basc test D. melanogaster NR 8309 µg/ml Negative (Wild et al., 1983) Published non-GLP study. Details of study protocol 
reported elsewhere,. However, results sufficiently 
reported. Study is considered valid. 
In vivo Micronucleus test Male BDF1 mice IP injection Not reported Negative (Furukawa et al., 1989) Only abstract available. Insufficient report of 
experimental details and result to evaluate the 
validity of the study. 
In vivo Micronucleus test NMRI mice NR 1000 mg/kg bw Negative (Wild et al., 1983) Published non-GLP study. Details of study protocol 
and results insufficiently reported. Effect on 
PCE/NCE ratio not reported. No positive control. 
Validity of the study cannot be evaluated. 
(Piperonyl acetate [09.220]) In vivo Basc test D. melanogaster NR 4855 µg/ml Negative (Wild et al., 1983) Published non-GLP study.  Details of study protocol 
reported elsewhere,. However, results sufficiently 
reported. Study is considered valid. 
In vivo Micronucleus test NMRI mice NR 970 mg/kg bw Negative (Wild et al., 1983) Published non-GLP study. Details of study protocol 
and results insufficiently reported. Effect on 
PCE/NCE ratio not reported. No positive control. 
Validity of the study cannot be evaluated. 
(Piperonal [05.016]) In vivo Dominant lethal 
assay 
ICR/Ha Swiss mice IP injection 0, 124, 620 mg/kg 
bw 
Negative (Epstein et al., 1972) Published non-GLP study evaluating 174 substances. 
Study protocol not fully in accordance with OECD 
guideline 478 (lower number of animals and of dose 
levels used, limited report of experimental 
observations). However, due to the large body of 
control data available the  results are considered 
valid. Doses were selected in preliminary acute 
toxicity tests. Parameters recorded were percent 
pregnancy, total implants and early and late fetal 
deaths.  
In vivo Dominant lethal 
assay 
ICR/Ha Swiss mice Oral gavage 0, 1000 mg/kg bw 
(repeated doses 
on 5 successive 
days) 
Negative (Epstein et al., 1972) Published non-GLP study evaluating 174 substances. 
Study protocol not fully in accordance with OECD 
guideline 478 (lower number of animals and of dose 
levels used, limited report of experimental 
observations). However, due to the large body of 
control data available the  results are considered 
valid. Doses were selected in preliminary acute 
toxicity tests. Parameters recorded were percent 
pregnancy, total implants and early and late fetal 
deaths. 
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 ABBREVIATIONS 
ADI  Acceptable Daily Intake 
AFC  Additives, Flavourings and Food Contact Materials 
AUC  Area Under Curve 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoA  Coenzyme A 
CoE  Council of Europe 
DMSO  Dimethyl sulphoxide 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
FSH  Follicle-stimulating hormone 
GI   Gastroinstinal 
GLP  Good Laboratory Practice  
HPLC  High Performance Liquid Chromatography 
ID   Identity 
IP   Intraperitoneal 
IV   Intravenous 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
LH  Luteinizing hormone 
MNNG  N'-nitro-N-nitrosoguanidine  
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
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NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PAFA  Priority-based assessment of food additives  
RACB  Reproductive assessment by continuous breeding  
 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
SC  Subcutaneous 
TAMDI Theoretical Added Maximum Daily Intake 
TLC  Thin Layer Chromatography 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
